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SUMMARY 
 
As one of the main lysosomal membrane proteins, lysosomal integral 
membrane protein, type 2 (LIMP-2) contributes to the biogenesis and maintenance of 
the endosomal/lysosomal system. Besides this general role, LIMP-2 takes specifically 
care of the transport to lysosomes of newly formed glucocerebrosidase (GCase), the 
enzyme responsible for lysosomal degradation of glucosylceramide (GlcCer). In 
humans, inherited defects in the LIMP-2 protein lead to Action Myoclonus Renal 
Failure syndrome (AMRF). AMRF patients show a marked decrease in cellular 
GCase activity. This reduction seems however cell-type specific, being almost 
complete in fibroblasts but relatively small in leucocytes. This thesis reports the 
research done on the impact of LIMP-2 deficiency on GCase in human and mice. 
The availability of fluorescent activity-based probes (ABPs), which sensitively 
label GCase molecules, allowed a detailed investigation of the residual GCase activity 
in AMRF samples. It was re-confirmed with ABP labelling that leukocytes of AMRF 
patients contain relatively high residual GCase, contrary to fibroblasts. It was 
observed that a substantial amount of GCase was incorrectly secreted by AMRF 
fibroblasts into the medium. In accordance, inspection of AMRF plasma revealed 
increased GCase activity. Since GCase rapidly loses its enzymatic activity at neutral 
pH condition, as in plasma, it is not recommended to use plasma GCase 
measurement for laboratory diagnosis of AMRF. A close examination of 
glycosphingolipids in AMRF fibroblasts using LC-MS/MS analyses pointed to 
increased levels of glucosylsphingosine (GlcSph), likely formed by de-acylation of 
accumulating GlcCer. GlcSph was also increased in the plasma of AMRF patients 
and LIMP-2 Knock-out mice. Since AMRF patients lack the chitotriosidase, seen in 
Gaucher disease (GD), detection of increased plasma GlcSph in the absence of 
elevated chitotriosidase in an individual is an indication for AMRF. Demonstration of 
markedly reduced GCase activity in fibroblasts points to the diagnosis AMRF, which 
can be further, substantiated with the sequencing of the SCARB2 gene. 
Next, the lysosomal proteome of hepatocytes from LIMP-2 KO mice was 
analyzed. It was found that only GCase is absent among the soluble matrix lysosomal 
SUMMARY/RESUMO 
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proteins detected. Next, in various tissues of WT and LIMP-2 KO mice, GCase was 
studied by measurement of enzymatic activity as well as by labelling with selective 
fluorescent ABPs. Deficiency of GCase protein and activity was noted in almost all 
organs. Recapitulating findings for AMRF patients, it was observed that LIMP-2 KO 
mice show a marked tissue dependence regarding GCase reduction. Whereas liver 
and pancreas contain very little residual GCase, enzyme levels are relatively high in 
brain and leukocytes.  Subsequent investigation of sphingolipids in tissues of WT and 
LIMP-2 KO mice showed no significant elevations in GlcCer. However, a correlation 
was noted between increased GlcSph levels and the extent of GCase reduction in 
various tissues. It seems that cellular deficiency of GCase caused by LIMP-2 defects 
is compensated by deacylation of GlcCer to GlcSph. The lipid abnormalities develope 
rapidly in LIMP-2 KO mice: already at 2 months of age animals show an extreme 
increase in GlcSph in various tissues and its levels do not increase further with age. 
The observed ability of LIMP-2 KO mice to avoid prominent GlcCer storage in tissues 
likely explains the lack of prominent pathological abnormalities in the animals. 
Analysis of tissues of LIMP-2 KO mice revealed the presence of increased amounts 
of cholesterol-glucoside (GlcChol), a recently discovered metabolite, suggesting that 
GCase normally largely degrades glucosylated sterol.  
The marked differences in clinical symptoms of AMRF and GD patients are 
likely due to the absence of “Gaucher cells” in AMRF patients and their prominent 
presence in GD patients. The cause for this prominent difference was further 
investigated. It was observed a considerable uptake through (dynamin-dependent) 
endocytosis of GCase from the medium by AMRF lymphoblasts, but not fibroblasts. 
Based on this observation, it seems likely that in AMRF patients the re-uptake of 
secreted GCase from plasma by leukocytes and macrophages may render sufficient 
GCase activity in these cells to prevent formation of “Gaucher cells” and 
accompanying visceral symptoms.  
At present, there is still no treatment available for AMRF. Since LIMP-2 
deficiency in AMRF causes a secondary GCase deficiency, present therapies for GD 
were examined for potential use in AMRF patients. For GD enzyme replacement 
therapy (ERT) and substrate reduction therapy (SRT) are registered treatments. 
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AMRF fibroblasts and mannose-receptor expressing LIMP-2 deficient HEK293T cells 
were exposed to recombinant GCase, to mimic ERT. After uptake of GCase into 
LIMP-2 deficient lysosomes, the stability of the enzyme was strongly reduced as 
compared to normal cells. This difference disappeared upon inhibition of lysosomal 
cathepsins with leupeptin. This suggests that LIMP-2 stabilizes the fold of GCase 
inside lysosomes by transient interactions, and consequently protects it against 
proteolytic breakdown. Thus, LIMP-2 has a dual action as transporter and as 
intralysosomal chaperone of GCase. For this reason, recombinant GCase cannot be 
used to treat LIMP-2 deficiency.  However, one of the new recently developed brain-
permeable and potent GCS inhibitors, biphenyl-pentoxy-ido-deoxynojirimycins, was 
given to LIMP-2 KO mice to analyze their feasibility as a treatment. The applied 
amount of compound was too small to render prominent reduction of 
glycosphingolipids in the animals. Higher doses will have to be tested to establish 
therapeutic efficacy in LIMP-2 KO mice.  
In conclusion, the work here presented has rendered several new insights 
regarding LIMP-2 and its deficiency causing AMRF. It has resulted in a novel 
procedure for differential laboratory diagnosis of AMRF, it has offered an explanation 
for the different clinical outcome of secondary GCase deficiency in AMRF as 
compared to primary GCase deficiency in GD, it has rendered indications for an 
important stabilizing interaction of LIMP-2 and GCase inside lysosomes, and finally it 
has generated a rational basis for future development of a substrate reduction based 
treatment of AMRF.   
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RESUMO  
 
Uma das mais abundantes proteínas da membrana do lisossoma, a proteina 
integral da membrana do lisossoma, tipo 2 (LIMP-2) contribui para a biogénese e 
manutenção do sistema endossoma/lisossoma. Para além desta função, a LIMP-2 é 
responsável pelo transporte específico da recém formada glucocerebrosidase 
(GCase) para o lisossoma, que por sua vez é responsável pela degradação da 
glucosilceramida (GlcCer). Em humanos, deficiências heriditárias na proteína LIMP-2 
estão na origem da doença Mioclonia de Acção com Falência Renal (AMRF). Os 
doentes com AMRF apresentam uma redução dos níveis celulares de GCase. No 
entanto, esta redução célula-dependente, sendo praticamente total em fibroblastos e 
relativamente baixa em leucócitos. Nesta tese é apresentado o estudo sobre o 
impacto que a deficiência em LIMP-2 tem na GCase, em humanos e em ratinho. 
O recente desenvolvimento de sondas específicas de actividade (ABP), 
bastante sensíveis, que detectam GCase activa, permitiram um estudo detalhado 
sobre a actividade residual de GCase em doentes de AMRF. Confirmou-se, através 
do uso das ABPs, que os leucócitos destes doentes têm uma actividade 
remanescente bastante alta quando comparada com a obtida em fibroblastos. Foi 
observado que níveis significativos de GCase eram secretados para o meio de 
cultura de fibroblastos. Em concordância, foi verificado que os os doentes de AMRF 
apresentam um aumento da actividade de GCase no plasma. No entanto, como esta 
actividade decresce rapidamente devido ao pH neutro, a sua medição no plasma não 
é recomendada para efeitos de diagnóstico da doença AMRF. 
O estudo de glicosesfingolipidos em fibroblastos de doentes de AMRF 
demonstrou que existe um aumento de glucosilesfingosina (GlcSph), provavelmente 
formada pela de-acilação da glucosilceramida acumulada. A glucosilesfingosina 
também se encontra acumulada no plasma de doentes de AMRF assim como no 
ratinho LIMP-2 KO. Uma vez que os doentes de AMRF não apresentam aumento de 
quitotriosidase como os doentes da doença de Gaucher (GD), o aumento de 
glucosilesfingosina detectado na ausência do aumento de quitotriosidase aponta 
para um diagnóstico de AMRF. O diagnóstico pode ser confirmado pela actividade 
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reduzida de GCase em fibroblastos, acompanhado da sequenciação do gene 
SCARB2.  
O subsequente estudo do proteoma lisossomal de hepatócitos revelou que, 
entre as enzimas lisossomais solúveis identificadas,  apenas a proteína GCase está 
ausente no ratinho LIMP-2 KO. Foi analisada a actividade da GCase através da 
medição actividade e do uso de ABP em vários tecidos de ratinho WT e LIMP-2 KO, 
o que revelou que esta se encontra reduzida em quase todos os tecidos de ratinho 
de LIMP-2 KO analisados. O ratinho LIMP-2 KO parece recapitular os resultados 
previamente obsercados, ao apresenta uma deficiência em GCase dependente do 
tipo celular. A deficiência em GCase pode ser correlacionada com os níveis de 
acumulação de GlcSph, mas não com a acumulação de GlcCer. Tal sugere que a 
redução da actividade de GCase, resultante da deficiência em LIMP-2, é 
compensada pela de-acilação de GlcCer para GlcSph. Estas alterações lipídicas são 
desenvolvidas rapidamente no ratinho LIMP-2 KO, uma vez que aos 2 meses os 
níveis máximos são atingidos. A análise dos tecidos provenientes do ratinho LIMP-2 
KO revelou um aumento, comparativamente com o ratinho WT, de colesterol-
glucosídeo (GlcChol), um metabolito recentemente descoberto, sugerindo que a 
GCase é responsável pela degradação de esterois glucosilados. 
 A diferença fenotípica entre doentes de AMRF e de GD deve-se 
essencialmente à ausência de “células de Gaucher” nos doentes de AMRF e à sua 
abundante presença nos doentes de GD. A causa para tal diferença foi investigada e  
foi observado que GCase é endocitada do meio de cultura no caso dos linfoblastos e 
não no caso dos fibroblastos, por um processo dependente de dinamina. Este 
resultado, sugere que os leucócitos e os macrófagos re-absorvem a GCase que foi 
secretada, o que providencia actividade enzimática suficiente para prevenir o 
aparecimento das “células de gaucher” e os sintomas viscerais que as acompanham. 
Presentemente não existe qualquer tratamento para a doença AMRF. No entanto, 
como a deficiência em LIMP-2 origina uma depleção secundária de GCase, os 
tratamentos disponivéis para a GD, foram avaliados para o tratamento da doença 
AMRF. Para a GD estão disponíveis dois tratamentos: o tratamento de substituição 
enzimática (ERT) e o de redução de substrato (SRT). Fibroblastos e células 
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HEK293T deficientes em LIMP-2, transfectadas com com receptores manose, foram 
cultivadas na presença de GCase recombinante para simular a ERT. Verificou-se 
que após a absorção de GCase recombinante, esta apresenta uma menor 
estabilidade nas células deficientes em LIMP-2 comparativamente com as células 
controlo. Esta diferença desaparece quando as células são tratadas com um inibidor 
de catepsinas, a leupeptina. Tal sugere que a LIMP-2 tem uma dupla função: 
transporta a GCase para o lisossoma e funciona como chaperone intralisossomal, 
estabilizando a GCase dentro do lisossoma, evitando a sua degradação proteolítica. 
Assim, a ERT não é uma opção válida para tratar doentes com AMRF. Um dos 
recém desenvolvidos inibidores da glucosilceramida sintetase, da classe dos bifenil-
pentoxi-ido-deoxinojirimicinas, que consegue atravessar a barreira hemato 
encefálica, foi administrado ao ratinho LIMP-2 KO, para testar a sua eficácia como 
tratamento. Contudo, a concentração usada não foi a mais adequada, não 
conduzindo a reduções significativas nos níveis glicosesfingolipidos nos animais 
tratados. Para testar a sua eficácia como tratamento aplicável a doença de AMRF, 
concentrações maiores terão que ser testadas. 
 Em conclusão, o trabalho aqui apresentado demonstra novos detalhes sobre a 
proteína LIMP-2 e a sua deficiência que origina a doença AMRF. Descreve uma nova 
metodologia de diagnóstico diferencial para a doença AMRF, fornecendo uma 
explicação para as diferenças clínicas observadas entre a deficiência secundária em 
GCase observada na doença AMRF e a deficiência primária em GCase na doença 
de GD. É igualmente descrito o papel importante da LIMP-2 na estabilização da 
GCase na matriz lisossomal e finalmente apresenta as bases científicas para um 
futuro tratamento da doença AMRF com base na redução de substrato. 
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ABBREVIATIONS 
 
4-MU-TCT – 4-methylumbelliferyl β-DNN'N''-triacetylchitotrioside  
4-MU-β-D-Glc – 4-methylumbelliferyl-β-D-glucopyranoside   
aa – amino acid 
ABP – Activity based probe 
AF – Abdominal fat 
AG – Adrenal gland 
AMRF – Action myoclonus renal failure 
AP – Adaptor protein 
BAT – Brown adipose tissue 
BBB – Blood brain barrier 
BM – Bone marrow 
BSA – Bovine serum albumin 
CBE – conduritol β-epoxide  
CD36 – Cluster of differentiation 36 
DMEM – Dulbecco’s modified Eagle’s medium 
EBV – Epstein-Barr virus 
EF – Epidydimal fat 
EP – Epidydimis 
ER – Endoplasmic reticulum 
ERAD –Endoplasmic reticulum associated degradation 
ERT – Enzyme replacement therapy 
EV71 – Enterovirus 71 
FACS – Fluorescence-activated cell sorting 
FBS – Fetal bovine serum 
FDG – Fluorescein di-β-D-glucopyranoside  
FSGS – Focal and segmental glomerular sclerosis 
Gb3 – Globotriaosylceramide 
GCase – Glucocerebrosidase 
GCS – Glucosylceramide synthase  
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GD – Gaucher Disease 
GlcCer – Glucosylceramide 
GlcChol – Cholesterol-glucoside 
GlcSph – Glucosylsphingosine 
GM2 – Ganglioside monosialic 2 
HEK293T – Human embryonic kidney 293 (HEK293) cells (ATCC CRL 1573) 
hrGBA – Human recombinante GBA (Cerezyme®) 
IF – Inguinal fat 
LAMP-2 – Lysosome associated membrane protein 2 
LIMP- 2 – Lysosomal integral membrane protein, type 2 
LIMP-2 KO mice – LIMP-2 knock-out mice 
LMP – Lysosomal membrane protein 
LN – Lymph node 
LSD – Lysosomal storage disorder 
M6P – Mannose-6-phosphate 
M6PR – Mannose-6-phosphate receptor 
MBP – Myelin basic protein 
MPS – Mucopolysaccharidoses 
NPC – Niemann Pick disease, type C 
OF – Omental fat 
OPA – o-phthaldialdehyde 
PBMC – Peripheral blood mononuclear cells/Leukocytes/White blood cells 
PBS – Phosphate buffered saline 
PD – Parkinson disease 
PI4K – Phosphatidylinositol 4 kinases 
PME – Progressive myoclonic epilepsy 
PMP – Peripheral myelin protein  
RPMI – Roswell park memorial institute medium 
SCARB2 – Scanvenger receptor class B, member 2 
SDS-PAGE – Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SG – Salivary gland 
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SN – Sciatic nerve 
SPE – Solid phase extraction 
SRT – Substrate reduction therapy 
TBS – Tris-buffered saline 
TE – Testis 
TGN – Trans golgi network 
THP-1 – Human acute monocytic leukemia cell line 
WT – Wild type 
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1.1. Lysosomes 
 
Lysosomes were firstly described in 1955 by Christian De Duve [1]. They are 
ubiquitous, single membrane bound, organelles specialized in the degradation of 
macromolecules. Lysosomes are viewed as the terminal station of the 
endosomal/lysosomal system of cells. They are distinguished from endosomes by 
their lack of recycling mannose-6-phosphate receptors (M6PR) [2] and by their 
heavily glycosylated membrane containing glycan-rich integral membrane proteins [3, 
4].  
Macromolecular substrates for degradation reach the lysosome either by 
autophagy or endocytotic events like pinocytosis, phagocytosis or receptor-mediated 
endocytosis involving clathrin-coated vesicles or by early endosomes and late 
endosomes [5–7].  Intralysosomal digestion is accomplished by the sequential and 
coordinated, action of individual hydrolases, each one with a unique specificity 
towards a particular chemical linkage. Lysosomes constitute 0.5 - 5% of the total cell 
volume and are located close to the microtubule centers. Lysosomes normally 
present a mean size of 1 µm diameter but they can reach several µm, depending on 
their content and the stage of the lysosomal degradation process [6, 8]. They are 
important in supplying the cell with building blocks released from macromolecule 
degradation, like amino acids (aa), nucleotides, fatty acids and sugars that are re-
used in biosynthesis [9–11]. Their lumen is characterized by presenting a very low 
pH, ranging from 4.0 to 5.0, which is maintained by the vacuolar membrane proton 
pump. This V-type H+-ATPase actively translocates protons against the gradient from 
the cytosol into the lysosome [12–14]. The acid intralysosomal pH provides an 
optimal environment for the action of more than 50 distinct lysosomal hydrolases 
(phosphatases, nucleases, glycosidases, proteases, sulfatases, and lipases) [15]. 
Moreover, it promotes denaturation of protein substrates, thus increasing the 
efficiency of their proteolytic breakdown.  
The protein constituents of the lysosomal membrane are integral membrane 
glycoproteins that prevent leakage and protect the cell from toxic release of protons 
and lysosomal hydrolases [16, 17]. The physiological importance of lysosomes is 
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illustrated by the existence of several inherited metabolic disorders that result from 
the malfunction of the lysosome in general or specific catabolic hydrolases. More than 
50 inherited lysosomal storage disorders (LSDs) are presently known. Most are the 
result of an impairment of a catabolic enzyme, leading to the accumulation of the 
corresponding specific substrate or substrates and subsequent pathology [18]. 
Besides their role in macromolecule turnover, lysosomes are also essential for other 
processes like degradation of phagocytosed microorganisms, cholesterol 
homeostasis, cell death regulation by cathepsins and repair of plasma membrane 
[19–21].  
Recently, it is has been recognized that lysosomes also play a key role in 
metabolism. Lysosomes act as an important cellular sensor of the cellular nutrient 
status. Attached to the surface of lysosomes is a key regulator of cellular metabolism, 
the mechanistic/mammalian target of rapamycin (mTOR) [22]. This is crucially 
involved in cellular responses to nutrient availability. Amongst others, mTOR 
regulates the nuclear location of the transcription factor EB (TFEB), the transcription 
factor that controls the rate of lysosome biogenesis and autophagy [23]. Another 
recently identified crucial role of lysosomes is the efflux of Ca2+ to the cytosol [13, 24].  
 
1.2. Lysosomal biogenesis 
 
Lysosomal proteins are synthesized at the endoplasmic reticulum (ER). 
Correct trafficking of newly formed lysosomal proteins from ER via the Golgi 
apparatus is an essential step in lysosomal biogenesis and crucial to the maintenance 
of the lysosomal function [15, 25, 26]. Soluble lysosomal matrix proteins are all 
synthesized at the ER. They are imported co-translationally into the lumen of the ER 
and their N-terminal signal sequence (20-25 aa) is cleaved after termination of 
translation by a ER resident signal peptidase [27, 28].  Inside the ER, the newly 
formed proteins fold into their correct conformation. Misfolded proteins are usually 
removed by the ER associated protein degradation (ERAD) machinery and targeted 
to degradation in the cytosolic proteasomes [29, 30]. Correctly folded soluble 
lysosomal proteins leave the ER to traverse the Golgi apparatus from cis to trans 
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cisternae. Already co-translationally in the ER, lysosomal proteins acquire N-linked 
glycans which are covalently attached to specific asparagine residues. This co-
translational glycan modification is crucial for correct folding of the newly formed 
protein in the ER, and its subsequent receptor-mediated sorting and transport to the 
lysosome (see section below for the recognition mechanism and receptors involved) 
[31, 32]. After passing through the Golgi apparatus, newly formed soluble lysosomal 
proteins reach the Trans Golgi Network (TGN). From this sorting location, receptor-
bound lysosomal proteins reach the endosomal/lysosomal system by different routes 
[7]. In acid pre-lysosomal (endosomal) structures, dissociation of soluble lysosomal 
proteins from their transport receptors occurs, the latter returning to the TGN to bind a 
new round of newly formed lysosomal proteins [33]. 
 
1.2.1. Mannose-6-phosphate recognition signal-mediated transport of newly 
synthesized acid hydrolases to lysosomes 
 
In mammalian cells, targeting of most soluble lysosomal matrix proteins, like 
the acid hydrolases, is mediated by the presence of a specific recognition signal in 
their N-linked glycans, the mannose-6-phosphate (M6P) moieties, recognized by 
M6PR.  The attachment of one or more M6P residues on N-linked glycans of soluble 
lysosomal proteins occurs shortly after entry in the cis Golgi apparatus [4]. The 
addition of M6P groups in glycans is a multi-step process. The enzyme N-
acetylglucosamine-1-phosphotransferase first generates a N-acetylglucosamine-
phosphate group, followed by N-acetylglucosamine-1-phosphodiesterase, which 
removes the capping N-acetylglucosamine, generating M6P [34–36]. The exposed 
M6P groups of soluble lysosomal proteins are then recognized in the TGN by M6P 
receptors. Following binding, the receptor-ligand complex is targeted to pre-lysosomal 
compartments [37]. M6PR are type 1 transmembrane proteins, containing a dileucine 
signal [DXXLL] in their cytosolic domain [15, 38]. In mammalian cells, two M6PR 
occur in the late TGN [39]. One is the M6PR46 dimer (46 kDa), which is cation 
dependent (also named CD-MPR) and it has only one M6P binding site. M6PR300 
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(300 kDa), is cation independent (also named CI-MPR) and has two M6P binding 
sites [6, 40].  
After the binding of lysosomal proteins to M6PR, these complexes are packed 
into clathrin-coated vesicles. These structures then traffic to the endo-lysosomal 
system, directly or via plasma membrane. After exposure to the relatively low pH of 
late endosomes, dissociation of lysosomal proteins from the recycling M6PR takes 
place [41]. In late endosomes and lysosomes, phosphate residues are removed from 
M6P groups by the lysosomal acid phosphatase [4, 42, 43]. A small proportion of both 
M6PR are also present at the plasma membrane, but only the M6PR300 seems to be 
involved in endocytosis of extracellular lysosomal enzymes.   
An important role in sorting to lysosomes is played by the so-called adapter 
proteins (AP), in particular AP-1 and AP-2. The AP-1 and GGAs (Golgi localized, γ-
ear-containing, Arf-binding family of proteins) mediate transport from the TGN to the 
endo/lysosomal system [44]. The AP-1 complex interacts with the cytoplasmic tail of 
M6PR [45, 46]. Four binding motifs were identified in the cytoplasmic tail: a tyrosine-
based motif (26YSKV29), an internal dileucine-based motif (39ETEWLM44), and two 
casein kinase 2 (CK2) sites (84DSEDE88) and (154DDSDED159). The YSKV motif 
mediats the strongest interaction with AP-1, and the two CK2 motifs bound AP-1 only 
when they are phosphorylated. The C-terminal dileucines are not required for 
interaction with AP-1 [47]. The AP-2 complex, on the other hand, mediates 
endocytotic trafficking of M6PR from the cell surface via clathrin-coated vesicles. AP-
2 interacts with tyrosine sorting signals in the cytoplasmic tail of M6PR [15]. 
 
1.2.2. Mannose-6-phosphate independent transport 
 
In several cell types (e.g. fibroblasts), most soluble lysosomal proteins are 
targeted to the lysosome in M6P dependent manner. However, it is also clear that 
many proteins may reach lysosomes in a M6P independent manner. For example, 
lysosomal membrane proteins (LMP) do not acquire M6P moieties. Their features and 
transport to lysosomes is discussed in section 1.4.1. Specific proteins such as 
lysosomal acid phosphatase and glucocerebrosidase (GCase) use a unique 
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mechanism to reach lysosomes as it is discussed below. Finally, in some cell types 
like hepatocytes, many soluble lysosomal proteins manage to reach lysosomes 
independently of the M6P sorting mechanism [48].  
The first indications for sorting mechanisms of newly formed lysosomal 
proteins were provided by the LSD Mucolipidosis type II (ML II) (I-cell disease, OMIM 
252500) [49]. This disease is caused by mutations in the gene encoding N-
acetylglucosamine-1-phosphotransferase (GNPTG, EC 2.7.8.17) that is important for 
the addition of M6P groups [50, 51]. While total loss of N-acetylglucosamine-1- 
phosphotransferase activity results in ML II, a partial reduction in its activity causes 
ML III, also known as pseudo-Hurler polydystrophy (OMIM 252600). In both cases, 
the lack of M6P in lysosomal enzymes causes faulty intracellular sorting and 
secretion from cells [52]. The generalized lack of hydrolases in lysosomes in certain 
cells, like fibroblasts of ML II and ML III patients, causes massive storage of multiple 
non-degraded substrates, the so-called inclusion bodies [53]. The same phenomenon 
occurs in the mouse model of ML II disease deficient in GPNTG [54]. However, both 
in ML II and III patients and in ML II mice, some soluble lysosomal proteins are 
correctly sorted to lysosomes of hepatocytes and other cell types despite the lack of 
M6P moieties in lysosomal proteins. The molecular basis for this alternative transport 
has not yet been established. Several examples of M6P independent transport of 
lysosomal matrix proteins are known in fibroblasts. As mentioned above, one 
example is the lysosomal acid phosphatase. This initially membrane bound enzyme is 
targeted as such to the plasma membrane and thereafter transported to lysosomes 
through endocytosis, via its tyrosine-based motif YRHV present in its cytosolic 
domain [55]. Inside the lysosome, the enzyme is partly released as a soluble protein 
through proteolytic cleavage. Another example is GCase, the lysosomal acid β-
glucoside (GCase, E.C.3.2.1.45), encoded by the GBA gene. Its levels are normal in 
I-cell fibroblasts and its N-linked glycans never acquire M6P groups [56]. The 
lysosomal integral membrane protein type 2 (LIMP-2) was identified as the 
responsible protein for transport of GCase to lysosomes [57]. As described in more 
detail in section 1.4.2.1, LIMP-2 binds GCase in the ER and releases the enzyme at 
acid pH in lysosomes [58]. 
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Alternative M6P independent transport mechanisms have also been described 
for other lysosomal enzymes like acid sphingomyelinase and cathepsins D and H.  
The type I transmembrane protein sortilin has also been proposed to be involved in 
targeting of some lysosomal proteins trought this alternative routing [59, 60]. There is 
more compelling evidence for an active role of sortilin in the transport to lysosomes of 
GM2 activator protein and prosaposin, the precursor of the small molecular weight 
sphingolipid activator proteins saposin A-D [61]. GM2 activator protein assists in the 
degradation of the ganglioside GM2 by β-hexosaminidases [62, 63]. Saposins 
enhance the activity of lysosomal hydrolases towards sphingolipid substrates by 
favouring the access to their hydrophobic lipid substrates. This facilitating action is 
essential for β-galactocerebrosidase (by saposin A), GCase (by saposin A and C), 
arylsulfatase A (by saposin B), α-galactosidase A (by saposin B) and 
sphingomyelinase (by saposin D) [64, 65]. The physiological importance of activator 
proteins is illustrated by the outcome of genetic deficiencies. For example, patients 
with a mutated saposin C develop a similar phenotype to those with a GCase 
deficiency [66]. 
 
1.3. Lysosomal storage disorders 
 
LSDs are individually rare diseases, but as group they affect about 1 in 5,000 
live births [67]. The prevalence in Portugal is similar, being about 1 in 4,000 live births 
[68]. However, the true incidence can exceed this due to misdiagnosed/undiagnosed 
cases.  Besides defects in soluble hydrolases, LSDs can also be caused by defects in 
non enzymatic accessory proteins like activator proteins, transporters or proteins 
involved in post-translational modifications and trafficking of lysosomal proteins [5, 33, 
69]. Lysosomes may also be defective due to mutations in structural membrane 
components, like the lysosome associated membrane protein 2 (LAMP-2) or LIMP-2, 
impairing mobility of lysosomes and their fusion with other cellular structures including 
autophagosomes [70, 71].  LSDs are generally still classified according to the nature 
of the substrate stored (Table 1.1).  The traditional classification discerns:  i) 
sphingolipidoses (sphingolipid accumulation); ii) mucopolysaccharidoses 
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(glycosaminoglycan accumulation); iii) oligosaccharidoses (oligosaccharide 
accumulation); iv) defects in membrane proteins and v) others [72].  
Most LSDs are inherited in an autosomal recessive manner, with the exception 
of Fabry, Hunter and Danon diseases, being X-linked disorders [73]. LSDs usually 
display a very diverse clinical phenotype, manifesting as infantile, juvenile or adult 
forms. The clinical presentation of LSDs is heterogeneous, depending of the primary 
defect, the nature of the substrate and the affected organs, in particular the possible 
involvement of the central nervous system. Many patients with LSDs are 
asymptomatic at birth and young age, leading to a delay of several years until the 
correct diagnosis is made. Although many LSDs may present some characteristic 
neurological involvement, others entirely lack it, like Fabry disease and type 1 GD 
[72].  Prediction of severity of an LSD based on genotyping is increasingly employed. 
For some diseases, particular mutations in the corresponding gene result in a 
complete absence of enzymatic activity and therefore a severe disease while others 
result only in a slight decreased deficiency and milder clinical presentation. However, 
for several LSDs it is recognized that predictions of disease severity based on 
genotype are not accurate. Patients with the same mutant genotype can sometimes 
exhibit very different clinical symptoms and disease severity [74–76]. Although the 
genetic and biochemical background of the majority of the LSDs are well described, 
the way lysosomal storage interferes with other metabolic pathways and impairs cell 
function is still unknown. For most LSDs, it is still enigmatic how epigenetic and/or 
external factors can influence their progression [77, 78].  
Sphingolipidoses comprise the most prevalent group of LSDs. These disorders 
result from a block in lysosomal degradation of sphingolipids due to an enzymatic 
deficiency. In sphingolipids, sphingoid bases are acylated with a fatty acid. These 
ceramide structures can carry hydrophilic headgroups (e.g. phosphorylcholine in the 
case of sphingomyelin, carbohydrate residues in the case of glycosphingolipids, and 
a phosphate moiety in the case of ceramide-1-phosphate). Glycosphingolipids are 
important components of cellular membranes and are expressed in a cell-type 
specific pattern [79, 80]. The presence of sialic acids in glycosphingolipids underlies 
their classification into neutral or acidic types [81, 82]. Major classes are gangliosides 
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and globosides. The shared precursor of most glycosphingolipid series is 
glucosylceramide (GlcCer). This lipid is synthesized at the cytoplasmic face of the 
Golgi membrane by the transfer of a glucose moiety from UDP-glucose to ceramide 
by the enzyme glucosylceramide synthase (GCS) (E.C. 2.4.1.80). [83]. All 
subsequent complex glycosphingolipids are the result of a stepwise addition of sugars 
to GlcCer in the lumen of the Golgi [5, 84, 85].  
Degradation of glycosphingolipids largely occurs in lysosomes by sequential 
action of specialized glycosidases, ultimately rendering ceramide which on its turn is 
cleaved into sphingosine and free fatty acid by acid ceramidase [5, 84, 85].  
Deficiencies in one of multiple glycosidases are the cause of various 
sphingolipidoses. The most frequent sphingolipidosis is Gaucher disease (GD). This 
recessively inherited disease is caused by deficiency in GCase, which degrades 
GlcCer intralysosomally [86]. In most GD patients with a non-neuronopathic disease, 
GlcCer storage is most prominent, even exclusive, in tissue macrophages [87]. The 
features and therapy of GD are described below in more detail in sections 1.3.1 and 
1.3.2. Another prevalent sphingolipidosis is Fabry disease, in which 
globotriaosylceramide (Gb3) accumulates as the result of a deficient activity of α-
galactosidase A [88]. Both in GD and Fabry disease, the primary storage lipids are 
partly converted to the corresponding sphingoid bases which are markedly elevated 
in plasma: glucosylsphingosine (GlcSph) from GlcCer in Gaucher patients and 
lysoGb3 from Gb3 in Fabry patients [89].  Lysosomal sphingolipid accumulation may 
also be caused indirectly. For example, accumulation of another substrate in 
lysosomes may interfere with local degradation of sphingolipids as occurs in 
Niemann–Pick disease type C (NPC). Defects in the lysosomal membrane protein 
NPC1, which mediates the efflux of cholesterol from lysosomes, not only leads to 
accumulation of cholesterol, but also to storage of sphingomyelin, several 
glycosphingolipids, sphingosine and others lipids [84, 90]. 
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Table 1.1 – Lysosomal storage disorders. Adapted from [72].  
 
 DISORDERS ENZYME OR CO-FACTOR DEFICIENCY MAIN STORAGE COMPOUNDS 
S
ph
in
go
lip
id
os
is
 
Fabry α-galactosidase A Gb3 and blood-group-B compounds 
Farber lipogranulomatosis Ceramidase Ceramide 
Gaucher 
β-glucocerebrosidase Glucosylceramide/ 
Glucosylsphingosine Saposin-C activator 
GM1 gangliosidosis β-galactosidase GM1 ganglioside 
GM2 
gangliosidosis 
GM2-activator protein 
deficiency GM2-activator protein GM2 ganglioside and related 
glycolipids Sandhoff β-hexosaminidase A and B 
Tay Sachs β-hexosaminidase A 
Niemann-Pick A and B Sphingomyelinase Sphingomyelin 
Sphingolipid activator protein S  Sphingolipid activator Glycolipids 
    
M
uc
op
ol
ys
ac
ch
ar
id
os
es
 
(M
P
S
) 
Morquio A disease N-acetylglucosamine-6-sulphatesulphatase Keratan sulphate, chondroitin-6-sulphate 
Morquio B disease β-galactosidase Keratan sulphate 
MPS I (Hurler, Scheie, Hurler/Scheie) α-iduronidase 
DS and HS 
MPS II (Hunter) Iduronate-2-sulphatase 
MPS III (Sanfilippo) 
  A Heparan N-sulphatase (sulphamidase) 
HS 
  B N-acetyl-α-glucosaminidase 
  C Acetyl-CoA:α-glucosamide N-acetyl transferase 
  D N-acetylglucosamine-6-sulphatase 
MPS VI (Maroteaux-Lamy) N-acetylgalactosamine-4-sulphatase (arylsulphatase B) DS 
MPS VII (Sly) β-glucuronidase HS, DS, chondroitin-4-sulphate, chondroitin-6-sulphate 
    
O
lig
os
ac
ch
ar
id
os
is
 
Pompe 
 
(glycogen storage disease type II) 
α-glucosidase Glycogen 
    
D
ef
ec
ts
 in
 m
em
br
an
e 
pr
ot
ei
ns
 
Cystinosis Cystinosin Cystine 
Danon disease LAMP-2 Cytoplasmic debris and glycogen 
Infantile sialic-acid-storage disease Sialin Sialic acid 
AMRF LIMP-2 Glucosylsphingosine 
Mucolipidosis IV Mucolipin-1 Lipids and acid mucopolysaccharides 
Niemann-Pick C NPC1 and NPC2 Cholesterol and sphingolipids 
Salla disease Sialin Sialic acid 
   
O
th
er
s 
Galactosialidosis Cathepsin A Sialyloligosaccharides 
ML II (I-cell and pseudo-Hurler polydystrophy) N-acetylglucosaminyl-1-phosphotransferase Oligosaccharides, mucopolysaccharides and lipids 
Multiple sulphatase deficiency Cα-formylglycine-generating enzyme Sulphatides 
   
Batten disease 
NCL1 CLN1 (protein palmitoylthioesterase-1) Lipidated thioesters 
NCL2 CLN2 (tripeptidyl amino peptidase-1) Subunit c of the mitochondrial ATP 
synthase NCL3 Arginine transporter 
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1.3.1  Gaucher disease 
 
GD is the most frequent sphingolipidosis in Portugal with a prevalence of 1.4 
per 100,000 live births [68]. A patient suffering from this recessively inherited disease 
was firstly described in 1982, by the French dermatologist Philippe Gaucher. GD 
results from a deficiency in the lysosomal hydrolase GCase, which is responsible for 
the intralysosomal hydrolysis of GlcCer into ceramide and glucose [87]. GCase is 
encoded by the GBA gene that has been mapped to chromosome 1q21 [91, 92].  The 
GBA gene is 7.5 kb long and contains 11 exons [93]. The enzyme consists of 497 aa, 
with 4-5 occupied N-glycosylation sites, with the mature glycosylated form with a 
molecular weight of 65 kDa [87]. A highly homologous pseudogene sequence located 
16 kb downstream from GBA gene has also been described, presenting 96% of 
homology [93]. GCase does not acquire M6P residues in order to be sorted into 
lysosome [94], instead, its targeting to lysosomes is mediated by the LIMP-2 [57]. 
More than 200 different mutations have been described in GBA gene [95]. The most 
common mutation is the N370S aa substitution, constituting 70% of the mutant alleles 
within Ashkenazi Jews and 25% worldwide [96]. Presence of GBA N370S in patients, 
even in heteroallelic state, is sufficient to prevent neurological manifestations as seen 
in types 2 and 3 GD patients. Another common GBA mutation is the L444P aa 
substitution. In this case, the enzyme folds poorly in the ER and is largely degraded 
via ERAD [95, 97, 98]. Homozygosity for GBA L444P is associated with 
neuronopathic (type 2 or 3) GD [87]. Despite these trends, a strict GBA genotype - 
GD phenotype correlation does not exist [99, 100].  
GD presents a large phenotypic variability, ranging from death at birth to 
asymptomatic adults [76]. The traditional classification of GD is based on presence 
and  the age of onset of neurological involvement [87]. Most common is the non-
neuronopathic type 1 GD (OMIM 230800), characterized by the absence of 
neurologic involvement and with a very variable age of onset. Type 1 GD has a 
frequency of 1:50,000 - 200,000 births, but is more prevalent in the Ashkenazi 
population (1:1,000 births) [68, 101]. Type 2 GD (OMIM 230900), is characterized by 
the development of severe neurological symptoms at infancy, with a survival 
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prognosis of less than two years. In type 3 GD (OMIM 231000), neuronopathic 
degeneration usually starts at the end of the first decade of life [87]. The neuropathic 
forms (types 2 and 3) comprises only 5 - 10% of GD births in Caucasians [102]. 
Complete absence of GCase activity leads to serious skin problems incompatible with 
life. Such cases are called  "collodion babies " [103, 104].   
GD is a multi-systemic disorder affecting most organs, resulting in cytopenia, 
hepatosplenomegaly and skeletal abnormalities [87, 105]. Bone involvement is the 
most disabling feature of adult GD patients and causes pain, immobility, bone 
fracture, frequently followed by infection and osteomyelitis [106]. Several attempts 
have been made to generate a genuine mouse model of GD presenting symptoms 
similar to Gaucher patients, however the GBA knock-out mice proved to be inviable 
[107–110]. Introduction of common aa substitutions in GBA mouse did not lead to a 
phenotypic copy of human disease, but resulted in far more severe disease in the 
animals. The best phenocopy of type 1 GD in mice is obtained by inducible knock-out 
of GCase expressed in the white blood cell lineage [111, 112].  
Although the enzymatic activity of GCase is reduced in all cell types, only 
macrophages store large amounts of GlcCer in their lysosomes. The morphology of 
the lipid-laden macrophages is very characteristic and they are referred to as 
“Gaucher cells”. In type 1 GD, “Gaucher cells” are the hallmark of the disease [113, 
114]. The prominent GlcCer storage in macrophages has been explained by the 
relatively large load of glycosphingolipids on the endo/lysosomal system of these 
cells. Macrophages phagocytoze old and damaged erythrocytes and leukocytes rich 
in glycosphingolipids [87]. Since “Gaucher cells” are the hallmark of GD disease, it is 
not surprising that the biomarkers discovered for GD manifestation are proteins that 
are selectively produced by alternatively activated macrophages. Such proteins are 
chitotriosidase, a chitinase, and CCL18, a chemokine, being on average 1000- and 
40-fold elevated, respectively, in the plasma of symptomatic type 1 GD patients [115, 
116]. The primary storage lipid in GD, GlcCer, is only modestly increased in plasma of 
symptomatic patients. Moreover, in most cell types of GD patients, abnormalities in 
GlcCer are not detected. A possible explanation for the modest GlcCer abnormalities 
is the deacylation of GlcCer to GlcSph. In plasma of type 1 GD patients, GlcSph is 
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200-fold increased [116, 117]. GlcSph was earlier noted to be increased in brain of 
type 2 and 3 GD [118, 119]. It is assumed that GlcSph is formed by intralysosomal 
deacylation of GlcCer by acid ceramidase (Ferraz et al, to be published). A type 3 GD 
like phenotype is observed in patients suffering from specific mutations in the 
prosaposin gene [64, 66, 120].  
 
1.3.1.1 Pathologies associated with Gaucher disease 
 
In recent years it has been recognized that some pathologies are linked to GD 
or GCase deficiency. It has been proposed by some clinical researchers that GD 
patients suffer from a significantly increased risk for cancer, particularly leukemias 
[121]. This is not unexpected since gammopathies occur frequently in GD patients, 
pointing to chronic stimulation of B cells [122]. Unexpected is the relatively recent 
finding that deficiency of GCase imposes a risk factor of α-synucleinopathies like 
Parkinson disease  (PD) and Lewy-Body dementia [123–125].  
Of interest, not only GD patients but even carriers of mutated GBA alleles are 
at increased risk for these neurodegenerative disorders. The exact mechanism by 
which GCase abnormalitiy promotes α-synuclein aggregation and the corresponding 
pathology is not known. However, evidence is present that GCase and α-synuclein 
may interact with each other and that abnormalities in GCase may drive a 
pathological cascade [126]. In brain of a neuronopathic GD mouse model, α-synuclein 
deposits are noticed and introduction of GCase by gene therapy ameliorates the 
aggregate [127, 128]. The same therapeutic effect has been noticed in a mouse 
model of PD [129].  
Studies on GCase have enormously profited from the development of specific 
antisera and monoclonal antibodies since the eighties. These tools allowed new 
insights in the life cycle of the enzyme and have assisted in problematic diagnostic 
questions. Very recently, a completely novel research tool became available, the so-
called activity-based probes (ABP), named inhibodies [130]. These probes are 
cyclophellitol epoxides with a fluorescent tag. They resemble the known suicide 
inhibitors of GCase, conduritol-β-epoxide (CBE) and cyclophellitol, that covalently, 
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and irreversibly, bind to the catalytic nucleophile (E340) in the pocket of GCase [131]. 
These inhibody probes covalently label only active GCase molecules. Due to their 
amphiphilic nature, inhibodies spontaneously cross membranes by diffusion, allowing 
GCase labelling in vivo in cells and mice. The availability of such probes allows 
therefore investigations on GCase in a disease condition [131–134]. The inhibodies 
can be also employed in diagnosis through the quantification of active GCase enzyme 
molecules [131]. Future applications may include in vivo monitoring of trace amounts 
of infused inhibody labelled therapeutic enzyme in GD patients. In this way the tissue 
distribution of the costly therapeutic enzyme may be non-invasively followed in 
individual patients. Finally, the generation of highly specific cyclophellitol epoxide type 
GCase inhibitors offers new possibilities to generate GD research animal models 
(mice, zebrafish).  
 
1.3.1.2 GBA2 and Gaucher disease 
 
Lysosomal GCase is not the only cellular enzyme that can degrade GlcCer. 
Researchers in Amsterdam firstly noticed the existence of a non-lysosomal 
glucosylceramidase, now known as GBA2 [135]. This enzyme is not related to GCase 
and is encoded by a separate gene, the GBA2 located on chromosome 9p13.3 [135, 
136]. GBA2 degrades GlcCer in the cytosolic leaflet of membranes, but the precise 
cellular location of the enzyme is not entirely clear since it has been claimed to be 
associated with endosomes [137] as well as with the ER [138]. The levels of GBA2 
tend to be increased during GCase deficiency in GD patients [139] as well as in the 
modest GCase reduction in NPC [140, 141]. It has been speculated that 
compensatory over activity of GBA2 occurrence during reduced GCase activity, 
results in the formation of toxic levels of ceramide in the cytosol [142]. Inhibition of 
GBA2 might, in view of this, exert positive effects. Indeed, Mistry and colleagues 
demonstrated that genetic loss of GBA2 has beneficial effects in GD mice [143]. 
Consistent with this, a beneficial protective effect on Purkinje cell loss and associated 
deterioration of motor coordination has been noted in NPC mice upon genetic loss of 
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GBA2, as well as with pharmacological inhibition of GBA2 activity (Marques et al, 
unpublished results). 
 
1.3.2  Therapy of Lysosomal storage disorders as illustrated by Gaucher 
disease 
 
GD has been a frontrunner among the LSDs in development of therapy. Until 
twenty-five years ago, the only treatments available for GD were interventions to treat 
specific symptoms like splenectomy and hip replacement. Few patients were 
subjected to bone marrow transplantation in the eighties. Successes were reported, 
but this invasive procedure was rarely used given the high mortality risk associated 
[144].  
Nowadays, there are two registered therapies for type 1 GD: enzyme 
replacement therapy (ERT) and substrate reduction therapy (SRT). Since tissue 
macrophages are the sole pathological cells in GD patients without neurological 
involvement, the so-called type 1, Brady and colleagues considered specific 
supplementation of these cells with lacking GCase. For this purpose, they developed 
a macrophage targeted human enzyme containing N-linked glycans with terminal 
mannose moieties, thus allowing selective endocytotic uptake by mannose receptors 
expressed at the surface of tissue macrophages [145, 146].  
Initially, enzyme was isolated from human placenta and enzymatically modified 
in glycan structure. In 1994, recombinant enzyme became available for ERT of type 1 
GD [147]. The ERT treatment implies bi-weekly intravenous administration of 
enzyme. As treated patients register reduction of organomegaly, pancytopenia and 
amelioration of skeletal disease, the clinical response is very satisfactory [145, 148]. 
Several recombinant enzyme preparations, including one produced in carrot cells, are 
now registered for ERT of type 1 GD. However the costs of the treatment remain very 
high (exceeding 200.000 €/adult patient/year) [149–151].  
The success of ERT for GD, led to the development of several other 
recombinant enzymes for treatment of LSDs as it is the case of Fabry [152], Pompe 
[153], MPSI [154], MPSII [155], MSPVI [156] and Morquio IV A [157]. The remarkable 
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clinical success of ERT for type 1 GD, unfortunately it is not observed for most of the 
other disorders. Despite the success of ERT in type 1 GD, some limitations of the 
approach have become apparent. Most importantly, ERT is not able to prevent 
neurological symptoms in Gaucher patients with a neuronopathic course of disease 
(types 2 and 3). This failure is ascribed to the inability of the 60 kDa enzyme to pass 
the blood brain barrier (BBB).   
As alternative to ERT, SRT was developed [158, 159]. SRT aims to reduce 
glycosphingolipid overload by inhibiting GCS. The first generation of suitable GCS 
inhibitors was azasugar, which mimics GlcCer. N-butyl-deoxynojirimycin (Zavesca®, 
miglustat, Actelion) was registered as therapeutic SRT drug for type 1 GD [160]. 
Clinical studies have revealed that oral SRT with Zavesca® is able to treat visceral 
symptoms in mild to moderately affected type 1 GD patients [160, 161]. However, 
Zavesca® is a relatively poor GCS inhibitor and high doses are poorly tolerated due to 
off target side effects. Prevention of neuropathology in type 2 or 3 GD patients with 
Zavesca® treatment is not feasible [162]. A new generation of more potent inhibitor 
iminosugars, resembling ceramide, has been designed. Very recently, Eliglustat, a 
low nanomolar GCS inhibitor was registered for SRT of type1 GD [163, 164]. Recent 
clinical investigations reported very beneficial clinical responses in patients, such as 
reduced organomegaly and hematological improvements [165, 166]. Again, Eliglustat 
offers no solution for neuronopathic GD patients since the compound is actively 
removed from the brain. To generate brain permeable GCS inhibitors, series of 
biphenyl-substituted iminosugars of both configurations (D-gluco and L-ido) have 
been designed [167]. One of these, it is the 1307RB20, which is very promising, 
showing an IC50 of 2.5 nM for GCS and not affecting GCase (IC50 >5 µM) (Fig. 1.1) 
[167]. The same compound also inhibits GBA2 (IC50= 0.6 nM). Such inhibition is 
thought to be beneficial in individuals with reduced GCase activity (see section 
1.3.1.2).   
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Figure 1.1 – Structure of the GCS inhibithor compound, the 1307RB20. 
 
Under investigation are two other approaches to treat GD: chaperone therapy 
and gene therapy. Pharmacological chaperones are low molecular weight chemical 
compounds that through interaction with the catalytic pocket of GCase assist in the 
correct protein folding and stabilization of this proper fold. This approach is used in 
patients carrying specific mutated forms of GCase.  A successful chaperone should 
increase the amount of mutant GCase that reaches lysosomes and improve 
degradative capacity [168]. Trials regarding gene therapy of type 1 GD were already 
conducted in the early nineties. The approach is based on ex vivo correction of 
hematopoietic stem cells with genetic information to produce the correct GCase and 
their subsequent re-introduction in patients. Technical limitations have hampered 
earlier attempts, but presently, approaches employing new generation lentiviral 
constructs have rendered very promising results in genuine type 1 GD mouse models 
[169]. Since gene therapy offers a cure, rather than chronic therapy, the outcome of 
translation of experimental gene therapy in mice to application in GD patients is 
eagerly awaited.  
 
1.4. Lysosomal membrane proteins 
 
The lysosomal membrane has a peculiar composition, being extremely rich in 
carbohydrates linked to membrane proteins, in cholesterol and with a characteristic 
phospholipid composition [170, 171]. Several LMPs have been identified by proteomic 
approaches [172–174].  The four most abundant LMP are LAMP-1 and 2, and  LIMP-
1 and 2 [70], representing approximately 50% of total LMPs. The LMPs generate a 
thick glycocalyx, which is thought to protect the limiting lysosomal membrane from 
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destruction by the luminal acid hydrolases. In addition, the integrity of the lysosomal 
membrane is essential to protect the cell against leakage of harmful components from 
the interior of the lysosome [70].  
LAMPs are type I transmembrane proteins with a large luminal ectodomain 
and a short homologous cytoplasmic tail. LIMPs, on the other hand are type III 
transmembrane proteins [33, 70, 174]. The LMPs not only fulfil a structural role in the 
limiting lysosomal membrane but are also implicated in the sorting of lysosomal 
enzymes, fusion of lysosomes with other organelles, integrity of the 
endosomal/lysosomal compartment, transport of metabolites across the lysosomal 
membrane into the cytoplasm and chaperone mediated autophagy [70] .  
 
1.4.1 Sorting of lysosomal membrane proteins to lysosomes 
 
LMPs reach the lysosomes in different ways.  One route is direct and runs from 
the TGN directly to endosomes and subsequently to lysosomes. The alternative route 
is indirect and involves routing trought plasma membrane via the secretory pathway, 
hereafter via endocytosis, reaching the lysosomes [175, 176]. In both cases, the 
transport of LMPs is dependent on tyrosine (YXX) or dileucine motifs (DXXLL) sorting 
signals, located in their cytoplasmic tail [7]. While LAMPs and LIMP-1 use the tyrosine 
motif, LIMP-2 requires the dileucine DXXLL motif in its cytoplasmic domain for 
efficient routing to lysosomes [177, 178]. These sorting signals in the cytoplasmic tails 
of LMPs are recognized by cytosolic APs, which are involved in the targeting to the 
lysosome [177, 179].  
 
1.4.2  LIMP-2 
 
Lysosomal integral membrane protein type 2 (LIMP-2) is encoded by the 
SCARB2 gene. The gene is also known as CD36L2, HLGP85 and LIMPII.  It was 
firstly identified and biochemically characterized in 1985, without a specific function 
attributed to it [176]. As a type III transmembrane protein, LIMP-2 spans twice the 
lysosomal membrane, with its N-terminal and C-terminal both located in the cytosol 
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[180]. The luminal portion of LIMP-2 protein is highly conserved and contains a 
coiled-coil domain [57, 181, 182]. LIMP-2 is palmitoylated at cysteine residues, further 
anchoring it in the membrane [183].  
LIMP-2 belongs to the cluster of differentiation 36 (CD36) superfamily, which 
includes several cell adhesion proteins, lipid receptors and other LMPs [184]. LIMP-2 
is ubiquitously expressed in cells [185] and presents a 34% aa homology with the 
multifunctional CD36 [186]. CD36 is involved in binding of collagen, thrombospondin, 
erythrocytes parasitized with plasmodium falciparum, platelet aggregation, oxidized 
low density lipoproteins, native lipoproteins, oxidized phospholipids and long chain 
fatty acids [186, 187]. Another member of the CD36 scavenger receptor family is 
CLA1/SCARB1 isoform 1 (SR-BI) and its splice variant CLA2/SCARB1 Isoform 2 (SR-
BII). Both proteins are involved in the import of cholesterol and cholesterol esters 
from HDL particles [188]. SR-BI and CD36 are both linked to lipid transport and are 
equipped for this with a presumed tunnel. Homology modelling suggests the presence 
of a similar tunnel in LIMP-2, which is conserved from zebrafish to man [189].  
The SCARB2 gene coding for LIMP-2 protein is located on the human 
chromosome 4 in the region 4q21.1 [190]. The gene comprises 52.7 kb and contains 
12 exons. The human SCARB2 and the mouse LIMP-2 gene have a sequence 
identity of 84% at the nucleotide level and 85% at the aa level [191]. The cDNA 
encodes a protein of 478 aa, with a predicted molecular weight of 53 kDa. The real 
molecular weight of LIMP-2 is 73-85 kDa as the result of extensive N-glycosylation at 
potential 11 sites [180, 191–193]. The glycosylation of LIMP-2 is essential for its 
correct folding, sorting, lysosomal localization and stability [58, 194]. The C-terminal 
cytoplasmic tail of LIMP-2 has 20 aa, which contains the di-leucine motif (L475, I476) 
essential for sorting [195]. In the case of the LIMP-2, AP-3 mediates its intracellular 
sorting [196–198]. Mutations within the conserved consensus motif lead to the 
incorrect localization of the protein at the plasma membrane [195, 199]. Other 
mutations can also lead to its incorrect localization. For example, these LIMP-2 
mutant forms may accumulate at early and late endosomes, or even, be retained in 
the ER [58, 185, 200, 201]. Surprisingly, a recent study suggests that LIMP-2 
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acquires M6P moieties [202]. The significance of this finding is questioned particularly 
since in I-Cell disease GCase is correctly targeted to the lysosome [56, 202]. 
 
1.4.2.1 Glucocerebrosidase and LIMP-2 
 
Studies by Reijnbout et al. indicated that newly synthesized GCase soon gets 
membrane bound in the ER [203, 204]. The responsible membrane bound receptor 
remained enigmatic for several decades. Only in 2007, LIMP-2 was identified as the 
protein responsible for the targeting of GCase to the lysosome [57]. Binding of GCase 
to LIMP-2 occurs in the ER and disruption of the complex takes place at acidic pH, 
characteristic of late endosomes and lysosomes lumen [58] (Fig. 1.2). The highly 
conserved coiled-coil domain (aa 150-167) in the luminal domain was shown to bind 
to GCase [194]. The histidine residues in the coiled coil domain, particularly H171, 
are responsible for the pH dependence binding of GCase to LIMP-2. At acid pH the 
histidines are protonated and GCase is released from LIMP-2 [58]. Recently, Zhao et 
al. have claimed that H150 is also important in the pH dependent binding of GCase to 
LIMP-2 [202]. Moreover, it has been reported that two phosphatidylinositol 4 kinases 
(PI4K) are important in the trafficking of the LIMP-2/GCase complex to the lysosome: 
PI4KIIα and PI4KIIIβ. PI4KIIIβ was proposed to be involved in the transport through 
the complex in the Golgi apparatus, while PI4KIIα would be important to transport of 
the complex between TGN and late endosomes or lysosomes [205, 206]. 
 
 
Figure 1.2 – Schematic representation of GCase sorting in wils type (WT) and LIMP-2 (-/-) deficient cells. “EL/LL” - Early and 
late endosome; “Lyso” – Lysosome; “ER” - Endoplasmatic reticulum. 
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1.4.2.2 LIMP-2 KO mice 
 
In mice, the LIMP-2 gene is located on chromosome 5 [190]. Saftig and co-
workers, following their discovery of some of the functions of LIMP-2 protein, 
generated a LIMP-2 KO mouse [190]. The animals show increased postnatal mortality 
due to the hydronephrosis [190]. The main pathological change in the kidney, uni- or 
bilateral hydronephrosis, develops variably at the age of 3-16 months. It is caused by 
mislocalization of the protein uroplakin in the coating cells of the urothelium. In the 
LIMP-2 KO mice, uroplakin cannot protect the epithelium of the bladder and ureter 
from the acid urine and, consequently, there is hyperproliferation of the 
urothelium. This process leads to pathological thickening, causing reflux of urine into 
the kidney [190]. LIMP-2 KO mice also develop deafness and peripheral neuropathy 
[190]. The deafness and numbness of LIMP-2 KO mice might be due to 
mislocalization of the potassium channel KCNQ1, β-subunit KCNE1, and megalin in 
the stria vascularis of the inner ear, which contributes to the atrophy of the stria 
vascularis and collapse of the endochochlear potential [207]. The neuronal changes 
result from demyelination of the peripheral nervous system. The myelin proteins, the 
myelin basic protein (MBP) and the peripheral myelin protein 22 (PMP22), that are 
involved in the stability and in the strength of the concentric rings of myelin, are 
decreased in the LIMP-2 KO mice [190]. Characteristic of the LIMP-2 KO mice is the 
increased diameter of the peripheral nerves, next to the reduced number of fibers 
[190]. The same phenomenon occurs in the hereditary neuropathy Charcot-Marie-
Tooth Disease. The so-called onion bulbs are formed due to hypomyelination of the 
peripheral nervous system and Schwann cell hypertrophy, resulting in constant de- 
and re-myelination. This results in reduced nerve conduction velocity and impaired 
muscle reflexes [208, 209]. LIMP-2 deficient Schwann cells also present abnormal 
inclusions and vacuoles in their cytoplasm [190]. Some changes observed in the brain 
of LIMP-2 KO mice are comparable to those seen in LIMP-2 deficient patients, such 
as intracellular deposits and inclusion bodies similar to those observed in certain 
cases of ataxia [210, 211]. 
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1.4.2.3 LIMP-2 and Action Myoclonus Renal Failure Syndrome 
 
LIMP-2 deficiency causes the Action Myoclonus Renal Failure Syndrome 
(AMRF, OMIM 254900). This autosomal recessive disorder has been unequivocally 
shown to be due to mutations in the SCARB2 gene [194, 201, 210, 212, 213]. AMRF 
was initially described in Canada [214] and years later several patients were identified 
in  other countries like Australia, Canada, Italy, Germany and Portugal [194, 201, 210, 
212, 213, 215–218]. Nowadays, a wide spectrum of mutations in LIMP-2 has been 
identified, ranging from missense to nonsense mutations [194, 201, 210, 213, 215–
217, 219] (Table 1.2). As in other LSDs, no strict genotype-phenotype correlation 
seems to exist [220]. 
 
Table 1.2 – Mutations in the SCARB2 gene causing AMRF. 
MUTATION  NUCLEOTIDE CHANGE  TYPE  REFERENCE 
       
IVS10DS, G-T, +1  1239+1G-T  Splice-site mutation; premature truncation  [210] 
2-BP INS, 435AG  c.435_436insAG  Frameshift, premature truncation  [210] 
G288X  c.862C-T  Nonsense  [210] 
W178X  c.533G-A  Nonsense  [201] 
IVS8AS, A-C, -2  1116-2A-C  Intron mutation  [213] 
1-BP DEL, 1258  c.1258delG  Nonsense  [213] 
1-BP INS, T, IVS9  1187+3insT  Intron mutation  [221] 
 
AMRF shows major phenotypic heterogeneity, including patients presenting 
classical features of the disease without any renal involvement [213, 216, 217, 222, 
223]. However, most AMRF patients present renal dysfunction and failure due to focal 
glomerulosclerosis [210, 224]. In addition, they show myoclonic epilepsy and ataxia 
with progressive neurological impairment [201, 210, 212, 217]. The neurological 
symptoms usually appear between 15-25 years of age [220]. Patients first manifest 
tremors, which develop to progressive myoclonus, generalized seizures and later to 
ataxia. In postmortem brain biopsies, an extra brown pigment accumulation was 
detected. No cognitive deficit is noted [212, 216, 217]. AMRF patients, like LIMP-2 KO 
mice, develop neurological and renal symptoms [190, 210, 218].  
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1.4.2.4 LIMP-2 and other pathologies 
 
Besides causing AMRF, SCARB2 mutations also can influence the severity of 
GD manifestations. The heteroallelic SCARB2 mutation was found to cause 
neuronopathic GD in patients with a GBA genotype normally associated with non-
neuronopathic type I disease [225]. LIMP-2 is also partly present at the plasma 
membrane. There, it acts as a receptor for the Coxsackievirus [226, 227] and 
enterovirus 71 (EV71) [228, 229], that are responsible for causing Hand-Foot-Mouth 
Disease [230]. The region 142-204 aa of LIMP-2 protein was identified as essential 
for EV71 binding [231].  
LIMP-2 is also important in the activation of the innate immune system during 
infection with Listeria monocytogenes by influencing the transport of bacteria to the 
phagosome [232]. It also acts as a functional receptor of β-catenin and N-cadherin 
within the intercalated discs of the cardiac muscle cells, and consequently linked to 
cardiac hypertrophy and heart failure [233]. For unknown reasons, LIMP-2 expression 
is found to be correlated with regeneration of injured sensory spinal axons [234].  
Finally, mutations in the SCARB2 gene, like those in the GBA gene, have been 
reported to impose an increased risk for developing PD [235]. In addition to this, 
LIMP-2, like GCase, has been shown to play an important role in the progression and 
development of α-synucleinopathies [236, 237].  
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AIMS 
AMRF is caused by mutations in the SCARB2 gene encoding the lysosomal 
membrane protein LIMP-2. It has been recognized that LIMP-2 takes care of the 
transport of newly synthesized GCase to lysosomes where it degrades the 
glycosphingolipid GlcCer. In AMRF patients, a cell type dependent reduction of 
GCase activity occurs: GCase being markedly reduced in fibroblasts, but not in 
leukocytes.  
In this thesis work, investigations are described on the function of LIMP-2, with 
focus on its crucial interaction with GCase.  The consequences of LIMP-2 deficiency 
for GCase are broadly examined. In the reported investigations, besides AMRF 
patient’s materials, use is made of LIMP-2 KO mice. GCase is investigated with 
classical research tools and new ones like ABPs. The lipid metabolites of GCase are 
studied with novel LC-MS/MS based measurements.  
In chapter 2, the cell-type specific deficiency are analyzed in different type of 
cells either by using classic methods as well as the new developed ABP tools. 
Special attention is given to the fate of GCase in cultured fibroblast of AMRF patients, 
demonstrating partial secretion of active enzyme into the medium. Since 
phenotypically GD and AMRF are very distinct diseases, but share a common 
deficiency in GCase, glycosphingolipid GlcCer and its deacylated form GlcSph are 
measured in different samples.  With the obtained results, a differential laboratory 
diagnosis is suggested for the correct and accurate identification of AMRF and GD 
patients.  
In chapter 3, LIMP-2 KO mice are used to study the impact of the lysosomal 
membrane protein on GCase at cellular and tissue level. Highly purified lysosomes of 
hepatocytes from LIMP-2 KO mice are analyzed to identify new binding partners of 
LIMP-2. Since it is described a cell-type specific deficiency in AMRF patients as 
extensive biochemical analysis are performed regarding GCase activities. 
Subsequently, a correlation of the activities measured and its effect on direct and 
indirect catabolic pathways is evaluated. Attention is also paid to the cause of the 
high residual GCase activity in white blood cells of LIMP-2 mice, recapitulating 
findings in AMRF patients.  
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In chapter 4, investigations are described that aim to establish directions for 
treatment of AMRF. The impact of LIMP-2 on the efficacy of restoring lysosomal 
GCase capacity by exposure of cells to recombinant enzyme is described. Pilot 
studies on the use of substrate reduction by means of oral administration of a brain 
permeable inhibitor of glycosphingolipid synthesis are described. 
The outcome of the various investigations and the envisioned future directions 
of research are discussed in the conclusions chapter.   
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3.1 Abstract 
 
The LIMP-2 has been identified as the receptor involved in the intracellular 
sorting and trafficking of the enzyme GCase to lysosomes. Deficiency of LIMP-2 
causes AMRF. Fibroblasts of AMRF patients virtually lack GCase similarly to cells of 
patients with GD. GD is caused by mutations in the GBA gene encoding GCase, and 
is characterized by the accumulation of GlcCer-laden macrophages. Recently 
developed fluorescent ABPs allow a sensitive and specific visualization of active 
GCase. Using these probes, we show that GCase is incorrectly secreted in AMRF 
fibroblasts, leading to markedly reduced levels of active enzyme in those cells. In 
contrast, AMRF leukocytes present almost normal intracellular GCase levels. Our 
findings are consistent with the lack of lipid-laden white blood cells and the absence 
of increased plasma levels of macrophage markers such as chitotriosidase in AMRF 
patients, in contrast to Gaucher patients.  We further evaluated the consequences of 
LIMP-2 deficiency with respect to plasma glycosphingolipid levels. Plasma GlcCer 
concentration was normal in the AMRF patients investigated as well as in LIMP-2 KO 
mice. However, a marked increase in the sphingoid base GlcSph was observed in 
AMRF patients and LIMP-2 KO mice. Our results suggest that combined 
measurements of chitotriosidase and GlcSph can be used for convenient differential 
laboratory diagnosis of AMRF and GD. 
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3.2  Introduction 
 
Lysosomes contain a variety of integral membrane proteins among which the 
most abundant are LAMP-1, LAMP-2 and LIMP-2 [33]. Defects in LMPs may result in 
several pathologies [70]. An example are mutations in the LIMP-2 gene (SCARB2) 
causing AMRF, a fatal recessively inherited disorder characterized by 
glomerulosclerosis, progressive myoclonus epilepsy, ataxia and accumulation of 
undefined storage material in the brain [57, 194, 201, 210, 211, 238]. More recently it 
has become clear that not all AMRF patients develop renal complications [213, 217, 
222, 223].   
It has been demonstrated that LIMP-2 deficient fibroblasts of AMRF patients 
lack the lysosomal enzyme GCase, whereas this appears not to be the case for their 
white blood cells [201]. The transport of newly formed GCase to lysosomes has been 
an enigma for a long time. Earlier, it had been observed that GCase does not acquire 
M6P moieties [56]. GCase is not deficient in fibroblasts of ML II and III patients which 
suffer from defects in the formation of M6P recognition signals [56]. In contrast, most 
soluble lysosomal enzymes are incorrectly secreted in these fibroblasts since their 
sorting is dependent on M6PR [33]. GCase was shown to become membrane bound 
in the ER by interaction with an unknown protein [203, 204]. Only a few years ago the 
receptor protein was identified as LIMP-2 [57].   
GCase, an acid β-glucosidase, catalyzes the lysosomal degradation of GlcCer 
into ceramide and glucose. GD is caused by mutations in the GBA gene encoding 
GCase. GD is clinically very heterogeneous, ranging from severe neonatal variants to 
very mild variants with onset at old age. The most common phenotype is the non-
neuronopathic type 1, showing almost exclusive storage of GlcCer in tissue 
macrophages, the so-called “Gaucher cells” [114]. These lipid-laden macrophages 
accumulate in various tissues, such as spleen, liver, bone marrow and lung, resulting 
in clinical symptoms of which cytopenia, hepatosplenomegaly and skeletal 
abnormalities are the most prominent [87]. These “Gaucher cells” secrete a variety of 
cytokines and hydrolases [239]. Of interest, AMRF patients do not show the massive 
occurrence of lipid-laden macrophages and some of the characteristic clinical 
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symptoms of the GD patients [218]. Consistently, plasma chitotriosidase, a biomarker 
of Gaucher cells, is normal in AMRF patients but several hundred-fold elevated in GD 
patients [115, 201]. This suggests that their macrophages are not deficient in GCase. 
These findings point to cell-type specific consequences of LIMP-2 deficiency. Another 
biochemical characteristic of GD is the several hundred-fold increased plasma 
concentration of the sphingoid base GlcSph [117]. The sphingoid base is likely 
formed from accumulating GlcCer in GCase deficient cells.  
GCase is a low abundant protein, particularly in leukocytes and difficult to 
detect with antibodies [240]. To study more closely GCase in leukocytes of AMRF 
patients, we employed novel ABPs that allow visualization of active GCase molecules 
[130, 131, 133]. It was recently shown that epoxides like CBE and cyclophellitol form 
a covalent bond with the nucleophile E340 in GCase. Attaching a BODIPY moiety 
through a linker to C6 of cyclophellitol resulted in an even more potent irreversible 
inhibitor of GCase. Different ABPs have been designed by variation of the BODIPY 
(MDW941, Inhibody Red; and MDW933, Inhibody Green) that allow ultrasensitive 
detection of GCase in cell types containing enzyme levels below the level of detection 
by antibodies. The probes have also the ability to spontaneously cross membranes  
allowing in vivo labelling studies [131]. The availability of ABPs allowing sensitive 
detection GCase in leukocytes prompted us to study the fate of GCase in different cell 
types obtained from AMRF patients as well as from LIMP-2 KO mice. 
GCase is very unstable at neutral (plasma) pH and rapidly loses its enzymatic 
activity. This reduces the ABP labelling, since active enzyme molecules are required 
for labelling. More recently, an other ABP has been designed for labelling GCase, 
MDW1033 (Anybody Green), which besides labelling active enzymes also labels 
enzyme molecules that have lost enzymatic activity, but conserved their structure 
[133].  
Here, we report the outcome of these investigations, confirming cell-type 
specific decreases in GCase caused by LIMP-2 deficiency. Furthermore, we studied 
the consequence of LIMP-2 deficiency for GlcCer and GlcSph levels, the products of 
degradation by GCase. In this chapter, we also highlight the outcome and possible 
use in differential diagnosis of AMRF and GD. 
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3.3 Methods 
3.3.1 Activity-based probes, anybody and antibodies 
 
MDW941 (Inhibody Red), MDW933 (Inhibody Green) and MDW1033 (Anybody 
Green) were synthesized as described earlier [131, 133]. The rabbit polyclonal anti-
LIMP-2 antibody was acquired from Novus Biologicals, Littleton, USA (NB400-129). 
 
3.3.2 Patients’ samples 
 
Materials from donors were obtained after informed consent. Leukocytes and 
fibroblasts were obtained from AMRF patients homozygous for the SCARB2 mutation 
W178X [201], LIMP-2 obligate carriers of the same mutation, Gaucher patients with 
the GBA genotype L444P/L444P and control subjects. Fibroblasts obtained from skin 
biopsies were cultured in Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal bovine serum, 2 mM L-glutamine, 1% penicillin–streptomycin, 100 mg/ml 
kanamycin sulfate and 2.5 mg/ml fungizone (Gibco, Invitrogen). Cells were harvested 
when reaching confluence. Leukocytes were isolated from whole blood as described 
earlier [201].  
Monocytes were isolated with CD14 MicroBeads (Miltenyi Biotec) according to 
the manufacturer’s protocol. Isolated monocytes were differentiated into 
macrophages for 7 days in Roswell Park Memorial Institute medium (RPMI) 
supplemented with 10% human AB serum [115]. 
 
3.3.3 Mice 
 
Mice were housed and plasma was collected according to the local protocol 
approval from the review board of the Christian-Albrechts-University in Kiel 
(Germany). LIMP-2 KO mice were generated as described earlier [190].  
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3.3.4 Preparation of cell lysates 
 
Isolated fibroblasts, macrophages and leukocytes were homogeneized in 
potassium phosphate buffer (PBS) (25 mM, pH 6.5, 0.1% (v/v) Triton X-100). Protein 
was quantified with a BCA Kit (Thermo Scientific). Cell extracts were prepared by 
sonication (40% power, 40% amplitude for 6 s). All homogenates were stored at -80 
ºC. 
 
3.3.5 Labelling with activity-based probes 
 
Cell homogenates were incubated with MDW941 (100 nM) in McIlvaine buffer 
(150 mM citrate-Na2HPO4, pH 5.2, 0.2% (w/v) sodium taurocholate, 0.1% (w/v) Triton 
X-100) for 30 min at 37 ºC. Subsequently proteins were denatured with 5x Laemmli 
buffer (50% (v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) DTT, 10% (w/v) 
SDS, 0.01% (w/v) bromophenol blue) by boiling for 10 min at 100 ºC, and separated 
by electrophoresis on 10% acrylamide (w/v) SDS-PAGE gels running at 90 V [131, 
133]. Wet slab gels were scanned for red fluorescence using a Typhoon variable 
mode imager (Amersham Bioscience), λex 532 nm and λem 610 nm (band pass filter 
30 nm). 
Fibroblasts were incubated with MDW941 (5 nM) for 72 h. Subsequently, the 
culture medium was collected and the cells were harvested. Detection of fluorescent 
GCase in the culture medium was performed as described above upon capture of 
enzyme from 1 ml of medium using monoclonal antibody 8E4 immobilized in 
Sepharose beads [94]. 
For Fluorescence-Activated Cell Sorting (FACS), fibroblasts and macrophages 
were incubated with MDW933 (50 nM) for 5 h in the medium. Cells were harvested 
with 0.25% Trypsin prior analysis. 
In the case of white blood cells, the leukocyte layer was collected from freshly 
drawn blood by centrifugation for 10 min at 2500 rpm. The remaining erythrocytes 
were lysed with lysis solution 0.8% (w/v) ammonium chloride at 4 ºC. Leukocytes 
were next incubated with MDW933 (100 nM) during 30 min in phosphate buffered 
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saline containing 1% (w/v) bovine serum albumin. FACS analysis was performed with 
a FACS Calibur Becton Dickinson (B.D. Bioscience), λex 488 nm, λem 530 nm (band 
pass filter 30 nm) [131]. 
 
3.3.6 Western-Blotting 
 
SDS–PAGE gels were electroblotted onto a nitrocellulose membrane 
(Schleicher&Schuell®). Membranes were blocked with 5% skimmed milk and 0.05% 
Tween-20 in Tris-buffered saline (TBS) for 1 h at room temperature and incubated 
overnight with the primary antibody at 4 °C. Membranes were then washed three 
times with 0.01% Tween-20 in TBS and incubated with the appropriate IRDye 
conjugated secondary antibody for 1 h at room temperature. After washing, detection 
was performed using the Odyssey® Clx, Infrared Imaging System (LI-COR). 
 
3.3.7 Measurement of in vivo glucocerebrosidase activity 
 
GCase activity in intact cells was measured using fluorescein di-β-D-
glucopyranoside (FDG) as a substrate (20 µM for fibroblasts and 40 µM for 
leukocytes and macrophages). Cells were suspended by trypsinization and analyzed 
by FACS exactly as described by Witte et al [131].  
 
3.3.8 Fluorescence microscopy 
 
Fibroblasts were cultured on glass slides. Cells were incubated with MDW933 
(50 nM) for 2 h in medium. Next, cells were washed, fixed with 3% (v/v) 
paraformaldehyde in PBS for 15 min, washed, incubated with 0.1 mM NH4Cl in PBS 
for 10 min and then with 3% (w/v) bovine serum albumin (BSA) and 10% (w/v) goat 
serum albumin in PBS for 1 h. Nuclei were stained with DAPI. Filter blocks used were 
A4 (360/40 nm band pass excitation, 400 nm dichromatic mirror, 470/40 nm band 
pass suppression) for DAPI and K3 (470-490 nm band pass excitation, 510 nm 
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dichromatic mirror, 515 nm long pass suppression) for MDW933. Analysis was 
performed with multispectral imaging, essentially as detailed in [131]. 
 
3.3.9 Glucosylceramide and Glucosylsphingosine measurements 
 
GlcCer and GlcSph in fibroblasts, leukocytes and plasma specimens were 
measured as described earlier [117, 241].  
 
3.3.10 Enzymatic assays  
Enzymatic assays were performed according to Aerts et al [242]. β-
Glucosidase activity was measured with 3.73 mM 4-methylumbelliferyl-β-D-
glucopyranoside (4-MU-β-D-Glc), dissolved in 150 mM McIlvaine buffer (pH 5.2 
supplemented with 0.2 % (w/v) sodium taurocholate, 0.1% (v/v) Triton X-100 and 
0.1% BSA. Chitinase enzyme was measured with 1 mM 4-methylumbelliferyl β-
DNN'N''-triacetylchitotrioside (4-MU-TCT) in a citrate/phosphate buffer, pH 5.2. After 
stopping the reaction with NaOH-glycine (pH 10.3), fluorescence was measured with 
a fluorimeter LS55 (Perkin-Elmer, Beaconsfield, UK), λex 366 nm and λem 445 nm. 
 
3.3.11 Anybody labelling 
 
GCase from fresh plasma was immunoprecipitated with the monoclonal 
antibody 8E4 immobilized in Sepharose beads according to Aerts et al [94]. After 
washing, the beads were incubated with MDW1033 (100 nM) for 30 min and then 
subjected to SDS-PAGE. Fluorescent GCase was visualized using a fluorescence 
scanner (Typhoon Variable Mode Imager, Amersham Biosciences) [131]. 
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3.4 Results 
3.4.1 Activity-based labelling of glucocerebrosidase in fibroblasts 
 
To evaluate the amount of active GCase, fibroblasts homogenates from three 
AMRF patients  (SCARB2 W178X/W178X), two LIMP-2 carriers (SCARB2 
W178X/WT), two control subjects and one type 2 Gaucher patient (GBA 
L444P/L444P) were labelled with MDW941 (100 nM) for 30 min and then subjected to 
SDS-PAGE to detect active GCase molecules. Labelled GCase was detected by 
fluorescence imaging of the slab gel (Fig. 3.1). Fibroblasts of AMRF patients showed 
a markedly reduced amount of fluorescently labelled GCase. Similarly, the amount of 
labelled enzyme is markedly reduced in cells from the type 2 GD patient. In the case 
of the carriers of LIMP-2 deficiency a normal amount of labelled GCase was detected 
when compared to control individuals. These results highlight the absence of active 
GCase in fibroblasts of AMRF patients.  
 
 
Figure 3.1 - Detection of GCase with fluorescent ABP MDW941 in homogenates from cultured fibroblasts (30 µg): labelling 
followed by SDS-PAGE and detection by fluorescence imaging. “WT” - Wild type; “AMRF” - AMRF patient (SCARB2 
W178X/W178X); “Car” - Carrier of AMRF (SCARB2 W178X/WT); “GD” - Type 2 GD patient (GBA L444P/L444P); “hrGBA” - 
Recombinant GCase (Cerezyme®); “ABP” - Activity based probe; “LIMP-2” - Western-blot against LIMP-2 protein. 
 
3.4.2 Fluorescence microscopy of glucocerebrosidase 
 
Using multi-spectral imaging analysis, which allows identifying and 
distinguishing the respective fluorescence emission spectra from autofluorescence, 
intact fibroblasts were incubated with MDW933 to visualize by fluorescence 
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microscopy the active GCase molecules (Fig. 3.2). We observed almost no labelling 
of GCase in AMRF fibroblasts when compared to the control fibroblasts (Fig 3.2). 
AMRF fibroblasts were found to be clearly deficient in lysosomal GCase when 
compared to WT, in line with the results described in Fig. 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 - Visualization of GCase with fluorescent ABP MDW933 by fluorescence microscopy. Fibroblasts were labelled in 
vivo with MDW933 and DAPI. Left micrograph: Wild type fibroblasts; Right micrograph: AMRF patient. The scale bar represents 
20 µm. 
 
3.4.3 Activity based labelling of glucocerebrosidase in leukocytes and 
macrophages 
 
Leukocyte lysates were labelled in vitro with MDW941 (100 nM) for 30 min and 
subjected to SDS-PAGE. The findings from leukocytes of an AMRF patient are very 
different from those obtained in the fibroblasts. The amount of active GCase in 
leukocytes was similar for all subjects (control, LIMP-2 deficient carrier and AMRF 
patients) (Fig. 3.3A). Western-blot analysis using anti-LIMP-2 antibody showed that 
LIMP-2 protein was expressed at higher levels in fibroblasts compared to leukocytes. 
LIMP-2 protein was decreased in fibroblasts of LIMP-2 deficient carriers when 
compared to controls (Fig. 3.1 and 3.3A). 
Next, GCase was analyzed in monocyte–derived macrophages. Monocytes 
were isolated from blood of an AMRF patient and a healthy subject, and differentiated 
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into macrophages. Detection of active GCase in homogenates of the generated 
macrophages revealed again only a slight reduction of GCase in the patient’s cells 
(Fig. 3.3B). 
 
 
 
Figure 3.3 - Detection of GCase in homogenates of leukocytes (50 µg) (A) and cultured macrophages (20 µg) (B): labelling 
followed by SDS-PAGE and detection by fluorescence imaging. “WT” - Wild type; “AMRF” - AMRF patient (SCARB2 
W178X/W178X); “Car” - Carrier of AMRF (SCARB2 W178X/WT); “hrGBA” - Recombinant GCase (Cerezyme®); “ABP” - Activity 
based probe; LIMP-2 - Western-blot against LIMP-2 protein.  
 
3.4.4 FACS analysis 
 
The amount of active GCase in intact cells was assessed by FACS analysis, 
either by labelling it with ABP MDW933 or by measuring the GCase activity with the 
substrate FDG (Fig. 3.4). The labelling of GCase in fibroblasts with MDW933 showed 
that control fibroblasts presented higher labelling when compared to the AMRF 
fibroblasts (Fig. 3.4A and 3.4C). GCase enzyme activity of fibroblasts towards FDG 
was measured using FACS (Fig. 3.4B and 3.4C). The results obtained were identical 
to those with MDW933. Control fibroblasts showed higher GCase activity when 
compared to AMRF fibroblasts. Similar experiments showed that the amount of active 
GCase is relatively high in different blood cells types of an AMRF patient, especially 
when compared to levels found in fibroblasts (Fig. 3.4C). Significant residual GCase 
levels (values >30%) were noted in lymphocytes, monocytes and cultured 
macrophages of the AMRF patient, both with ABP labelling and PFB-FDG incubation. 
The same finding was made for total leukocytes from LIMP-2 KO mice (Fig. 3.4C).  
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These results are in line with GCase enzymatic activity measured in cell 
lysates using the artificial substrate 4-MU-β-D-Glc, as it was previously published 
[201]. 
 
 
 
Figure 3.4 – FACS analysis of active GCase detected with ABP MDW933 and FDG as substrate. A: Example of FACS analysis 
of fibroblasts with ABP. Left panel: Primary FACS data (dotted line not labelled with MDW933, solid line labelled with MDW933). 
Right panel: Representative FACS dot plot. B: Example of FACS analysis of fibroblast enzymatic activity toward FDG. Similar to 
A. C: Overview of detected residual active GCase by analysis of cells with ABP and FDG. 
 
3.4.5 Secretion of glucocerebrosidase by LIMP-2 deficient fibroblasts 
 
Misrouting of GCase to lysosomes may result in its accumulation in the 
extracellular space. To study this, cultured fibroblasts were labelled with MDW941 for 
72 h and the culture medium was collected. Labelled GCase present in 1 mL of 
medium was immunoprecipitated with the anti-GCase monoclonal antibody 8E4 and 
visualized after SDS-PAGE in a fluorescent scanner (Fig. 3.5). Labelled GCase was 
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clearly detected in the medium of cells from AMRF patients and it was almost absent 
in the case of controls and LIMP-2 deficient carriers.  
 
 
Figure 3.5 – Partial secretion of GCase by fibroblasts.  Fibroblasts were labelled for 72 h with MDW941. From 1 ml medium 
GCase was immunoprecipitated with anti-GCase monoclonal antibody 8E4 immobilized in Sepharose beads. The 
immunoprecipitate subjected to SDS-PAGE and fluorescent GCase labelled with MDW941 was visualized by imaging. “WT” - 
Wild type; “AMRF” - AMRF patient (SCARB2 W178X/W178X); “Car” - Carrier of AMRF (SCARB2 W178X/WT); “hrGBA” - 
Recombinant GCase (Cerezyme®); “ABP” - Activity based probe. 
 
We next looked for the presence of GCase in the plasma of AMRF patients by 
measuring its enzymatic activity with the artificial substrate 4-MU-β-D-Glc. We noted 
an increased activity in the case of fresh specimens from AMRF patients when 
compared to healthy subjects Fig. 3.6A. Such increase was only detected in freshly 
obtained plasma. Storage of plasma, even frozen, led to inactivation of the enzymatic 
activity of GCase (in samples frozen for a long period at - 20 ºC, less than 2% of 
original GCase activity was detected). In line with the data obtained for the freshly 
AMRF patient plasma, LIMP-2 KO mice also showed increased GCase in fresh 
plasma specimens (Fig. 3.6B).  Using another sensitive probe developed, MDW1033 
(Anybody Green), a large amount of GCase was found in the plasma of AMRF patient 
upon imunoprecipitation, when compared to control plasma (Fig. 3.6C). Given the 
loss of enzyme activity in plasma, measurement of plasma GCase activity is in 
practice not a very reliable test to identify AMRF patients. 
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Figure 3.6 – Detection of GCase in the plasma specimen. Measurement of GCase activity in human plasma (A) and in mice 
plasma (B). GCase detection in human plasma using the probe MDW1033 (C). “WT” - Wild type; “AMRF” - AMRF patient 
(SCARB2 W178X/W178X); “LIMP-2 KO” - LIMP-2 KO mice; “hrGBA” - Recombinant GCase (Cerezyme®) 
 
To evaluate the macrophage involvement in the disease, chitotriosidase levels 
were measured in the plasma specimens from AMRF patients and LIMP-2 KO mice 
(Fig. 3.7). 
 
Figure 3.7 - Detection of chitotriosidase in the plasma specimen. Measurement of chitotriosidase activity in human (A) and in 
mice (B) plasma. “WT” - Wild type; “AMRF” - AMRF patient (SCARB2 W178X/W178X); “GD” - Gaucher patients; “LIMP-2 KO” - 
LIMP-2 KO mice. 
 
As it was expected, both AMRF patients and LIMP-2 KO mice didn´t present 
increased levels of chitotriosidase when compared to control samples (Fig. 3.7). 
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3.4.6. Lipid abnormalities in LIMP-2 deficiency 
 
The lack of lysosomal GCase as a result of LIMP-2 deficiency might 
theoretically result in abnormalities in GlcCer breakdown as seen in Gaucher patients. 
We therefore determined GlcCer and GlcSph concentrations in fibroblasts and 
plasma from AMRF patients as well as in plasma of LIMP-2 KO mice. 
In AMRF fibroblasts GlcCer was not elevated when compared to the control 
subjects (Fig. 3.8A). Importantly, a marked increase in GlcSph was noted (Fig. 3.9A). 
The same was found in leukocytes (Fig. 3.9B). Also in plasma of three AMRF patients 
we could detect elevated GlcSph levels (Fig. 3.9C). However, no clear concomitant 
increase in GlcCer was observed when compared to the matched control plasmas 
(Fig. 3.8B). To further validate the finding of the sphingoid base abnormality we also 
examined plasma of LIMP-2 KO mice. Again, a clear elevation in GlcSph 
concentration was observed (Fig. 3.9D).  
 
 
Figure 3.8 - GlcCer levels in fibroblasts (A) and plasma (B). “WT” - Wild type; “AMRF” - AMRF patient (SCARB2 
W178X/W178X). 
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Figure 3.9 - GlcSph content of cells and plasma. Upper panels: GlcSph (pmol/mg total protein); Lower panel: GlcSph (pmol/ml); 
(A) Fibroblasts, (B) Leukocytes, (C) Human plasma and (D) Mice plasma. “WT” - Wild type; “AMRF” - AMRF patient (SCARB2 
W178X/W178X); “GD” - Gaucher patients; “GD car” - Carriers of mutations in the GBA gene; “LIMP-2 KO” - LIMP-2 KO mice. 
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3.5 Discussion 
The intracellular sorting of GCase has been an enigma for a long time. It was 
clear that it is transported to the lysosomes independently of the M6PR system. The 
study by Reczeck and coworkers firstly revealed that the LIMP-2 mediates the 
trafficking of GCase [57]. Soon afterwards, Berkovic et al. and Balreira and 
colleagues [201, 210], demonstrated that LIMP-2 deficiency is the the basis of AMRF. 
Surprisingly, AMRF patients do not show lipid-laden macrophages, but present a cell-
type specific GCase deficiency [201, 218]. In Gaucher patients, with a primary defect 
in GCase, macrophages are particularly sensitive to store GlcCer and form the so-
called “Gaucher cells”. These cells produce and secrete unique marker proteins such 
as chitotriosidase and CCL18 [113]. In contrast, AMRF patients do not show elevated 
levels of chitotriosidase like Gaucher patients do. This suggests that macrophages in 
AMRF individuals degrade GlcCer and that GCase is correctly present in their 
lysosomes.  This paradox may be explained by our present findings. Using ABPs we 
were able to examine very sensitively GCase in leukocytes. We noted that in white 
blood cells of AMRF individuals the levels of enzymatically active GCase are almost 
normal, in sharp contrast to fibroblasts.  
Firstly, we showed that in homogenates of AMRF fibroblasts much less active 
GCase can be detected with ABP. In white blood cells and cultured macrophages this 
abnormality is far less striking. Next, we labelled intact cells with ABP and noted by 
FACS analysis that AMRF fibroblasts are markedly deficient in active GCase. 
Significant amount of active GCase was again detected in lymphocytes, monocytes 
and cultured macrophages. The same phenomenon was observed in an independent 
manner by exploiting PFB-FDG as substrate for in vivo detection of GCase enzymatic 
activity. Again, FACS analysis revealed a marked deficiency in AMRF fibroblasts, but 
considerable residual enzyme in white blood cell types. We then looked into the fate 
of GCase in fibroblasts of AMRF patients, observing that these cells abnormally 
secrete some active GCase to the medium where the enzyme rapidly loses its 
enzymatic activity. In freshly obtained plasma from AMRF patients, a labile GCase 
activity is demonstrable, either by measuring its activity or by using a different probe 
that allows labelling of GCase at higher pH, despite its inactivity. Apparently, another 
 LIMP-2 deficiency in humans: 
Action Myoclonus Renal Failure Syndrome 
64 
 
mechanism can compensate in white blood cells, but not in fibroblasts, for the 
absence of LIMP-2 and mediate the trafficking of GCase to lysosomes. The most 
likely explanation is the presence of a receptor involved in this alternative sorting of 
GCase whose identity is not yet known and warrants further investigation. It also 
cannot be discarded the possible phenomenon in which secreted GCase might be 
taken up by an endocytic process and delivered via this secretion-recapture manner 
to lysosomes of white blood cells. 
In lysosomes, assisted by the activator protein saposin C, GCase takes care of 
degradation of GlcCer. Deficiency of GCase causes formation of GlcCer storage 
tubules, most prominent in macrophages. Of interest, part of the accumulating GlcCer 
during GCase deficiency is deacylated into the sphingoid base GlcSph which can 
leave lysosomes and cells [117]. This explains the marked increase in GlcSph in 
plasma of Gaucher patients. Our investigation of GlcCer and GlcSph concentrations 
in cultured fibroblasts of AMRF patients revealed that only the sphingoid base GlcSph 
is markedly increased. In agreement, GlcSph is abnormally high in plasma of AMRF 
patients. This finding was also made with plasma specimens of LIMP-2 KO mice. 
Apparently, other cells in AMRF patients than macrophages can also form GlcSph 
during GCase deficiency, which is partly released into circulation. Our investigation 
renders a workflow suitable for laboratory diagnosis of AMRF, prior to sequencing of 
the SCARB2 gene. If markedly increased plasma GlcSph is detected in an individual, 
in the absence of elevated chitotriosidase, this is an indication for AMRF. 
Measurement of GCase activity in white blood cells will not be very informative, but in 
fibroblasts enzymatic activity must be reduced to further consider the diagnosis of 
AMRF. Such diagnosis can be validated with the sequencing of the SCARB2 gene. 
Demonstration of a cell-type specific functional GCase deficiency by detection of 
abnormally high GlcSph in plasma should be considered as an important step in the 
identification of individuals suffering from a truly functional deficiency in LIMP-2.
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4.1 Abstract 
 
Degradation of GlcCer in lysosomes is mediated by the enzyme GCase. 
Primary defects in this enzyme resulting from mutations in the GBA gene cause GD. 
Mutations in the SCARB2 gene cause defects in the protein LIMP-2, which mediates 
transport of newly formed GCase to lysosomes. The corresponding disease, AMRF, 
differs clinically from GD. The marked phenotypic difference between GD and AMRF 
prompted us to study more closely the abnormalities in GCase and the functionally 
related lipid abnormalities in tissues of LIMP-2 KO mice. We first determined the 
proteome of isolated lysosomes from hepatocytes of wild type and LIMP-2 KO mice. 
No significant differences were noted in lysosomal matrix proteins, except for a major 
deficiency in GCase. Next, we analyzed the level of active GCase molecules in 
various tissues of LIMP-2 KO mice using recently developed ABP. Here, we report a 
gradient in deficiency of functional GCase along LIMP-2 deficient tissues. The GCase 
reductions are very prominent in organs like the liver, but more benign in others like 
brain and in leukocytes. The concentrations of GlcCer did not correlate with the extent 
of GCase deficiency. For example, GlcCer was normal in liver despite the severe 
GCase reduction. Another outspoken lipid abnormality in LIMP-2 KO mice is the 
elevation of GlcSph, which correlates with GCase deficiencies in tissues.  Here, we 
also firstly document another metabolite abnormality in LIMP-2 KO mice, i.e. elevated 
levels of GlcChol. Experimentally we studied the potential cause for the considerable 
high residual GCase activity in LIMP-2 deficient leukocytes, sharply contrasting with 
the low residual GCase in fibroblasts. An explanation can be provided by our finding 
of considerable endocytotic re-uptake of enzyme by cultured lymphoblasts but not 
fibroblasts. In conclusion, among cell types and tissues of LIMP-2 KO mice, marked 
differences exist in the degree of deficiency of GCase and related lipid abnormalities. 
These findings may help to understand the remarkable difference in clinical and 
biochemical manifestation associated with primary GCase deficiency in Gaucher 
patients and that associated with secondary GCase deficiency in AMRF patients. 
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4.2 Introduction 
 
Marked differences exist in the clinical picture of patients with GD suffering 
from primary defects in GCase, when compared to patients with bi-allelic mutations in 
the gene encoding LIMP-2. Gaucher patients largely develop a storage macrophage 
driven disease, characterized by hepatosplenomegaly, skeletal deterioration and 
pancytopenia [87]. On the other hand, mutations in SCARB2 gene cause AMRF, a 
rare form of progressive myoclonic epilepsy (PME). It is associated with nephritic 
range of proteinuria, kidney failure, histological appearances of collapsing focal and 
segmental glomerular sclerosis (FSGS) and neurological symptoms including PME 
and ataxia with uncharacterized storage material in brain, but without cognitive 
decline [201, 210, 211, 218, 243]. While the majority of the initially reported AMRF 
patients had severe renal disease, a small group has subsequently been reported 
with disease restricted to the neurological system [211, 213, 217, 223].  
To date, several SCARB2 mutations have been identified in AMRF, as well as 
in some PME cases [201, 210, 211, 213, 215, 216, 222, 223, 244, 245]. The 
difference in clinical expression between GD and AMRF patients is surprising since 
LIMP-2 has been unequivocally shown to play an essential role in transport of newly 
formed GCase to lysosomes [57, 201, 210]. LIMP-2 belongs to the CD36 superfamily 
and it is among the most abundant proteins of the lysosomal membrane [33, 184, 
246]. It is a type III membrane glycoprotein that transverses the membrane twice with 
a large luminal domain and a second membrane spanning domain preceding a 20 aa 
cytoplasmic tail at the C-terminal. A leucine-isoleucine motif within the C-terminal 
cytoplasmic tail of LIMP-2 determines its lysosomal localization [178, 195, 247]. In the 
endoplasmic reticulum the integral membrane protein LIMP-2 binds through its 
conserved coiled-coil domain (aa 152-167) to the correctly folded GCase [194]. The 
LIMP-2/GCase complex is next transported to acidic (pre)lysosomal compartments 
where dissociation occurs [58, 202].  
Cell studies showed that absence of functional LIMP-2 has a devastating 
impact on the routing of GCase to lysosomes. Enzyme that manages to pass the 
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endoplasmic reticulum appears to be exclusively secreted to the extracellular space 
[248, 249]. In view of this, prominent lipid storage in macrophages of AMRF patients 
might have been expected, however clinical evidence for this is not observed [201, 
218]. For example, circulating markers of lipid-laden macrophages, like 
chitotriosidase and CCL18, are markedly increased in Gaucher patients [89, 130], 
however this was not observed in the AMRF patients [201, 218].  
The deficiency in active GCase molecules and its consequences at the lipid 
metabolite level remains to be studied in detail in the AMRF patients, largely due to 
the scarcity of patients for investigation. Fortunately, LIMP-2 KO mice have been 
generated by Saftig and co-workers [190], and shown to be a valid disease model 
with similar symptoms to those seen in AMRF and PME patients [190, 201, 210, 212, 
213, 215, 216, 218, 224, 243, 250, 251]. These animals allow investigation on the 
biochemical impact of the absence of the lysosomal membrane protein LIMP-2. In this 
regard, attention for the lipid metabolites resulting from GCase activity is required. 
The deficiency of GCase in Gaucher patients is known to be not only restricted to the 
accumulation of GlcCer, but also by storage of GlcSph, which is markedly increased 
in tissue as well as plasma [89, 116, 117, 130].  
Recently, GlcCer was also described as a glucose donor for the reaction 
catalyzed by GCase, which leads to the formation of cholesterol-glucoside (1-O-
cholesteryl-β-D-glucopyranoside) (GlcChol) [252]. The occurrence of GlcChol and its 
potential abnormalities have not been studied so far in the context of LIMP-2 
deficiency. Next, to the determination of lipid metabolites like GlcCer, GlcSph and 
GlcChol, the impact of LIMP-2 deficiency on GCase can be studied using recently 
developed ABP that specifically labels active GCase molecules through covalent 
binding to the catalytic nucleophile residue [131, 132, 134, 253]. 
Here, we report our investigation of functional deficiency of GCase in mice 
lacking LIMP-2 protein by the measurements of active GCase levels and 
abnormalities in lipids in various tissues in mice with increasing age.  Marked cell-type 
and tissue specific differences in deficiency of functional GCase in the absence of 
LIMP-2 were observed. Strikingly, white blood cells present high residual levels of 
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GCase. We offer a possible explanation for this phenomenon based on the 
demonstration of compensatory endocytotic uptake of GCase by lymphocytes, but not 
fibroblasts, obtained from AMRF patients.  
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4.3 Methods 
 
4.3.1 Animal studies 
 
Breeding pairs of LIMP-2 KO mice were kindly provided by Prof. Paul Saftig 
(Kiel. Germany) [190]. Homozygous WT animals (LIMP-2 +/+) and homozygous 
affected animals (LIMP-2 -/-) were generated by crossing heterozygous (LIMP-2 +/-) 
mice. Genotyping was determined by PCR using genomic DNA isolated from a small 
piece of the ear. Principles of laboratory animal care were followed, and approval for 
the study was obtained from the ethics committee of Academic Medical Center, 
Amsterdam, The Netherlands. A total of 45 animals were used, equally distributed in 
genotype (wild type; LIMP-2 KO), gender (male; female) and in age (2, 4, 6 and 12 
months). 
 
4.3.2 Tissue collection  
 
Animals were first anesthetized with a dose of Hypnorm (0.315 mg/ml phenyl 
citrate and 10 mg/ml fluanisone) and Dormicum (5 mg/ml midazolam) according to 
their weight. The given dose was 80 µl/10 g body weight. Blood was collected by 
heart puncture into EDTA tubes and used for lipid measurements. Tissues and 
organs were collected by surgery and rinsed with PBS. Each one was sliced in half: 
one half was directly snap-frozen in liquid nitrogen and stored at -80 °C and the other 
half was conserved in 10% (v/v) formaldehyde for posterior pathology analysis.  Bile 
was collected for 15 min via cannulation of the gall bladder. Urine was collected 
through aspiration of the bladder. 
 
4.3.3 Bone marrow isolation 
 
Bone marrow was extracted from the hind legs. The skin and flesh were 
removed in order to expose the tibia and femur. Both ends of the collected femur 
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were excised and bone marrow was removed by rinsing with ice cold PBS and the 
fluid was collected in a 50 ml tube. The cells in the aspirate were centrifuged for 10 
min at 2.500 rpm (4 °C).  The supernatant was discarded and the pellet was washed 
again. The pellet was taken up in 1 ml ice cold PBS, transferred to a 1.5 ml Eppendorf 
tube and centrifuged for 5 min at 13.200 rpm (4 °C). The supernatant was discarded 
and the pellet stored at -80 °C. 
 
4.3.4 Plasma and leukocytes isolation 
 
Blood collected in EDTA tubes was centrifuged for 10 min at 4.000 rpm. 
Plasma was collected in an Eppendorf tube and stored at -80 °C. The leukocyte layer 
was transferred to a 50 ml tube with 45 ml of erythrocyte lysis buffer (NH4Cl/EDTA 
buffer, pH 7.4). After 20 min shaking in the cold room, on a roller mixer, the tube was 
centrifuged at 4 °C at 2.500 rpm for 10 min. The supernatant was discarded and 45 
ml of lysis buffer was added. This procedure was repeated to remove all erythrocytes. 
The pellet was then resuspended in 1 ml ice cold PBS and transferred to a 1.5 ml 
Eppendorf tube and centrifuged for 5 min at 13.200 rpm (4 °C). The supernatant was 
discarded and the leukocyte pellet was stored at -80 °C. 
 
4.3.5 Tissue homogenization 
 
Homogenization procedures were performed with RNAse-free glass beads in 2 
ml screwcap Eppendorf tubes. Twenty-five mM potassium phosphate buffer (pH 6.5), 
containing 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche) was added 
to tissue in a 1:5 ratio. Samples were homogenized with a Tissue Lyzer FastPrep (R)-
24 M. P. Biomedicals (Irvine, CA, USA) set 6 ms-1 for 30 s. Homogenates were 
cooled for 1 min on ice between runs. Smaller tissues (eye, salivary gland, sciatic 
nerve, lymph node, epididymis and adrenal gland) were homogenized by sonication 
(40% power, 40% amplitude for 6 s) using the sonicator Vibra Cell(TM) Model no. 
CV18. Sonics (Danburry, CT, USA). These were similarly cooled. In the case of 
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leukocyte and bone marrow preparations, 100 µl of the same extraction buffer was 
added to the pellets and these were homogenized by sonication as described above. 
All homogenates were stored at -80 ºC. 
 
4.3.6 Protein measurement with the Bicinchoninic acid (BCATM) assay 
 
Protein content measurement was performed according to the manufacturer’s 
protocol with Pierce™ BCA Protein Assay Kit (Pierce Biotechnology Inc., No. 23225), 
when necessary diluted with MilliQ water. 
 
4.3.7 Lysosomes isolation (Tritosomes) 
The lysosome enriched samples (tritosomes) were obtained from Dr. Markus 
Damme and Prof. Paul Saftig (University of Gottingen and University of Kiel, 
respectively). Briefly, mice were treated with a single injection of 0.75 mg of tyloxapol 
(Triton WR1339, Sigma) per g of body weight, 4 days prior to liver withdrawal. This 
treatment leads to the accumulation of the non-digestible Triton WR 1339 in 
lysosomes in the liver cells. Four days after the tyloxapol administration, animals were 
sacrificed and the livers collected. Cells were gently disrupted leaving lysosomes 
intact. The density of tyloxapol-laden lysosomes (named tritosomes) is below 1 g/mL, 
facilitating their separation from other cell organelles. The isolation of tritosomes from 
tyloxapol-treated mice included differential centrifugation and isopycnic centrifugation 
and resulted in a lysosome enriched fraction as described earlier [1, 254, 255].  
4.3.8 LC-MS/MS proteomics 
Tritosomes for LC-MS/MS were prepared using Rapigest detergent (Waters 
Corporation) and tryptic fragments were analyzed by label free data independent LC-
MS/MS as previously described [256]. 
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4.3.9 In vitro activity-based probe labelling of glucocerebrosidase 
Homogenate (50 µg total protein) was incubated with 100 nM cyclophellitol-
epoxide type activity based probe with a red BODIPY-containing fluorophore 
MDW941, the so-called Inhibody Red [131]. The incubation of tissue homogenate 
with MDW941 was performed in 150 mM McIlvaine buffer (150 mM citrate-Na2HPO4, 
pH 5.2, with 0.2% (w/v) sodium taurocholate and 0.1% Triton X-100) supplemented 
with protease inhibitor cocktail (Roche) for 45 min at 37 °C. Subsequently, protein 
was denatured with 5x Laemmli buffer (50 % (v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) 
glycerol, 10% (w/v) DTT, 10% (w/v) SDS, 0.01% (w/v) bromophenol blue) by boiling 
for 10 min at 100 ºC. and separated by electrophoresis on 10% (w/v) acrylamide 
SDS-PAGE gels running at 90 V [131, 133]. Wet slab gels were scanned for red 
fluorescence using a Typhoon variable mode imager (Amersham Bioscience) using 
λex 532 nm and λem 610 nm (band pass filter 30nm). ABP-emitted fluorescence was 
quantified using ImageJ software (NiH). Gels were electroblotted onto a nitrocellulose 
membrane (Schleicher&Schuell®) and the protein bands detected with Ponceau S 
staining. 
 
4.3.10 Enzymatic assays 
 
Enzymatic assays were performed according to Aerts et al [242]. GCase 
activity was measured with 3.73 mM 4-MU-β-D-Glc, dissolved in 150 mM McIlvaine 
buffer (pH 5.2) supplemented with 0.2% (w/v) sodium taurocholate, 0.1% (v/v) Triton 
X-100) and 0.1% BSA. After stopping the reaction with NaOH-glycine (pH 10.3), 
fluorescence was measured with a fluorimeter LS55 (Perkin-Elmer, Beaconsfield, UK) 
at λex 366 nm and λex 445 nm. 
 
4.3.11 HPLC and MS/ MS lipid measurements 
 
Neutral glycosphingolipids, lysoGb3, GlcSph and GlcChol were determined in 
the homogenates as described earlier [117, 241, 257, 258]. An internal standard mix 
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(13C5-Lyso-Gb3. 13C5-GlcSph and 13C6-GlcChol) was added to the samples for 
calculation. After protein precipitation with CHCl3:MeOH  1:1 (v:v), one step of 
extraction and two washing steps were carried out, always with the ratio 
CHCl3:MeOH:H20  1:1:0.9 (v:v:v). With this procedure, lysoGb3 and GlcSph are in the 
hydrophilic phase (upper phase), and GlcChol and neutral lipids will be in the 
hydrophobic phase (lower phase). The upper phase was dried under N2 gas stream 
and the pellet redissolved in MeOH (LysoGb3 and GlcSph). The lower phase was 
halved. One half, for GlcChol measurement, was dried under a N2 gas stream and the 
pellet redissolved in solution A (100% MeOH, 10 mM ammonium formate). Lipids 
were measured using an Acquity TQD (Waters Inc.). For determination of neutral 
glycosphingolipids, a known amount of internal standard (C17-Sphinganine) was 
added to the sample and then deacylated with 0.1 M NaOH in MeOH in a microwave 
for 1 h at 60 ºC. Neutral lipids were next analyzed using a Dionex HPLC system with 
a C18 reversed-phase chromatography and automated derivatisation with fluorescent 
o-phthaldialdehyde (OPA). The fluorescent derivatized structures derived from 
glycosphingolipids were quantitatively detected by measurement of fluorescence at 
λex 340 nm and λex 435 nm. Quantification of GlcCer in brain and sciatic nerves 
required an optimized protocol given the abundant presence of interfering 
galactosylceramide in these materials. After total lipid extraction by modified Folch 
extraction [259], neutral lipids glycosphingolipids (ceramides and phospholipids) were 
separated by solid phase extraction (SPE) using a silica gel (SiOH) SPE column. 
After deacylation with sphingolipid ceramide N-deacylase (SCDase, Takara Bio Inc., 
Japan), GlcCer was digested with recombinant GCase (Imiglucerase, Genzyme). The 
subsequent increase in ceramide levels after digestion, measured as described 
above, was assumed as derived from GlcCer degradation. 
 
4.3.12 Lymphocyte immortalization 
 
Materials from donors and patients were obtained after informed consent. 
B95–8 culture supernatants containing the transforming strain of Epstein-Barr virus 
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(EBV) were used to establish a lymphoblastoid cell lines in vitro as described earlier 
[260]. Briefly, leukocytes from healthy donors and from two LIMP-2 deficient patients 
homozygous for the SCARB2 mutation W178X [201] were isolated by sedimentation 
on Ficoll-Hypaque density gradients. Mononuclear cells were resuspended in RPMI 
1640 medium containing 10% fetal calf serum and viral supernatants (107 
mononuclear cells/ml) and incubated for 2 h at 37 °C. Cultures were maintained in 25 
cm2 tissue culture flask for 3 weeks containing 1 µg/ml cyclosporin A. The cells were 
washed twice with PBS and then cultured in RPMI 1640 medium containing 10% fetal 
calf serum and 5% (v/v) Pen/Strep (Life Technologies). 
 
4.3.13 Generation of lentivirus particles and infection 
 
Recombinant lentivirus particles encoding shRNAs targeting SCARB2 were 
produced, concentrated and titrated as described previously [261]. Cultured THP-1 
were infected with recombinant lentivirus particles for 24 h in 400 ml of RPMI 1640 
medium containing 10% fetal calf serum and 5% Pen/Strep. In the next day, 400 ml 
RPMI 1640 medium containing 10% fetal calf serum and 5% Pen/Strep were added. 
After 48 h, the cells were carefully washed and cultured for another 48 h, to be finally 
harvested. Transduction efficiency was determined by western-blot and qRT-PCR. 
 
4.3.14 RNA extraction and quantitative RT-PCR 
 
Total RNA was harvested from cells using the Total RNA mini kit (Bio-Rad) or 
Trizol reagent (Invitrogen) according to the manufacturer's instructions. cDNA was 
made using the iScript cDNA synthesis kit (Bio-Rad). Real-time reverse transcription 
PCR was performed using the MyIQ system (Bio-Rad) and the primer LIMP-2 forward 
5′-TTGGCCCTCTGGACATTATC-3′ and the LIMP-2 reverse 5′-
AGAACCGCATGAAGTGAACC-3′. Acidic ribosomal phosphoprotein P0 was 
determined as an internal control for cDNA content of the samples with the primer P0 
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forward 5′-TCGACAATGGCAGCATCTAC-3′ and P0 reverse 5′-
ATCCGTCTCCACAGACAAGG-3′. 
 
4.3.15 Western-Blotting 
 
Homogenates containing 20 µg of total protein were denatured with 5x 
Laemmli buffer (50% (v/v) 1 M Tris-HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) DTT 
10% (w/v) SDS and 0.01% (w/v) bromophenol blue) by boiling for 10 min at 100 ºC, 
and separated by electrophoresis on 10% acrylamide (w/v) SDS-PAGE gels running 
at 90 V [131, 133]. SDS–PAGE gels were electroblotted onto a nitrocellulose 
membrane (Schleicher&Schuell®). Membranes were blocked with 5% skimmed milk 
and 0.05% Tween-20 in TBS for 1 h at room temperature and incubated overnight 
with the rabbit polyclonal anti-LIMP-2 antibody (NB400-129, Novus Biologicals) at 4 
°C. Membranes were then washed three times with 0.01% Tween-20 in TBS and 
incubated with the appropriate IRDye conjugated secondary antibody for 1 h at room 
temperature. After washing, detection was performed using the Odyssey® Clx. 
Infrared Imaging System (LI-COR). 
 
4.3.16 Inhibition of endocytosis 
 
Immortalized lymphocytes and THP-1 cells were seeded at 1x106 cells/well in 
6-well plates containing 1 mL of medium RPMI 1640 with 5% Pen/Strep. Fibroblasts 
were obtained from skin biopsies of control subjects and AMRF patients after 
informed consent. The patients’ cells were homozygous for the SCARB2 mutation 
W178X [201]. Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1% Pen/Strep, 100 
mg/ml kanamycin sulfate and 2.5 mg/ml fungizone (Gibco, Invitrogen). Fibroblasts 
were cultured in 6-well plates almost to confluency. Next, the medium was changed to 
1 ml of Dulbecco’s modified Eagle’s medium supplemented with 1% penicillin–
streptomycin (Gibco, Invitrogen). A pre-dilution of Dynasore to 160 µM was made in 
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RPMI 1640 or Dulbecco’s modified Eagle’s medium containing 5% Pen/Strep. One ml 
of this solution was added to cells to achieve a final concentration of 80 µM. After 8 h 
of incubation, the cells were washed with PBS and collected. Treatment of cells with 
mannan at a concentration of 1 mg/ml was performed overnight. Cells were disrupted 
by sonication (40% power, 40% amplitude for 6 s) in the sonicator Vibra Cell (TM) 
Model no. CV18. Sonics (Danburry, CT, USA). 
 
4.3.17 In vitro activity-based probe labelling of glucocerebrosidase in THP-1 
 
THP-1 homogenates (20 µg total protein) were incubated with 100 nM 
Inhibody-Red MDW941 [131] in 150 mM McIlvaine buffer (pH 5.2, with 0.2% (w/v) 
sodium taurocholate, 0.1% Triton X-100) and protease inhibitor cocktail (Roche) for 
30 min at 37 °C. Subsequently, protein was denatured with 5x Laemmli buffer (50% 
(v/v) 1 M Tris-HCl, pH 6.8. 50% (v/v) glycerol, 10% (w/v) DTT, 10% (w/v) SDS, 0.01% 
(w/v) bromophenol blue) by boiling for 10 min at 100 ºC and separated by 
electrophoresis on 10 % acrylamide (w/v) SDS-PAGE gels running at 90 V [131, 133]. 
Wet slab gels were scanned for red fluorescence using a Typhoon variable mode 
imager (Amersham Bioscience) using λex 532 nm and λem 610 nm (band pass filter 
30nm). ABP emitted fluorescence was quantified using ImageJ software (NiH). Gels 
were electroblotted onto a nitrocellulose membrane (Schleicher&Schuell®) and the 
proteins bands were detected with Ponceau S staining. 
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4.4 Results 
 
4.4.1 Impact of LIMP-2 deficiency on the protein composition of lysosomes. 
 
Presently, it is unknown whether lack of LIMP-2 also impairs other lysosomal 
proteins besides GCase. To address this, we analyzed the protein composition of 
isolated lysosomes from mice treated with non digestible Triton WR1339, so-called 
tritosomes.  
We employed non labelled quantitative proteomics using LC-MSe as described 
earlier [256]. No significant differences in any of the lysosomal proteins other than 
GCase were noted, when comparing the protein composition of tritosomes isolated 
from wild type and LIMP-2 KO mice (Table S4.1. supplemental data). Around 70 
lysosomal matrix proteins were identified and quantified. Table 4.1 shows that 
sphingomyelinase and lysosomal acid lipase tended to be about two fold decrease in 
tritosomes from LIMP-2 KO mice. About two-fold increase was noted for Cathepsin H 
and N-acetylglucosamine 6 sulfatase. In cases like α–galactosidase, the amount of 
protein was at the level of detection, not being detectable in some samples and 
making the data not interpretable. Importantly, both GCase and LIMP-2 protein were 
found to be absent in tritosomes from LIMP-2 KO mice. 
This finding indicates that LIMP-2 deficiency results in a very specific deficiency in 
GCase and does not affect other lysosomal proteins, at least in the studied 
hepatocytes. 
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Table 4.1 – Examples of proteins in tritosomes from LIMP-2 KO mice that were changed in comparison to wild type. 
 
Nº Protein Name Accesion No.  Description Ratio 
30 LICH_MOUSE Q9Z0M5 
Lysosomal acid lipase cholesteryl ester hydrolase OS 
Mus musculus GN Lipa PE 2 SV 2 0.44 
32 ASM_MOUSE Q04519 
Sphingomyelin phosphodiesterase OS Mus musculus 
GN Smpd1 PE 2 SV 2 0.59 
65 E9Q2Q0_MOUSE E9Q2Q0 
Uncharacterized protein OS Mus musculus GN Ctsc PE 
3 SV 1 0.59 
66 F7AF87_MOUSE F7AF87 
Uncharacterized protein Fragment OS Mus musculus 
GN Glb1 PE 4 SV 1 0.60 
61 D3Z437_MOUSE D3Z437 
Uncharacterized protein OS Mus musculus GN Ctsh PE 
4 SV 1 2.14 
33 GALNS_MOUSE Q571E4 
N-acetylgalactosamine 6 sulfatase OS Mus musculus 
GN Galns PE 2 SV 2 2.16 
 
 
4.4.2 Analysis of pathology  
 
Disease manifestation is relatively benign in LIMP-2 KO mice. As shown in Fig. 
S4.1 (supplemental data), despite the clear absence of lysosomal GCase in 
hepatocytes, no abnormalities in the liver are observed. Actually, no overt pathology 
was detected by an experienced pathologist in any organs of mice of 6 and 12 
months of age with the exception of signs of nephrohydrosis in the absence of clear 
abnormalities in the glomerulus. Of interest, a markedly thickness of sciatic nerve 
without apparent phenotypic consequences was observed in Fig. S4.2 (supplemental 
data). 
 
4.4.3 Levels of active glucocerebrosidase in tissues by enzymatic activity 
measurement 
 
Various tissues were collected from LIMP-2 KO and wild type mice of 4 months 
of age. In tissue homogenates, GCase activity was measured with the fluorogenic 
substrate 4-MU-β-D-Glc, (Table 4.2). Very little activity was detected for many of the 
tissues analyzed (eye, pancreas, heart, spleen, liver and lungs) when compared to 
wild type. In the case of the intestine (divided in duodenum, ileum and jejunum), no 
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clear differences were observed in the enzymatic activity between the genotypes, 
probably due to the abundance of bacterial glycosidases as well as endogenous 
lactase phloridzin hydrolase (LPH) which also hydrolyzes the artificial substrate [262, 
263]. Of interest, in the case of the sciatic nerve, leukocytes, brain and skin, no major 
reduction of GCase activity was found in LIMP-2 KO mice. Of note, plasma from wild 
type animals contains virtually no GCase activity, but it is detectable in plasma of 
LIMP-2 KO mice, likely due to faulty secretion of the mistargeted enzyme. 
Tissue and cell-type dependent impact of secondary  
glucocerebrosidase abnormalities due to LIMP-2 deficiency 
  
81 
 
 
Table 4.2 - GCase activity (nmol/h/mg protein or ml) in several tissues obtained from LIMP-2 KO mice and matched wild type 
animals of 4 months of age.  
 
Tissue GCase activity  
Genotype Wild type LIMP-2 KO  
   
Duodenum 728.58 ± 262.33 463.51 ± 54.80 
Jejunum 660.35 ± 167.74 812.48 ± 23.79 
Liver 142.05 ± 31.02 22.65 ± 11.43 
Ileum 114.95 ± 20.20 78.20 ± 51.22 
Testis (TE) 103.23 ± 10.02 39.85 ± 3.32 
Thymus 98.06 ± 35.16 27.23 ± 9.45 
Abdominal fat (AF) 96.79 ± 33.68 16.44 ± 3.79 
Bone Marrow (BM) 96.34± 7.65 21.09± 1.06 
Pancreas 94.77 ± 20.09 9.81 ± 2.20 
Omental fat (OF) 93.13 ± 22.63 16.16 ± 2.47 
Epidydimal fat (EF 90.02 ± 35.69 16.96 ± 3.96 
Epidydimis (EP) 88.01 ± 26.59 45.33 ± 32.51 
Inguinal fat (IF) 79.57 ± 24.69 10.81 ± 6.32 
Lymph node (LN) 62.88 ± 2.21 20.59 ± 1.93 
Spleen 60.30 ±  13.20 10.79 ± 2.52 
Adrenal gland (AG) 58.00 ± 3.82 18.64 ± 0.35 
Lungs 57.36 ± 12.87 9.59 ± 0.83 
Salivary gland (SG) 55.97 ± 10.60 16.27 ± 1.52 
Brain 54.20 ±  0.69 32.14 ± 2.74 
Brown adipose tissue (BAT) 48.92 ± 1.35 11.41 ± 4.02 
Leukocytes (PBMC) 46.78± 2.98 31.73± 1.47 
Kidney 34.94 ± 4.11 9.76 ± 0.51 
Skin 33.39 ± 4.24 18.75 ± 2.03 
Heart 29.32 ±  6.03 3.95 ± 1.29 
Sciatic nerve (SN) 23.97 ± 0.46 22.36 ± 12.78 
Eye 4.65 ± 2.05 0.85 ± 0.28 
Plasma 0.78 ± 0.0 8.48 ± 1.59 
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4.4.4 Detection of active glucocerebrosidase molecules in tissues by activity-
based probes labelling. 
 
Tissues were collected from LIMP-2 KO and wild type mice of 4 months of age. 
The following abbreviations are used hereafter: IF (Inguinal fat), AF (Abdominal fat), 
OF (Omental fat), EF (Epidydimal fat), BM (Bone marrow), BAT (Brown adipose 
tissue), SG (Salivary gland), AG (Adrenal gland), LN (Lymph node), TE (Testis) and 
SN (Sciatic nerve). 
Tissue homogenates were incubated with ABP MDW941 to detect active 
GCase following SDS-PAGE and fluorescence scanning (Fig. 4.1). Most tissues of 
LIMP-2 KO mice showed absence or a strongly reduced amount of active GCase, 
when compared to the controls. Only a few tissues of LIMP-2 KO mice, such as the 
brain and the leukocytes, showed considerable amounts of labelled GCase, although 
less than the corresponding wild type material.  
 
Figure 4.1 - Visualization of GCase with fluorescent ABP MDW941. Detection of active GCase in tissues and organs 
homogenates (50 µg) labelled with ABP followed by SDS-PAGE and visualization by fluorescence imaging. (+/+) -  Wild type; (-/-
) - LIMP-2 KO mice. 
 
Quantification of labelled GCase molecules and comparison with measured 
residual enzyme activity in tissue homogenates showed a good correlation. In Fig. 
4.2, tissues are ranked based on the residual enzyme activity measured in vitro (Fig. 
4.2A) and a comparison is provided for the residual GCase activity determined by 
enzymatic assay and ABP labelling (Fig. 4.2B). A very strong correlation between the 
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results obtained with both methods is apparent. Figure 4.2 illustrates the marked 
tissue dependence of deficiency of GCase in LIMP-2 deficiency. Of note, high 
residual GCase was detected for brain, leukocytes and SN when determined either by 
enzymatic assay and ABP labelling. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Residual GCase activity in LIMP-2 KO mice.  A - Ranking of the homogenates according to the residual enzymatic 
activity. B - Comparison of residual GCase activity determined as by enzymatic assay and ABP labelling.  
 
4.4.5 Detection of lipid metabolite abnormalities in LIMP-2 KO mice.  
 
To assess the functional deficiency of GCase, we analyzed lipid metabolites in 
various tissues of LIMP-2 KO mice. Given the fact that GlcCer is the primary storage 
lipid during GCase deficiency, we first determined its concentration in various tissues 
of LIMP-2 KO and wild type animals. Table 4.3 shows that GlcCer concentrations 
vary among tissues and that it is most prominently elevated in PBMC, OF, AF and LN 
of LIMP-2 KO mice. Of note, the presented values for GlcCer in brain and SN are 
suboptimal given the interference of the abundant isomer galactosylceramide in the 
GlcCer determination [80, 81].  
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Table 4.3 – GlcCer levels (nmol/wet weight tissue or mg protein or ml) in several tissues and organs of LIMP-2 KO and wild type 
mice. Lipid level for plasma bile and urine is presented as nmol/ml. Right column - Fold increase in LIMP-2 KO mice compared to 
wild type. “*” - (Gly)cosylceramide = galactosylceramide plus GlcCer. 
 
Tissue/ Organ GlcCer levels Fold of increase in the 
LIMP-2 deficiency Genotype Wild type LIMP-2 KO 
Pancreas 9.55±4.3 15.38±1.9 1.61 
Heart 4.18±2.6 2.99±0.4 0.72 
IF 8.15±6.3 27.48±11.9 3.37 
Liver 22.18±13.3 23.43±13.0 1.06 
Lungs 30.52±9.5 42.55±14.8 1.39 
AF 8.75±5.1 57.70±29.3 6.59 
OF 3.39±1.5 14.76±4.4 4.35 
Spleen 75.04±8.0 73.77±6.6 0.98 
Eye 571.77±179.1 171.03±107.2 0.30 
EF 3.50±2.0 3.95±0.4 1.13 
BM 0.49±0.3 0.73±0.4 1.49 
BAT 32.57±15.2 41.16±10.2 1.26 
Thymus 70.54±13.6 70.95±15.4 1.01 
Kidney 17.86±4.5 7.80±10.2 0.44 
SG 22.62±8.6 41.44±9.6 1.83 
AG 33.18±12.4 53.36±26.2 1.61 
LN 40.02±20.2 97.47±28.5 2.44 
TE 13.42±2.5 13.32±6.0 0.99 
EP 13.31±6.7 14.00±5.9 1.05 
Skin 23.34±5.1 23.71±14.2 1.02 
Brain* 3067.43±837.8 3248.91±473.7 1.06 
Duodenum 64.33±7.1 68.37±9.0 1.06 
PBMC 0.10±0.1 0.73±0.8 7.30 
Ileum 25.10±3.8 28.08±5.5 1.12 
SN* 10493.84 4898.21±1016.1 0.47 
Jejunum 41.35±9.2 47.93±11.2 1.16 
Plasma 3.17±0.9 1.80±1.1 0.57 
Bile 4.78±5.7 2.07±0.8 0.43 
Urine 0.26±0.1 0.19±0.1 0.73 
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Next, we determined the concentrations of GlcSph, the deacylated form of 
GlcCer, known to be prominently increased in GD. Much clearer abnormalities were 
detected for GlcSph, being increased in almost every tissue, most strikingly in 
pancreas, heart and OF (Table 4.4). A trend can be noted between GlcSph 
accumulation and residual GCase activity in tissues. Exceptions in this regard are OF, 
kidney, SG, LN and the different parts of the intestine.  
To establish if other catabolic pathways are also affected in the LIMP-2 
deficiency, the globoside Gb3 and its deacylated form, lysoGb3, were also measured. 
No significant increase in these lipids was detected (Fig. S4.3 and S4.4, in 
supplemental data). Interestingly, the levels of these lipids in spleen, thymus and 
testis were about half of those in wild type materials (Fig. S4.3 and S4.4, in 
supplemental data). The concentrations of GlcChol in tissues of LIMP-2 KO and wild 
type mice are presented separately. Very recently, an accurate LC-MS/MS for 
quantification of GlcChol was developed, employing an isotope 13C6-labelled internal 
standard (Marques et al., unpublished results). The presence of GlcChol in various 
tissues was demonstrable (Fig. 4.3). The lipid was found to be increased in most 
tissues, most clearly in adipose tissues (IF, AF, OF and BAT) (Fig. 4.3).  
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Table 4.4 – GlcSph levels (pmol/wet weight tissue or mg protein or ml) in several tissues and organs of LIMP-2 KO 
and wild type mice. Lipid level for plasma bile and urine is presented as nmol/ml. Right column - Fold increase in LIMP-2 KO 
mice compared to wild type. “*” - (Gly)cosylsphingosine. 
 
Tissue GlcSph levels Fold of increase in the 
LIMP-2 Genotype Wild type LIMP-2 KO 
Pancreas 2.33±0.7 178.35±24.1 76.55 
Heart 3.33±1.0 86.70±20.5 26.04 
IF 3.00±0.9 31.93±17.5 10.64 
Liver 32.06±2.6 214.91±157.9 6.70 
Lungs 34.86±8.0 738.37±285.0 21.18 
AF 1.94±0.7 40.50±35.7 20.88 
OF 0.97±0.7 128.44±41.0 132.41 
Spleen 20.65±2.3 399.98±143.7 19.37 
Eye 62.92±5.7 892.64±189.7 14.19 
EF 4.23±1.9 11.04±0.2 2.61 
BM 0.20±0.1 2.01±0.8 10.05 
BAT 4.07±1.7 49.67±38.8 12.20 
Thymus 13.44±2.4 85.63±23.1 6.37 
Kidney 25.82±0.7 557.45±115.4 21.59 
SG 4.97±1.6 95.17±37.4 19.15 
AG 7.04±5.1 75.69±65.1 10.75 
LN 4.97±4.3 95.56±69.0 19.23 
TE 5.18±1.8 24.69±4,68 4.77 
EP 29.42±4.3 233.17±112.1 7.93 
Skin 9.26±4.9 29.62±13.6 3.20 
Brain* 112.80±5.8 230.53±14.5 2.04 
Duodenum 8.79±3.8 139.00±26.5 15.81 
PBMC 0.30±0.3 1.67±0.3 5.57 
Ileum 9.31±1.3 180.50±22.9 19.39 
SN* 1111.88±651.5 860.89±543.6 0.77 
Jejunum 8.16±1.6 140.69±15.3 17.24 
Plasma 1.14±1.3 3.57±1.7 3.13 
Bile 1.39±0.5 6.31±2.2 4.54 
Urine 0.65±1.2 0.36±0.2 0.55 
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Figure 4.3 – GlcChol measured in the several homogenates from the LIMP-2 KO and wild type mice. Left panel - Absolute 
amounts; Right panel - Relative amount of increase when compared to wild type. Dashed line marks the normal values obtained 
in wild type mice. 
 
4.4.6 Biochemical course of disease 
 
Given the detected abnormalities in lipid metabolites in tissues of LIMP-2 KO mice of 
4 months of age, we next studied how these abnormalities develop with age in 
several tissues.  GlcCer changes were very small in all tissues from LIMP-2 KO mice 
when examined at various ages (Fig. 4.4). Only a very slight increase was noticed for 
the kidney and salivary gland at older age. In the case of the eye of LIMP-2 KO mice, 
a significant reduction of GlcCer was observed. In sharp contrast, GlcSph elevation 
was already detectable in animals of 2 months of age and generally did not further 
increase with age (Fig. 4.5). Only in the case of the thymus, IF, OF and the eye of 
LIMP-2 KO mice, the levels of GlcSph increased with age. The concentrations of 
globosides Gb3 and lysoGb3 were also determined in various tissues with increasing 
age. No differences in the wild type animals were detected, except for reduced levels 
in spleen (Fig. S4.5 and S4.6, in supplemental data).  
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Figure 4.4– GlcCer levels in wild type and LIMP-2 KO mice at different ages.  Black circle - wild type; Black square - LIMP-2 KO 
mice. 
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Figure 4.5 – GlcSph levels in wild type and LIMP-2 KO mice at different ages.  Black circle - wild type; Black square - LIMP-2 
KO mice. 
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Figure 4.6 – GlcChol levels in wild type and LIMP-2 KO mice at different ages.  Black circle - wild type; Black square - LIMP-2 
KO mice. 
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Determination of GlcChol in tissues from LIMP-2 KO mice revealed that the 
glucosylated sterol was already increased at the youngest age examined (2 months). 
In none of the tissues a marked accumulation of GlcChol with increasing age was 
observed (Fig. 4.6).  
 
4.4.7 Lipids in brain and sciatic nerve 
 
In most tissues GlcCer concentrations are known to be far higher than those of 
galactosylceramide. However in brain and nerves, galactosylceramide is abundant. 
The same holds for the sphingosine forms of these monoglycosylceramides. Our LC-
MS/MS procedure does not discriminate between GlcCer and galactosyceramide or 
between GlcSph and galactosylsphingosine. In the case of the brain of LIMP-2 KO 
mice, we observed no differences in the levels of (gly)ceramide and (gly)sphingosine. 
(see Fig. 4.4 and 4.5, respectively). In the case of the SN, (gly)ceramide was 
significantly reduced and less prominently (gly)sphingosine. Treatment of brain and 
SN homogenates with excess recombinant GCase allows the discrimination between 
GlcCer and galactosylceramide since the recombinant enzyme only degrades GlcCer. 
In the brain, almost no differences between wild type and LIMP-2 KO mice were 
observed, at any age analyzed, in the total (gly)ceramide (GlcCer+ 
galactosylceramide) (Fig. 4.4). Treatment with recombinant GCase reveals that the 
GlcCer content of brain from LIMP-2 KO mice is normal (Fig. 4.7). Only a small 
decrease in galactosylceramide is demonstrable. In the SN, clear abnormalities in 
(gly)ceramide are detected, in particular a prominent reduction in galactosylceramide 
is apparent with increasing age. Already at young age the concentration of ceramide 
is elevated in the SN, reaching a maximum at 4 months and being reduced after that. 
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Figure 4.7 – Glycosphingolipids and ceramide levels in brain and SN, before and after the treatment with recombinant GCase. 
 
4.4.8 Secretion and re-capture of glucocerebrosidase 
 
The mechanism by which GCase reaches lysosomes in the absence of LIMP-2 
is unknown. One of the cell types in AMRF patients and LIMP-2 KO mice with high 
residual GCase activity are the leukocytes. To generate AMRF-like leukocytes, THP-1 
cells were infected with lentiviral SCARB2 shRNA. The reduced expression of 
SCARB2 (qPCR and Western Blot) and the accompanying GCase activity were 
determined (Fig. S4.7, in supplemental data). Immortalized AMRF lymphocytes, 
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fibroblasts, AMRF-like THP-1 cells and the corresponding control cells were cultured 
in the presence of a potent inhibitor of dynamin (Dynasore), which inhibits 
endocytosis [264]. Dynasore treatment led to a 50% reduction in the cellular GCase 
activity in the immortalized AMRF lymphocytes and SCARB2 knocked-down THP-1 
cells. In the case of the AMRF fibroblasts, no alterations were observed (Fig. 4.8). 
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Figure 4.8 – Relative amount (%) of remaining GCase activity in different cell lines after treatment with Dynasore, compared to 
the non treated condition.  
 
Using ABP labelling of GCase, similar results were obtained for THP-1 cell lines (Fig. 
4.9). The Dynasore treatment reduced the amount of active GCase detected by ABP 
labelling. The concomitant presence of mannan in the culture medium did not 
influence the cellular content on active GCase (Fig. 4.9). This finding suggests that a 
mannose lectin receptor is not responsible for the endocytotic uptake of GCase. 
 
 
Figure 4.9 – Active GCase labelled with ABP in THP-1 cell lines.
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4.5 Discussion 
 
Primary GCase deficiency caused by mutations in the GBA gene occurs in all 
cells and tissues of GD patients [87]. Such GCase deficiency may lead to different 
phenotypes of GD, ranging from type 1 (non-neuronopathic manifestation) to type 2 
and 3 (neuropathic) manifestations [87]. With every phenotypic variant, storage of the 
substrate GlcCer in lysosomes from tissue macrophages is a distinctive feature. 
Presence of the GlcCer-laden macrophages, named “Gaucher cells”, is reflected by a 
marked increase in plasma concentrations of proteins specifically secreted by these 
abnormal cells, like chitotriosidase and CCL18 [89, 130]. Interestingly, secondary 
GCase deficiency as the result of a defective LIMP-2 protein does not result in a 
phenocopy of GD. Instead, it results in AMRF, a disorder with distinct symptoms from 
GD and lacking the formation of significant amounts of “Gaucher cells” [218]. The 
availability of a genuine mouse model of AMRF, LIMP-2 KO mice, allowed us to 
carefully investigate abnormalities in GCase in various cells and tissues and find 
clues for the discordant manifestation of GD and AMRF. Firstly, we studied the 
composition of highly purified lysosomes from liver cells obtained from LIMP-2 KO 
and wild type mice. Except for the absence of GCase, no major differences in 
lysosomal matrix proteins were observed. Of note, the lack of GCase did not appear 
to affect hepatocytes as indicated by pathology examination. Next, we investigated 
how the absence of LIMP-2 influences the levels of active GCase molecules. For this 
purpose, we first used enzymatic activity measurements with an artificial fluorogenic 
substrate, 4-MU-β-D-Glc. A variable deficiency in GCase activity was observed for 
various organs. In addition, we used an independent method to assess the presence 
of active GCase molecules by employing our recently developed fluorescent ABP, a 
suicide substrate which specifically covalently labels GCase. Consistent marked 
differences in relative decrease in GCase activity among tissues were found. 
Importantly, the findings made with both methods were similar. Some tissues, like 
pancreas, heart and liver contain very little GCase in LIMP-2 KO mice. In sharp 
contrast, leukocytes show a relatively high residual GCase. Next, we addressed the 
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functional consequences of the reductions in GCase activity in various tissues of 
LIMP-2 KO mice. For this purpose, we measured concentrations of GlcCer, the 
primary storage lipid, and GlcSph, a water-soluble metabolite of GlcCer formed by 
deacylation [89, 117]. In most tissues we hardly observed any increase in GlcCer, 
suggesting that the small amount of residual GCase is sufficient for its lysosomal 
degradation and/or that accumulating GlcCer is efficiently converted to GlcSph. 
Indeed, GlcSph was found to be highly increased in many tissues from LIMP-2 KO 
mice, suggesting that metabolism of GlcCer by its deacylation seems a remarkably 
effective pathway to avoid GlcCer accumulation. It is noteworthy that those tissues 
with low GCase activity tend to show the highest levels of GlcSph as, for example, the 
pancreas and the heart. The marked deficiency of GCase in most tissues of LIMP-2 
KO mice has therefore remarkably little consequences regarding GlcCer 
accumulation. Lysosomes seem to cope surprisingly well with the undegraded 
GlcCer. For example, we observed no abnormalities in lysosomal catabolism of 
globosides as reflected by normal Gb3 and lysoGb3 concentrations. In contrast, in 
Gaucher patients significant increase in lysoGb3 can be observed, suggesting 
secondary impaired lysosomal degradation and alternative metabolism of Gb3 
(Ferraz et al, unpublished results). 
  Our findings on peripheral blood leukocytes from LIMP-2 KO mice deserve 
special discussion. Only in these cells a significant, although modest, increase in 
GlcCer was demonstrable. On the other hand, the concentrations of GlcSph in 
leukocytes were meanwhile not exceptionally high when compared to other tissues of 
LIMP-2 KO mice. It therefore seems that peripheral leukocytes manage less well than 
other tissues to avoid GlcCer accumulation trough its conversion to GlcSph. In this 
regard, it is of interest to point out that of all materials studied, leukocytes of LIMP-2 
KO mice show high levels of residual GCase activity, reaching even about 60% of 
normal levels. Apparently, such residual capacity is sufficient to avoid prominent 
formation of GlcCer-laden macrophages, a characteristic feature in GD patients. 
Thus, it is not surprising that mutations in the SCARB2 gene have been reported to 
aggravate the severity of clinical manifestation in Gaucher patients [225, 265]. In this 
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work, we analyzed relatively young LIMP-2 KO mice. At older age animals are known 
to present tubular proteinuria associated with a reduced ability of endosomes, 
containing reabsorbed proteins, to fuse with lysosomes in the proximal convoluted 
tubule (PCT) of the kidney [190, 210, 243]. In the studied animals, no overt 
proteinuria had been developed yet. Residual GCase, measured by enzymatic assay 
or ABP labelling, was not strikingly different from other tissues. Likewise, lipid 
abnormalities were comparable to those in other tissues examined. 
Another tissue from LIMP-2 KO mice that deserves discussion is the brain. 
Only severe cases of GD develop characteristic neuropathology. However, carriers of 
GD also have been reported to have an increased risk of developing Parkinson and 
Lewy-Body dementia [123, 124]. The neurological manifestation of AMRF is distinct 
and is characterized by epileptic attacks, thus mimicking PME. Brain of LIMP-2 KO 
mice showed relatively high residual levels of GCase and no clear increase in GlcCer. 
At present, it is therefore unclear why this tissue is particularly vulnerable to 
pathology. Possibly, we missed in our analysis of total brain lipids abnormalities in 
specific neuronal cells associated with epileptic attacks. It cannot even be excluded 
that such cells metabolize GlcCer to other toxic metabolites causing epilepsy. Taking 
this into account, our observation of the occurrence of GlcChol is of interest. The 
glucosylated sterol has recently been identified in mammals and has been suggested 
to be formed by GCase through transglucosylation of cholesterol molecules. 
Abnormalities in this pathway related to GCase deficiency might cause neurological 
disease manifestations. Absence of LIMP-2 led to modestly increased levels of 
GlcChol in all examined tissues of mice. This finding suggests that GCase plays a 
physiologically role in degradation of GlcChol, rather than in its synthesis through 
transglucosylation as recently proposed [252]. 
A known feature of LIMP-2 deficiency is the occurrence of peripheral 
demyelinating neuropathy, being absent in neurons from the central nervous system 
as a consequence of repeated de- and re-myelination [190]. In view of this, our 
findings with the sciatic nerve (SN) are intriguing. A grossly swollen SN develops in 
LIMP-2 KO mice. Residual GCase is relatively high in the SN of LIMP-2 KO mice and 
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GlcCer appears relatively normal. In contrast, the concentrations of 
galactosylceramide and GlcSph are markedly abnormal. Galactosylceramide 
becomes markedly reduced in the SN of LIMP-2 KO mice, likely reflecting ongoing 
peripheral demyelination and explaining the tremors observed in animals. 
During our investigation, we have dedicated particular attention to the influence 
of the age of LIMP-2 KO mice with respect to lipid abnormalities. Interestingly, in 
almost all tissues, abnormalities in GlcSph and GlcChol were already present at 2 
months of age and did not dramatically worsen with age. Only in the case of thymus 
and adipose tissues, a continuous increase of GlcSph with age in LIMP-2 KO mice 
was observed. Our findings with LIMP-2 KO mice differ quite clearly from those 
observed in GD patients and mouse models, in which there is as increasing 
accumulation of GlcCer. A possible explanation for this may be that in LIMP-2 KO 
mice a new equilibrium is soon established by metabolism of excessive GlcCer to 
GlcSph. The latter may egress from lysosomes and then be degraded by the cytosolic 
enzyme GBA2 or even leave the body via the bile. Apparently, such pathway is not 
efficient enough in Gaucher patients to prevent accumulation of lipid-laden Gaucher 
cells. 
Our study fully confirms the earlier notion that LIMP-2 is essential in lysosomal 
targeting of GCase [57]. The observed relative high residual levels of GCase in 
leukocytes led us to look for alternative mechanisms of delivery of GCase in these 
particular cells. We obtained evidence for the uptake of GCase by lymphoblasts of 
AMRF patients and normal individuals, but not by the corresponding fibroblasts. The 
uptake seems to be mediated by endocytosis since it could be blocked by the 
dynamin inhibitor, Dynasore, although the receptor that is involved in this capture 
mechanism is presently not known. Mannan was not able to efficiently inhibit the 
endocytosis of GCase. Presently, it seems that the endocytic capture of secreted 
GCase offers an explanation for the relatively high residual GCase activity in 
leukocytes, being sufficient to prevent formation of GlcCer-laden Gaucher cells in 
AMRF patients. Indeed, in freshly obtained plasma of AMRF patients significant 
circulating GCase has been detected to allow such mechanism [248].  
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In conclusion, this work sheds some new light on the consequences of LIMP-2 
deficiency on residual GCase activity in various cells and tissues. Most tissues suffer 
from a marked deficiency in GCase. However, this does not lead to striking GlcCer 
accumulation but rather to elevated GlcSph. The water-soluble metabolite is either 
further degraded or able to exit the body via bile. In this way, a new equilibrium is 
established during LIMP-2 deficiency. Leukocytes seem to profit from their ability to 
re-uptake secreted GCase, acquiring sufficient residual enzyme activity to prevent 
formation of GlcCer-laden macrophages, the hallmark of GD. 
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4.6 Supplemental data 
Table S4.1 – List of the lysosomal matrix proteins identified in the tritosomes. “n.d.” - not detectable. 
Nº Protein Name Acces Nº  Description Countinj Ratio 
1 A2BFA6_MOUSE A2BFA6 
Alpha N acetylglucosaminidase Sanfilippo disease 
IIIB OS Mus musculus GN Naglu PE 4 SV 1 
9 1.06 
2 ARL8B_MOUSE Q9CQW2 
ADP ribosylation factor like protein 8B OS Mus 
musculus GN Arl8b PE 2 SV 1 
9 1.10 
3 CATH_MOUSE P49935 
Pro cathepsin H OS Mus musculus GN Ctsh PE 2 
SV 2 
9 1.22 
4 CATL1_MOUSE P06797 
Cathepsin L1 OS Mus musculus GN Ctsl1 PE 1 
SV 2 
9 0.98 
5 CATZ_MOUSE Q9WUU7 
Cathepsin Z OS Mus musculus GN Ctsz PE 2 SV 
1 
9 1.12 
6 CREG1_MOUSE O88668 
Protein CREG1 OS Mus musculus GN Creg1 PE 2 
SV 1 
9 1.45 
7 DPP2_MOUSE Q9ET22 
Dipeptidyl peptidase 2 OS Mus musculus GN 
Dpp7 PE 2 SV 2 
9 0.87 
8 GNS_MOUSE Q8BFR4 
N acetylglucosamine 6 sulfatase OS Mus 
musculus GN Gns PE 2 SV 1 
9 0.92 
9 LAMP1_MOUSE P11438 
Lysosome associated membrane glycoprotein 1 
OS Mus musculus GN Lamp1 PE 1 SV 2 
9 1.12 
10 LAMP2_MOUSE P17047 
Lysosome associated membrane glycoprotein 2 
OS Mus musculus GN Lamp2 PE 2 SV 2 
9 1.06 
11 LGMN_MOUSE O89017 Legumain OS Mus musculus GN Lgmn PE 1 SV 1 9 0.96 
12 LYAG_MOUSE P70699 
Lysosomal alpha glucosidase OS Mus musculus 
GN Gaa PE 1 SV 2 
9 1.07 
13 MA2B1_MOUSE O09159 
Lysosomal alpha mannosidase OS Mus musculus 
GN Man2b1 PE 2 SV 4 
9 0.84 
14 MANBA_MOUSE Q8K2I4 
Beta mannosidase OS Mus musculus GN Manba 
PE 2 SV 1 
9 0.76 
15 NAGAB_MOUSE Q9QWR8 
Alpha N acetylgalactosaminidase OS Mus 
musculus GN Naga PE 2 SV 2 
9 0.91 
16 NPC2_MOUSE Q9Z0J0 
Epididymal secretory protein E1 OS Mus musculus 
GN Npc2 PE 2 SV 1 
9 1.08 
17 PLBL2_MOUSE Q3TCN2 
Putative phospholipase B like 2 OS Mus musculus 
GN Plbd2 PE 1 SV 2 
9 0.93 
18 PPA5_MOUSE Q05117 
Tartrate resistant acid phosphatase type 5 OS Mus 
musculus GN Acp5 PE 2 SV 2 
9 0.72 
19 PPT2_MOUSE O35448 
Lysosomal thioesterase PPT2 OS Mus musculus 
GN Ppt2 PE 2 SV 1 
9 1.12 
20 RISC_MOUSE Q920A5 
Retinoid inducible serine carboxypeptidase OS 
Mus musculus GN Scpep1 PE 2 SV 2 
9 1.12 
21 RNT2_MOUSE Q9CQ01 
Ribonuclease T2 OS Mus musculus GN Rnaset2 
PE 2 SV 1 
9 0.82 
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22 NCUG1_MOUSE Q9JHJ3 
Lysosomal protein NCU G1 OS Mus musculus PE 
1 SV 1 
8 1.72 
23 PCP_MOUSE Q7TMR0 
Lysosomal Pro X carboxypeptidase OS Mus 
musculus GN Prcp PE 2 SV 2 
8 0.64 
24 CATF_MOUSE Q9R013 Cathepsin F OS Mus musculus GN Ctsf PE 2 SV 1 7 0.62 
25 CATS_MOUSE O70370 
Cathepsin S OS Mus musculus GN Ctss PE 2 SV 
2 
7 0.78 
26 HEXB_MOUSE P20060 
Beta hexosaminidase subunit beta OS Mus 
musculus GN Hexb PE 2 SV 2 
7 1.37 
27 CATC_MOUSE P97821 
Dipeptidyl peptidase 1 OS Mus musculus GN Ctsc 
PE 2 SV 1 
6 n.d. 
28 E9PVY4_MOUSE E9PVY4 
Uncharacterized protein OS Mus musculus GN 
Ppt1 PE 4 SV 1 
6 0.96 
29 GLCM_MOUSE P17439 
Glucosylceramidase OS Mus musculus GN GBA 
PE 1 SV 1 
6 n.d. 
30 LICH_MOUSE Q9Z0M5 
Lysosomal acid lipase cholesteryl ester hydrolase 
OS Mus musculus GN Lipa PE 2 SV 2 
6 0.44 
31 ARSB_MOUSE P50429 
Arylsulfatase B OS Mus musculus GN Arsb PE 2 
SV 3 
5 0.92 
32 ASM_MOUSE Q04519 
Sphingomyelin phosphodiesterase OS Mus 
musculus GN Smpd1 PE 2 SV 2 
5 0.59 
33 GALNS_MOUSE Q571E4 
N acetylgalactosamine 6 sulfatase OS Mus 
musculus GN Galns PE 2 SV 2 
5 2.16 
34 NICA_MOUSE P57716 Nicastrin OS Mus musculus GN Ncstn PE 1 SV 3 5 1.15 
35 SCRB2_MOUSE O35114 
Lysosome membrane protein 2 OS Mus musculus 
GN SCARB2 PE 1 SV 3 
5 n.d. 
36 ASAH1_MOUSE Q9WV54 
Acid ceramidase OS Mus musculus GN Asah1 PE 
1 SV 1 
4 n.d. 
37 E9PW67_MOUSE E9PW67 
Uncharacterized protein OS Mus musculus GN 
Hexa PE 4 SV 1 
4 0.97 
38 NPC1_MOUSE O35604 
Niemann Pick C1 protein OS Mus musculus GN 
Npc1 PE 1 SV 1 
4 n.d. 
39 PPT1_MOUSE O88531 
Palmitoyl protein thioesterase 1 OS Mus musculus 
GN Ppt1 PE 2 SV 2 
4 0.69 
40 SIAE_MOUSE P70665 
Sialate O acetylesterase OS Mus musculus GN 
Siae PE 2 SV 3 
4 n.d. 
41 ARL8A_MOUSE Q8VEH3 
ADP ribosylation factor like protein 8A OS Mus 
musculus GN Arl8a PE 2 SV 1 
3 n.d. 
42 E9Q9I3_MOUSE E9Q9I3 
Uncharacterized protein OS Mus musculus GN 
Acp2 PE 4 SV 1 
3 n.d. 
43 RAB7A_MOUSE P51150 
Ras related protein Rab 7a OS Mus musculus GN 
Rab7a PE 1 SV 2 
3 n.d. 
44 AGAL_MOUSE P51569 
Alpha galactosidase A OS Mus musculus GN Gla 
PE 1 SV 1 
2 n.d. 
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45 CD1D1_MOUSE P11609 
Antigen presenting glycoprotein CD1d1 OS Mus 
musculus GN Cd1d1 PE 1 SV 3 
2 n.d. 
46 DIAC_MOUSE Q8R242 
Di N acetylchitobiase OS Mus musculus GN Ctbs 
PE 2 SV 2 
2 n.d. 
47 E9Q515_MOUSE E9Q515 
Uncharacterized protein OS Mus musculus GN 
4930471M23Rik PE 4 SV 1 
2 n.d. 
48 HEXA_MOUSE P29416 
Beta hexosaminidase subunit alpha OS Mus 
musculus GN Hexa PE 2 SV 2 
2 n.d. 
49 HGNAT_MOUSE Q3UDW8 
Heparan alpha glucosaminide N acetyltransferase 
OS Mus musculus GN Hgsnat PE 1 SV 2 
2 n.d. 
50 Q3U2B2_MOUSE Q3U2B2 
Uncharacterized protein OS Mus musculus GN 
Npc1 PE 2 SV 1 
2 n.d. 
51 CATB_MOUSE P10605 
Cathepsin B OS Mus musculus GN Ctsb PE 1 SV 
2 
9 0.98 
52 Q8C243_MOUSE Q8C243 
Uncharacterized protein OS Mus musculus GN 
Ctsd PE 2 SV 1 
9 0.94 
53 SAP_MOUSE Q61207 
Sulfated glycoprotein 1 OS Mus musculus GN 
Psap PE 1 SV 2 
9 0.81 
54 SAP3_MOUSE Q60648 
Ganglioside GM2 activator OS Mus musculus GN 
Gm2a PE 1 SV 2 
9 0.68 
55 TPP1_MOUSE O89023 
Tripeptidyl peptidase 1 OS Mus musculus GN 
Tpp1 PE 1 SV 2 
9 1.22 
56 PPGB_MOUSE P16675 
Lysosomal protective protein OS Mus musculus 
GN Ctsa PE 1 SV 1 
8 1.40 
57 F6Y6L6_MOUSE F6Y6L6 
Uncharacterized protein Fragment OS Mus 
musculus GN Ctsd PE 3 SV 1 
7 0.95 
58 PAG15_MOUSE Q8VEB4 
Group XV phospholipase A2 OS Mus musculus 
GN Pla2g15 PE 1 SV 1 
4 n.d. 
59 CATD_MOUSE P18242 
Cathepsin D OS Mus musculus GN Ctsd PE 1 SV 
1 
3 n.d. 
60 VA0D1_MOUSE P51863 
V type proton ATPase subunit d 1 OS Mus 
musculus GN Atp6v0d1 PE 1 SV 2 
9 1.07 
61 D3Z437_MOUSE D3Z437 
Uncharacterized protein OS Mus musculus GN 
Ctsh PE 4 SV 1 
6 2.14 
62 E9Q5W3_MOUSE E9Q5W3 
Uncharacterized protein OS Mus musculus GN 
Ctsz PE 3 SV 1 
4 n.d. 
63 F6QKK2_MOUSE F6QKK2 
Uncharacterized protein Fragment OS Mus 
musculus GN Arl8a PE 3 SV 1 
4 n.d. 
64 VATB2_MOUSE P62814 
V type proton ATPase subunit B brain isoform OS 
Mus musculus GN Atp6v1b2 PE 1 SV 1 
4 n.d. 
65 E9Q2Q0_MOUSE E9Q2Q0 
Uncharacterized protein OS Mus musculus GN 
Ctsc PE 3 SV 1 
3 0.59 
66 F7AF87_MOUSE F7AF87 
Uncharacterized protein Fragment OS Mus 
musculus GN Glb1 PE 4 SV 1 
3 0.60 
67 CD68_MOUSE P31996-2 Isoform Short of Macrosialin OS Mus musculus 2 n.d. 
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GN Cd68 
68 HGNAT_MOUSE 
Q3UDW8-
2 
Isoform 2 of Heparan alpha glucosaminide N 
acetyltransferase OS Mus musculus GN Hgsnat 
2 n.d. 
69 LTOR3_MOUSE O88653 
Ragulator complex protein LAMTOR3 OS Mus 
musculus GN Lamtor3 PE 1 SV 1 
2 n.d. 
70 STOM_MOUSE P54116 
Erythrocyte band 7 integral membrane protein OS 
Mus musculus GN Stom PE 1 SV 3 
2 n.d. 
 
 
 
 
 Figure S4.1 – Hepatocyte from wild type and LIMP-2 KO mice, 6 months of age. 
 
 
 
Figure S4.2 – Sciatic nerves from a wild type (left) and LIMP-2 KO mice (right). 
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Figure S4.3 – Gb3 in the tissues of LIMP-2 KO and wild type mice. Left panel - Absolute amounts; Right panel - Relative 
increase when compared to wild type. Dashed line marks the normal values obtained in wild type mice. 
 
 
 
Figure S4.4 – LysoGb3 measured in tissues of LIMP-2 KO and wild type mice. Left panel - Absolute amounts; Right panel - 
Relative increase when compared to wild type. Dashed line marks the normal values obtained in wild type mice. 
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Figure S4.5 – Gb3 levels in wild type and LIMP-2 KO mice at different ages.  Black circle - wild type; Black square - LIMP-2 KO 
mice. 
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Figure S4.6 – LysoGb3 levels in wild type and LIMP-2 KO mice at differents ages.  Black circle - wild type; Black square - LIMP-
2 KO mice. 
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Figure S4.7 – Analysis of the THP-1 cell line with lentiviral SCARB2 knock-out. A - Western-blot against LIMP-2 protein in THP-
1 cells treated with SCARB2 siRNA and scrambled siRNA; B - SCARB2 gene expression; C - GCase activity measured with 4-
MU-β-D-Glc. 
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5.1 Abstract 
 
Deficiency of the lysosomal enzyme GCase is encountered in patients with GD as 
well as in individuals with AMRF. GD is caused by mutations in the GBA gene 
encoding GCase, whilst AMRF is due to mutations in the SCARB2 gene encoding the 
lysosomal membrane protein LIMP-2, which governs the transport of newly formed 
GCase to lysosomes. In AMRF patients, GCase deficiency is secondary, being the 
result of impaired transport of enzyme to lysosomes. AMRF manifest primarily as a 
neurological disorder without major visceral complications except for late onset renal 
disease. In the common non-neuronopathic (type 1) manifestation of GD, storage of 
the GCase substrate GlcCer almost exclusively occurs in macrophages. Two different 
kinds of therapies are registered for type 1 GD: macrophage-targeted ERT and 
glycosphingolipid SRT. No treatment is presently available for AMRF. 
Since GCase is the prominent biochemical abnormality in AMRF patients, we studied 
the feasibility to supplement LIMP-2 deficient cells with recombinant GCase (hrGBA). 
Studies were conducted with normal and AMRF fibroblasts as well as normal and 
LIMP-2 deficient HEK293T cells transduced with mannose receptor to promote 
uptake of mannose-terminated hrGBA. With both cell types we observed that 
following its endocytotic uptake and delivery to lysosomes, GCase is rapidly degraded 
in LIMP-2 deficient lysosomes. The half-life of the enzyme in LIMP-2 lysosomes is 
much shorter than in corresponding normal organelles. This finding suggests that, 
also intralysosomally, transient interactions of GCase with LIMP-2 stabilize the 
conformation of the enzyme and thus prevent proteolytic breakdown. This finding 
indicates that an intrinsic limit, installed by LIMP-2 presence, may exist in the efficacy 
of supplementing the GCase capacity of lysosomes by ERT. Next, we examined the 
feasibility of glycosphingolipid substrate reduction therapy. For this purpose LIMP-2 
KO mice were orally treated with a newly developed brain permeable azasugar. The 
dose used proved to be too small to render sufficient inhibition of glycosphingolipid 
synthesis. 
LIMP-2 deficiency: therapeutic approaches 
109 
 
In conclusion, ERT does not seem an attractive approach for treatment of AMRF and 
further investigations are warranted regarding the potential efficacy of SRT using oral 
inhibitors of GlcCer synthesis. 
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5.2 Introduction  
 
 GD is an autosomal recessive disorder caused by impaired GlcCer catabolism 
as the result of GCase deficiency. The defect leads to prominent storage of GlcCer in 
lysosomes of macrophages that lead to the formation of “Gaucher cells” (lipid-laden 
macrophages), the hallmark of the disease [87, 114]. GCase is encoded by the GBA 
gene and more than 200 different mutations have been described in GD patients [95, 
266, 267]. The symptomatology of GD is remarkably heterogeneous ranging from 
severe neonatal forms to an almost asymptomatic course until old age. Based on the 
occurrence and age of onset of the neurological involvement, GD has been classified 
into acute and juvenile neuronopathic forms and non-neuronopathic forms. The non-
neuronopathic form, type 1 GD, is the most common and may manifest either in 
childhood or adulthood. Type 2 GD is characterized by infantile onset and severe 
neurological involvement. Type 3 GD type is a less severe and slowly progressive 
neuronopathic form [87, 105]. Although there are no strict genotype-phenotype 
correlations, some mutations are associated with type 1 GD, like the homo- or 
heteroallelic presence of GBA with the N370S mutation. On the other hand, 
homozygosity for the GBA allele with the L444P mutation is associated with a 
neuronopathic form of the disease [266]. The accumulation of GlcCer in “Gaucher 
cells” leads to characteristic visceral features of the disease such as cytopenia, 
hepatosplenomegaly and skeletal abnormalities [113]. 
 For a long time, it remained unknown how GCase reaches the lysosome. In 
contrast to other lysosomal enzymes, GCase does not acquire any phosphomannosyl 
moieties in its 4 N-linked glycans. Clearly, the enzyme has to be targeted to the 
lysosomes by a mechanism independent of the M6PR [203, 204]. Only in 2007, 
LIMP-2 was identified as the protein responsible for the sorting of GCase to the 
lysosome, since its absence leads to GCase deficiency in almost all organs [57]. 
Mutations in the SCARB2 gene, which encodes the LIMP-2 protein, are the cause of 
a disorder called AMRF. This disease is characterized by reduced levels of GCase in 
the majority of the cells, and clinical symptoms such as glomerulosclerosis, 
progressive myoclonus epilepsy, and ataxia [201, 210, 212, 218]. In addition, 
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accumulation of undefined storage material in the brain has been reported [211]. 
Although, LIMP-2 deficient individuals share a GCase deficiency with GD patients, the 
clinical presentation of AMRF is markedly different from GD. Most striking is the 
absence of “Gaucher cells” in AMRF patients and the corresponding lack of elevated 
plasma chitotriosidase and CCL18. AMRF patients do not show visceromegaly or 
neurological symptoms seen in severe GD patients [218].  
 In addition to GD, alterations in the GBA gene have been recently also linked 
to PD. More specifically, GBA mutations have been found to be associated to an 
increased risk for α-synucleinopathies such as PD and Lewy-Body dementia [123, 
124]. This increased risk has also been reported for mutations in the SCARB2 gene 
[235, 268, 269]. In mice treated with the GCase inhibitor CBE, the reduction in GCase 
activity induces the storage of α-synuclein [126, 270]. Consistently, adenoviral 
overexpression of GCase in the brain decreases α-synuclein in transgenic mouse 
models of GD and PD [128]. Recently, α-synuclein storage was also described in 
LIMP-2 KO mice [236]. 
Several treatments have been developed, or are under investigation, for GD. 
Already in 1991, ERT was firstly introduced for type 1 GD using alglucerase 
(Ceredase®) (GCase isolated from human placenta). In 1994 imiglucerase 
(Cerezyme®) (hrGBA), a recombinant enzyme produced in chinese hamster ovary 
cells [147] was firstly employed for ERT of type 1 GD. Only a few years ago, in 2010, 
an alternative recombinant enzyme preparation became available following the 
registration of velaglucerase alfa (VPRIV®) produced in a human fibroblast cell line 
[271]. In all cases, (recombinant) GCases were remodeled to expose terminal 
mannose residues in order to be efficiently captured by the mannose receptor 
expressed by macrophages, the most prominently affected cells in type 1 GD 
patients. Recently a new recombinant enzyme was registered, Taliglucerase alfa 
(Elelyso®), produced in carrots, avoiding possible contamination with mammalian 
viruses [272, 273]. All ERT treatments are found to be effective for the majority of 
type 1 GD patients, but their inability to cross the BBB, makes them ineffective to treat 
or prevent neuropathology in type 2 and type 3 GD patients. An entirely different 
approach to treat GD is SRT. This aims to reduce the levels of GlcCer by inhibiting 
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the biosynthetic enzyme GCS [274]. SRT offers an alternative to ERT in those 
patients that are not willing to undergo, or do not tolerate, chronic bi-weekly enzyme 
infusions. The first compound registered for SRT was N-butyldeoxynojirimycin 
(Miglustat®), also named Zavesca® [160]. N-butyldeoxynojirimycin resembles in its 
structure GlcCer and inhibits GCS, but also, even more potently, the β-glucosidase 
GBA2 [158]. Since 2003, Miglustat (Zavesca®) has been used for SRT, although it is 
a relatively poor GCS inhibitor with a IC50 of 25 µM [158, 274–276]. Very recently, 
eliglustat tartrate (Cerdelga®) has been registered for use in SRT of type 1 GD [163–
165]. This compound is a ceramide mimic, being a far more potent GCS inhibitor with 
IC50 of about 50 nM and without inhibitory effects on β-glucosidases. Unfortunately, 
Eliglustat does not penetrate into the BBB and therefore is only registered for 
treatment of type 1 GD patients. The compound is also subjected to CYP2B 
metabolism and cannot be used in individuals with abnormalities in this detoxification 
enzyme. In the meantime, N-(5'-adamantane-1'-yl-methoxy)-pentyl-1- 
deoxynojirimycin (AMP-DNM) [277] also named MZ21, was also developed and 
tested as GCS inhibitor. This compound shows an IC50 for GCS of 150 nM and is 
BBB permeable, although it was never developed as a drug, due to the lack of 
industrial interest given its concomitant potent inhibition of GBA2 and to a lesser 
extent, also of the lysosomal GCase. It was observed that ido-variants of the 
deoxynojirimycins like AMP-DNM inhibit GCS with the same efficacy but with much 
less affinity for GCase. Based on these compounds, a new generation of 
deoxynojirimycin type GCS inhibitors with IC50 values in the very low nanomolar 
range has been recently developed [167]. One of the most promising compounds in 
this category is 1307RB20 [167].  Another approach for treating GD is the use of 
pharmacological chaperones. They are compounds that are able to promote folding of 
mutant GCase, promoting its delivery to lysosomes. Inside the lysosome, the 
chaperone and GCase ideally dissociate and the enzyme becomes thus available to 
degrade the substrate [278]. At present, no effective chaperone has yet been 
developed to treat neuronopathic GD, in part because the GD patients with 
neurological forms generally show almost no residual GCase activity [87]. Also, at the 
experimental stage as GD treatments are gene therapies approaches as well as 
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treatments aiming to beneficially manipulate downstream pathways that are affected 
in GD [127, 169]. 
Presently, there is no therapy available for AMRF. Although GD and AMRF 
differ in phenotype, they both share the deficiency in GCase activity. It is therefore of 
interest to investigate the potential beneficial impact of treating AMRF with 
approaches similar to the ones successfully employed for GD. Here, we report the 
outcome of supplementing AMRF cell lines with Cerezyme® (hrGBA) and the 
treatment of LIMP-2 KO mice with one of the most promising compounds in SRT, the 
1307RB20. These investigations aim to obtain insight into whether treatments 
available for GD might be potentially beneficial for individuals suffering from LIMP-2 
deficiency. 
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5.3. Impact of LIMP-2 on GCase:  
Consequences for Enzyme Replacement Therapy
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5.3.1 Methods   
 
5.3.1.1 Patients’ samples 
 
Materials used from donors and the respective culturing procedures are 
described in section 3.3.2. 
 
5.3.1.2 SCARB2 gene Knock-out in HEK293T cells  
 
SCARB2 gene knock-out in Human Embryonic Kidney 293 (HEK293) cells 
(ATCC CRL 1573) was generated using the CRISPR/Cas9 system. Guide RNA 
sequences were selected using the optimized CRISPR design tool 
(http://crispr.mit.edu) using the individual SCARB2 exon sequences as template. For 
the selected guides two complementary oligo´s containing the SCARB2 guide 
sequences and BbsI ligation adapters were annealed and ligated into pX335 (pX335-
U6-Chimeric_BB-CBh-hSpCas9n (D10A, Nickase, Addgene plasmid #42335) 
digested with BbsI according to the protocol described [279]. Primers used for 
SCARB2 exon 1 were: guide 1 5'- CACCGGACGTTGTCCCTGCTCCTGC-3 and 5'- 
AAACGCAGGAGCAGGGACAACGTCC-3'. SCARB2 exon 1 guide 2 5'- 
CACCGCCGCCGTGTAGAAGCAGCAT-3' and 5'- 
AAACATGCTGCTTCTACACGGCGGC-3'. For targeting the SCARB2 exon 7, the 
primers were: guide 1 5'-CACCGTATACCTGAGGGAAACTGCC-3' and 5'-
AAACGGCAGTTTCCCTCAGGTATAC-3'. guide 2 5'- 
CACCGGCCGGCATTGTCTGACGTAT-3' and 5'- 
AAACATACGTCAGACAATGCCGGCC-3'.  
HEK293T cells were transfected with a 1:1 ratio of pX335 guide 1 and pX335 
guide 2 for either exon 1 or exon 7 of the SCARB2 gene using FuGene6 (Roche) with 
a FuGene: DNA ratio of 3:1. Two days after transfection single cell clones were 
isolated. Clones were checked by PCR and sequencing for the presence of indels. 
One clone (N1F8) with sequence confirmed indels was shown to secrete GCase. 
Western-blot analysis (data not shown) showed that clone N1F8 lacks any LIMP-2 
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protein. HEK293T cells were cultured in DMEM with high glucose supplemented with 
10% FBS and 100 units/ml Pen/Strep. 
 
5.3.1.3. Transfection of HEK293T cells with macrophage mannose receptors 
 
HEK293T cells were cultured in DMEM with high glucose supplemented with 
10% FBS and 100 units/ml Pen/Strep. One day before transfection 4 x 105 cells/well 
were seeded in a 6 well plate.  HEK293T cells and HEK293T SCARB2 knock-out 
cells (clone N1F8) were infected with a human Mannose Receptor (CD206) 
pLenti6.3/TO/V5-DEST construct, generated via PCR and the Gateway cloning 
system (Invitrogen) using primers 5'-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGGTACCACCATGAGGCTACCCCT
GC-3' and 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTCGATGACCGAGTGTTCATTCTG-3', 
and pDONR221 as the cloning intermediate. All constructs were verified by 
sequencing. To produce lentiviral particles HEK293T cells were transfected with 
pLenti6.3-CD206 in combination with the envelope and packaging plasmids pMD2G, 
pRRE and pRSV. Subsequently, culture supernatant containing viral particles was 
collected and used for infection of HEK293T cells and HEK293T SCARB2 knock-out 
cells (clone N1F8). Infected cells were selected using blasticidin (Sigma) 2.5 µg/ml. 
 
5.3.1.4 Cell culture and experiments 
 
Fibroblasts were cultured in DMEM medium supplemented with 10% fetal 
bovine serum and 1% Pen/Strep. HEK293T cells were seeded one day before the 
experiment at 1 × 106 cells/well in a 6 well plate. The cells were subjected to the 
following 4 conditions during 4 days: no treatment; supplemented 20 µM of leupeptin 
(a broad spectrum cathepsin inhibitor); supplemented each day with 32 ng/µl of 
human recombinant GCase (hrGBA); and supplemented with 32 ng/µl of hrGBA each 
day, 1 h after the single addition of 20 µM of leupeptin. At the fourth day of exposure, 
the cells were harvested.  
LIMP-2 deficiency: therapeutic approaches 
Impact of LIMP-2 on GCase: Consequences for ERT 
118 
 
In a parallel experiment, to evaluate the effect of leupeptin in hrGBA, cells were 
exposed to leupeptin and hrGBA and only hrGBA. At the fourth day, the cells were 
washed with cold PBS, and the cells were cultured with or without leupeptin, as 
previous.  
 
5.3.1.5 Uptake of human recombinant glucocerebrosidase 
 
HEK293T cells were seeded one day prior to the experiment at 1 x 106 
cells/well in a 6 well plate. The cells were subjected to the following condition: 32 
ng/µl of hrGBA, one hour after the addition of 20 µM of leupeptin. The following time 
points were collected: 0, 10, 20, 30 min. 
 
5.3.1.6 Preparation of cell lysates 
 
Isolated fibroblasts and HEK293T cells were homogenized and protein content 
quantified as described in section 3.3.4. 
 
5.3.1.7 Labelling of glucocerebrosidase with activity-based probes 
 
Cell homogenates were incubated with MDW941 (100 nM) in McIlvaine buffer 
as described in detail in section 4.3.9.  
 
5.3.1.8 Western-Blotting 
 
Performed exactly as described in section 3.3.6. 
 
5.3.1.9 Immunofluorescence 
 
Fibroblasts were cultured on glass slides. The cells were subjected to the 
following 4 conditions during 4 days: no treatment; supplemented witg 20 µM of 
leupeptin; supplemented with 32 ng/µl of hrGBA each day and supplemented with 32 
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ng/µl of hrGBA each day one hour after of a single addition of 20 µM of leupeptin. 
Cells were incubated with 1 nM MDW941 overnight in HAM/DMEM with 10% FCS. 
Next, cells were washed, fixed with 3% (v/v) paraformaldehyde in PBS for 1 h, 
washed with PBS and incubated with 0.1% saponin in PBS. They were washed again 
with PBS, incubated with 0.1 mM NH4Cl in PBS for 10 min and then with normal 
antibody diluent (BD09-999;  Immunologic, Duiven, The Netherlands) for 2 h. Nuclei 
were stained with DAPI, LIMP-2 protein with an rabbit IgG anti-LIMP-2 antibody 
(NB400-129, Novus Biologicals, Abingdon, UK) and the LAMP-2 protein with a mouse 
IgG1 anti-LAMP-2 antibody (clone H4B4; 9840-01, Southern Biotechnology 
Associates, Birmingham, AL). Second step antibodies were Alexa Fluor 488-
conjugated goat IgG anti-rabbit (A11034; Life Technologies, Bleiswijk, The 
Netherlands) and ATTO647N-conjugated goat IgG anti-mouse IgG (610-156-121; 
Rockland, Limerick, PA). Slides were mounted using ProLong Gold (Life 
Technologies). Imaging was performed by confocal laser scanning microscopy using 
a TCS SP8 X mounted on a DMI 6000 microscope with a Plan APO 63x/1.40 Oil CS2 
objective. For excitation were applied a 405 nm UV diode for DAPI, and a 470-670 
nm WLL Pulsed laser, sequentially set at 488 nm, 592 nm and 647 nm for the 
respective fluorochromes. PMT and HyD detection was applied. Recorded images 
were analyzed and overlayed using LAS X software (Leica Microsystems, Son, The 
Netherlands). 
 
5.3.1.10 Enzymatic  assays  
 
Enzymatic assays were performed according to section 3.3.10.
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5.3.2 Results   
 
5.3.2.1 Human recombinant glucocerebrosidase and inhibitors of cathepsins 
 
To evaluate the proteolytic degradation inside the lysosome, fibroblasts (wild 
type, GD and AMRF) were treated during 4 days with leupeptin, a cysteine protease 
cathepsin inhibitor, to inhibit intralysosomal proteolytic degradation of GCase (Fig. 
5.1).  The presence of leupeptin resulted in increased cellular GCase activity, 
detected by enzymatic assay (Fig. 5.1, left panel) and by ABP labelling of active 
GCase molecules (Fig. 5.1, right panel). Both the detection of GCase activity with a 
fluorescent substrate or labelling of GCase with ABP showed that the presence of 
leupeptin led to an increase in GCase in wild type and AMRF fibroblasts.  No 
significant changes were observed in the case of the L444P homozygous GD cells. 
The latter finding is not surprising since the L444P mutation results in misfolding of 
the enzyme in the ER and its subsequent proteosomal degradation. 
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Figure 5.1 – Effect of leupeptin on cellular GCase. Left panel - GCase enzymatic activity determined with 4-MU-β-D-Glc; Right 
panel - ABP labelling followed by SDS-PAGE. Detection of LIMP-2 by Western blot. Symbols: “-“ no treatment; “+” Leupeptin 20 
µM; “WT” - wild type; “AMRF” - LIMP-2 deficient cell line; “GD” - Gaucher cell line; “ABP” - activity based probe. 
 
The same fibroblast cell lines were then supplemented with recombinant 
GCase (hrGBA) in the medium for 4 days, in the presence or absence of leupeptin 
(Fig. 5.2). Addition of hrGBA to the medium led to an increase in cellular GCase in the 
case of control fibroblasts and GD cell lines. The increase observed was almost null 
in the case of AMRF cultured in the absence of leupeptin. The increase, in all the cell 
lines analyzed, was more prominent in the presence of leupeptin, pointing to a higher 
stabilization of GCase in the lysosomes (Fig. 5.2, left panel). Analysis of GCase by 
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ABP labelling gave similar results (Fig. 5.2, right panel). Of note, the stabilizing effect 
of leupeptin was more striking in the case of the AMRF fibroblasts, suggesting that 
endocytozed GCase is particularly sensitive to lysosomal degradation in AMRF 
fibroblasts. 
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Figure 5.2 – Supplementation of fibroblasts with hrGBA, cultured with or without leupeptin. Left panel - GCase enzymatic activity 
with 4-MU-β-D-Glc; Right panel - ABP labelling followed by SDS-PAGE. Detection of LIMP-2 by Western blot. Symbols: “-“ 
hrGBA; “+” Leupeptin 20 µM plus hrGBA; “WT” - wild type; “AMRF” - LIMP-2 deficient cell line; “GD” - Gaucher cell line; “ABP” - 
activity based probe. 
 
5.3.2.2 Cellular localization of endocytozed human recombinant 
glucocerebrosidase 
 
To assess whether hrGBA indeed reaches the lysosome in the case of LIMP-2 
deficiency, immunofluorescence experiments were carried out with wild type and 
AMRF fibroblasts. For this purpose, we combined detection of GCase by ABP 
labelling with immune-detection of the lysosome with the markers LAMP-2 and LIMP-
2 (Fig. 5.3). Cells were pre-treated, or not with leupeptin and they were cultured in the 
presence or absence of hrGBA.  In all the conditions tested, we observed that GCase 
co-localized with the lysosome marker (LAMP-2) in control fibroblasts. With the three 
treatments (leupeptin, hrGBA or leupeptin plus hrGBA) the amount of active GCase 
inside the lysosomes of wild type fibroblasts increased when compared to non-treated 
cells (Fig. 5.3, left panel). Regarding AMRF fibroblasts treated with leupeptin, some 
lysosomal GCase colocalization with lysosomes was detected, particularly when it is 
followed by exposure of cells to hrGBA (Fig. 5.3, right panel). When only hrGBA is 
added, almost no increase of lysosomal GCase is observed (Fig. 5.3, right panel). 
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Again, these findings suggest that GCase, either endogenous or exogenously added, 
is particularly sensitive to lysosomal degradation in AMRF fibroblasts. 
 
 
 
 
Figure 5.3 – Detection of GCase in wild type and AMRF fibroblasts. Cells were treated with or without leupeptin and with hrGBA, 
Left panel - wild type fibroblasts; Right panel - AMRF fibroblasts; “ABP1” - Activity based probe; “DAPI” - Nucleus staining. 
 
5.3.2.3 Role of LIMP-2 in stability of human recombinant glucocerebrosidase as 
assessed in modified HEK293T cells 
 
Given the observed lability of GCase in lysosomes of AMRF fibroblasts, we 
attempted to recapitulate this finding by constructing HEK293T cells deficient in LIMP-
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2. For this purpose, in HEK293T cells, SCARB2 gene was knocked-out by CRISPR 
technology [279]. In addition, HEK293T cells were stably transfected with cDNA 
encoding the mannose receptor. Mannose receptor positive cells allow a more 
efficient uptake of hrGBA with terminal mannose residues in its N-linked glycans. 
Having available the different HEK293T cell lines, the experiments conducted with 
fibroblasts described above were repeated (Fig. 5.4). As observed with the wild type 
fibroblast cell lines (Figs 5.1 and 5.2), control HEK293T cells showed an increase in 
GCase in the presence of leupeptin, either transfected or non-transfected with 
mannose receptor. In the cases of the LIMP-2 deficient HEK293T cells, the presence 
of leupeptin also resulted in increased GCase activity, despite still being very low (Fig. 
5.4, left panel). Upon addition of hrGBA to the HEK293T cell lines, a marked increase 
in cellular GCase became apparent, particularly in cells transfected with the mannose 
receptor. GCase activity increased mostly when hrGBA was added after the treatment 
with leupeptin (Fig. 5.4, right panel). Just adding hrGBA alone to the LIMP-2 deficient 
HEK293T cells, hardly resulted in increased cellular GCase activity (Fig 5.4, right 
panel). The concomitant presence of leupeptin during incubation in LIMP-2 deficient 
cells expressing mannose receptor with hrGBA resulted in a very prominent increase 
of cellular GCase activity. Levels of GCase became almost identical to those seen in 
corresponding wild type cells (Fig 5.4, right panel). Thus, the findings with fibroblasts 
were recapitulated: endogenous as well as exogenous GCase in lysosomes of LIMP-
2 deficient cells are prone to leupeptin sensitive proteolytic degradation. This finding 
suggests that the presence of LIMP-2 in lysosomes strongly stabilizes GCase.  
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Figure 5.4 – GCase activities in wild type and LIMP-2 deficient HEK293T cells with or without mannose receptor: effect of LIMP-
2 and exposure to exogenous GCase. Cellular GCase was measured with the fluorescent substrate 4-MU-β-D-Glc. Left panel - 
Cells not exposed to exogenous hrGBA; Right panel - Cells exposed to exogenous hrGBA. “MR” - mannose receptor. 
 
5.3.2.4 Similar uptake of human recombinant glucocerebrosidase by wild type 
and LIMP-2 deficient HEK293 cells 
 
To evaluate whether the uptake of hrGBA differs in LIMP-2 deficient cells, hrGBA was 
added to the various HEK293T cells, with or without expression of the mannose 
receptor. At several time points up to 30 min, cells were harvested and analyzed for 
GCase content (Fig. 5.5). Leupeptin was present during the entire experimental 
procedure. Very similar rates of uptake were observed for wild type and LIMP-2 
deficient cells in the absence of mannose receptor, indicating that LIMP-2 plays no 
major direct role in endocytosis of hrGBA. Only the wild type cells expressing 
mannose receptor showed a slightly faster uptake of hrGBA in the experiment 
depicted.   
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Figure 5.5 – Increment in cellular GCase during exposure to hrGBA in different HEK293T cell lines in presence of leupeptin. 
GCase activities were measured with the fluorescent substrate 4-MU-β-D-Glc. The cellular GCase present prior to uptake was 
subtracted and the increment in cellular GCase activity over time is shown. 
 
 5.3.2.5 Stability of human recombinant glucocerebrosidase in wild type and 
LIMP-2 deficient lysosomes 
 
Fibroblast from a control subject, an AMRF patient and GBA L444P/L444P GD 
patient were incubated with hrGBA for 4 days, and then chased for different time 
points in the absence of leupeptin (Fig. 5.6). The reduction in cellular GCase activity 
during the chase was very prominent in AMRF fibroblasts when compared to wild 
type and GD cells. The half-life of GCase in the AMRF fibroblasts was only about 15 
h (Fig. 5.6, right side). 
 
 
Figure 5.6 – Chase of endocytozed hrGBA in different fibroblast cell lines. GCase activities measured with the fluorescent 
substrate 4-MU-β-D-Glc. Left panel - Absolute GCase activity; Right panel - Relative GCase activity. The activity at the beginning 
of the experiment (T0) was assumed to be 100% 
 
To assess whether hrGBA has a different sensitivity for proteolytic breakdown 
inside wild type and LIMP-2 deficient lysosomes, a 34 h chase of endocytozed hrGBA 
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was performed in the presence of leupeptin in the differents cell lines (wild type, GD 
and AMRF fibroblasts) (Fig. 5.7). In the presence of this protease inhibitor the stability 
of cellular GCase following uptake of hrGBA was very similar in wild type, GD and 
AMRF fibroblasts. This observation, together with the findings obtained in the 
absence of leupeptin (Fig. 5.6), indicates that proteolytic turnover of endocytozed 
hrGBA occurs faster in AMRF lysosomes compared to LIMP-2 positive lysosomes. 
Therefore, intralysosomally LIMP-2 may assist in conformational stabilization of 
GCase and thus reduce its intralysosomal proteolytic degradation. 
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Figure 5.7 – Half-life of hrGBA in presence (+) of leupeptin. Activity at T0 was assumed as 100% for each cell line. Upper panel - 
SDS-PAGE slab-gels with ABP labelling of GCase. Lower panel - GCase activity measured with fluorescent substrate. “Ø” - no 
treatment; “E” - hrGBA; “L” - Leupeptin; “E+L” - Leupeptin plus hrGBA. 
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5.3.3 Discussion 
  
In the present study we investigated the impact of LIMP-2 on GCase beyond 
it’s binding to the receptor protein and subsequent intracellular transport into the 
lysosome. The key role of LIMP-2 in sorting GCase from the ER to lysosomes has 
been unequivocally demonstrated. Binding of newly formed GCase to a specific 
domain in LIMP-2 governs its routing to lysosomes [194]. It has been proposed that at 
low pH the complex dissociates and GCase is released [58, 202]. However, binding of 
GCase to LIMP-2 is not completely abolished at pH values below 6.0 [58]. It is 
therefore conceivable that even inside lysosomes GCase and LIMP-2 may transiently 
bind with beneficial effects regarding GCase fold and resistance against proteolytic 
breakdown. To study this possibility we exposed wild type and LIMP-2 deficient 
HEK293T cells to leupeptin, an inhibitor of the lysosomal cathepsins B, F, L and S, all 
cysteine proteases. Leupeptin is known for a long time to effectively reduce 
intralysosomal degradation of GCase [280]. We observed that leupeptin caused a 
minor increase in GCase levels in fibroblasts obtained from a type 3 GD patient 
homozygous for GBA L444P. It is known that in such individuals, reduced amounts of 
enzyme reaches the lysosomes due to predominant misfolding in the ER. 
Consequently, little stabilization by leupeptin treatment can be observed (see also 
[280]). In contrast, some increase in GCase is induced in wild type fibroblasts by the 
presence of leupeptin. Striking is the response of AMRF fibroblasts. In this case, the 
leupeptin mediated increase in cellular GCase is very prominent. This suggests that 
the little amount of GCase that manages to reach lysosomes during LIMP-2 
deficiency is very prone to intralysosomal proteolytic degradation, which is leupeptin 
inhibitable. A similar observation was obtained from follow-up experiments in which 
cells were incubated with hrGBA. It was observed that in GD fibroblasts, as in wild 
type cells, hrGBA was taken up and delivered to lysosomes. Again, in lysosomes of 
AMRF cells, the hrGBA appeared far more sensitive to proteolytic, leupeptin-
inhibitable, degradation when compared to wild type fibroblasts. The half-life of 
endocytozed hrGBA in AMRF fibroblasts was surprisingly short, being only about 15 
h. To exclude if the differences observed between wild type and AMRF fibroblasts 
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were due to genetic differences beyond the SCARB2 gene in the two donors, we 
generated from the same HEK293T cell line by CRISPR technology, LIMP-2 deficient 
cells. The observations with fibroblasts were fully recapitulated in the HEK293T LIMP-
2 deficient cell lines: endogenous or exogenous GCase in LIMP-2 deficient 
lysosomes appears far more vulnerable to leupeptin-inhibitable proteolytic 
breakdown. Based on this observation, it can be speculated that indeed transient 
interactions between LIMP-2 and GCase in lysosomes exert a crucial beneficial 
effect. Therefore, ERT in AMRF patients may not be a very successful therapeutic 
approach. Moreover, it may even possible that the effectiveness of ERT is maximized 
by the endogenous finite presence of LIMP-2 in lysosomes. When ERT with very high 
doses of hrGBA would result in a far excess of exogenous GCase over endogenous 
LIMP-2 in lysosomes, the stability of such enzyme could be limited due to restricted 
availability of LIMP-2.  Theoretically, administration of very large amounts of hrGBA to 
cells may reduce the stability of endogenous GCase due to competition for LIMP-2 
stabilization inside lysosomes. It should be noted that a stabilizing effect of LIMP-2 on 
intralysosomal GCase has important implications. GD patients who concomitantly are 
carriers for LIMP-2 deficiency may present less lysosomal GCase compared to similar 
patients with normal LIMP-2. Indeed, it has been reported that carriership for LIMP-2 
deficiency acts as modifier and worsens the clinical course of GD [225]. 
We also investigated whether LIMP-2 may be involved in uptake of GCase, 
since low amounts of LIMP-2 are likely to be also transiently present at the cell 
surface. However, no evidence for this was obtained in experiments with wild type 
and LIMP-2 deficient HEK293T cells. Preliminary experiments regarding the uptake of 
hrGBA seemed very similar, in contrast to the subsequent stability of the endocytozed 
enzyme. The use of ERT to treat GCase deficiency in AMRF patients is not an 
attractive approach. We have earlier demonstrated that GCase is deficient in most 
cell types during LIMP-2 deficiency (see chapter 3). White blood cells, in particular 
monocytes-macrophages, do not seem to be implicated in the pathology of AMRF in 
sharp contrast to the situation in GD. The use of a macrophage targeted, mannose-
terminated recombinant GCase, as present in Cerezyme®, Velaglucerase® and 
Taliglucerase®, would likely not lead to the correction of clinically relevant cell types in 
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AMRF patients. Other therapeutical approaches such as gene therapy or 
pharmacological manipulation of the glycosphingolipid metabolism seem to be more 
attractive to ameliorate abnormalities in AMRF patients. Studies with LIMP-2 KO 
mice, which offer a genuine model for human AMRF, will be decisive to determine in 
the future, which approach is the most appealing to treat AMRF, a disorder with still 
unmet clinical needs. 
In summary, the interaction of LIMP-2 and GCase takes place in multiple parts 
of the cell. Immediately after synthesis, GCase is bound to LIMP-2 and routed to 
lysosomes in a complex. Inside lysosomes, LIMP-2 and GCase transiently dissociate 
and re-bind. The latter process seems essential for the stability of GCase 
conformation and its associated resistance against degradation by leupeptin-
inhibitable cathepsins. Thus, GCase is heavily dependent on LIMP-2 from its birth to 
death, from routing from ER to lysosomes and for its intralysosomal survival.  
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5.4 Pilot study on Substrate Reduction Therapy  
in LIMP-2 deficiency (Mice and cells)
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5.4.1 Methods  
 
5.4.1.1 Animal studies and tissue collection and homogenization 
 
LIMP-2 KO mice, kindly provided by Prof. Paul Saftig (Kiel, Germany), were 
generated as described in section 4.3.1. A total of 12 animals were used, all male of 
3-4 months of age, equally distributed in genotype (wild type and LIMP-2 KO). Three 
wild type and 3 LIMP-2 KO mice were treated on a daily basis, for 14 consecutive 
days with a single dose of the Vehicle (1% DMSO/PBS), while 3 WT and 3 LIMP-2 
KO mice were treated daily with the GCSi 1307RB20 (1 mg/kg/day). After 14 days, all 
mice were sacrificed for collection of blood and organs. The collection of the tissues 
and the homogenization procedure is detailed in section 4.3.2 and 4.3.5, respectively. 
 
5.4.1.2 SCARB2 gene knock-out in HEK293T cells and transfection of 
macrophage mannose receptors 
 
SCARB2 gene knock-out and transfection with cDNA encoding mannose 
receptor is described in section 5.3.1.2 and 5.3.1.3. 
 
5.4.1.3 Culturing of HEK293T cells 
 
HEK293T were cultured in DMEM with high glucose supplemented with 10% FBS 
(Bodinco) and 100 units/ml Pen/Strep. One day before transfection 4 x 105 cells were 
seeded in a 6 well plate.  During 4 days, HEK293T were cultured in DMEM with high 
glucose (Gibco) supplemented with 10% FBS and 100 units/ml Pen/Strep, with 
different concentrations (0; 0.1; 1; 10; 50; 100 nM) of the GCSi compound 1307RB20. 
At the fourth day, the cells were harvested and the homogenization procedure and 
protein quantification was performed as described in 3.3.4. 
 
 
LIMP-2 deficiency: therapeutic approaches 
Pilot study on SRT in LIMP-2 deficiency (Mice and cells) 
 
133 
 
5.4.1.4 Neutral glycosphingolipids, glucosylsphingosine and cholesterol-
glucoside measurements 
 
Neutral glycosphingolipids, GlcSph and GlcChol were determined in the 
homogenates as described in section 4.3.11.  
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5.4.2 Results  
 
5.4.2.1 Substrate reduction therapy and LIMP-2 KO mice 
  
A new generation of GCS inhibitors has been recently generated, with 
increased specificity [167]. These ido-deoxynojirimycin-type compounds strongly 
inhibit GCS and non-lysosomal β-glucosidase, GBA2, but very poorly GCase. From 
these new compounds available, it was selected the 1307RB20, which has an IC50 for 
GCS of 2.5 nM, for GBA2 of 0.6 nM and for GCase of 6 µM [167]. In order to 
decrease the levels of GlcCer, LIMP-2 KO mice were treated for 14 consecutive days 
with 1307RB20, which was administered daily at 1 mg/kg. The animals were 
sacrificed and the levels of ceramide, GlcCer, GlcSph and GlcChol in liver, kidney, 
spleen, eye, duodenum and ileum were analyzed (Fig. 5.8 to 5.11). 
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Figure 5.8 – Ceramide levels in wild type (+/+) and LIMP-2 KO (-/-) mice treated with vehicle or GCSi. 
 
Untreated wild type and LIMP-2 KO mice have similar levels of ceramide in the 
analyzed organs. The conducted treatment with the GCS inhibitor did not change the 
ceramide content of these organs (Fig. 5.8). Regarding GlcCer, no marked 
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differences exist between control and LIMP-2 KO mice in the liver, eye, duodenum 
and ileum (Fig. 5.9). Only the kidney of LIMP-2 KO mice presents a two-fold higher 
amount of GlcCer, when compared to wild type mice. The treatment with GCSi did not 
result in a clear reduction in the levels of this glycosphingolipid as expected (Fig. 5.9). 
Only in the case of the duodenum a slight decrease in the levels of GlcCer was 
observed in control and LIMP-2 KO mice subjected to treatment. In the eye, and more 
clearly in the spleen, the GCS inhibithor treatment led to an increase of GlcCer levels 
which can only be ascribed to GBA2 inhibition without concomitant major inhibition of 
GCS. Next, the deacylated form of GlcCer, GlcSph was measured (Fig. 5.10). 
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Figure 4.9 – GlcCer levels in wild type (+/+) and LIMP-2 KO (-/-) mice treated with vehicle or GCSi. 
 
LIMP-2 deficiency: therapeutic approaches 
Pilot study on SRT in LIMP-2 deficiency (Mice and cells) 
 
136 
 
Liver
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
100
200
300
Eyes
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
200
400
600
800
1000
Kidney
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
100
200
300
400
500
Duodenum
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
50
100
150
Spleen
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
200
400
600
800
1000
Ileum
G
lc
Sp
h
(p
m
ol
/w
et
w
ei
gh
t)
+/+
Ve
hic
le
+/+
GC
Si
-/-
Ve
hic
le
-/-
GC
Si
0
20
40
60
80
100
 
Figure 5.10 – GlcSph levels in wild type (+/+) and LIMP-2 KO (-/-) mice treated with vehicle or GCSi. 
 
LIMP-2 KO mice show increased GlcSph levels in all tissues when compared 
to control mice. The abnormality is particularly evident in the spleen and eye (Fig. 
5.10). The treatment with the GCS inhibitor failed to decrease GlcSph levels as it was 
expected (Fig. 5.10).  
Since 1307RB20 is a more potent inhibitor of GBA2 as compared to GCS 
[167], and GBA2 forms by transglucosylation GlcChol [252, 281] (Marques et al., 
unpublished results), the concentration of this lipid was also determined in untreated 
and treated mice (Fig. 5.11). 
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Figure 5.11 – GlcChol levels in wild type (+/+) and LIMP-2 KO (-/-) mice treated with vehicle or GCSi. 
  
LIMP-2 KO mice show higher tissue levels of GlcChol than wild type (Fig. 
5.11). Treatment with 1307RB20 reduced GlcChol levels in LIMP-2 KO mice as well 
as in the control group in all organs examined. This finding suggests that the 
concentration of 1307RB20 used was sufficient to inhibit GBA2. Apparently, however 
the concentration was not high enough to cause a major inhibition of 
glucosphingolipid de novo synthesis via GCS.  
 
5.4.2.2 Substrate reduction therapy and LIMP-2 deficient cells 
 
 In order to understand if the administered dose of 1307RB20 was sufficiently 
high, a cell-based experiment was carried out. Wild type HEK293T cells and 
HEK293T cells, with the SCARB2 gene depleted by CRISPR technology, were used 
to test the in vivo inhibitory activity of 1307RB20. Cells were treated with different 
concentrations of 1307RB20, ranging from 0-100 nM, for 3 days. The cells were 
collected and ceramide, GlcCer, GlcSph and GlcChol levels were measured (Fig. 
5.12). 
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Figure 5.12 – Levels of Ceramide, GlcCer, GlcSph, GlcChol in wild type and LIMP-2 deficient HEK293T cells treated with 
1307RB20. WT WT WT+MR WT+MR Limp-2 Def + MRLIMP-2 deficient LIMP-2 DefLIMP-2 deficient + MR 
 
 
No significant changes were observed in ceramide levels in the HEK293T cell 
lines treated with different concentrations of 1307RB20 (Fig. 5.12A). In the case of 
the GlcCer, wild type and LIMP-2 deficient cells showed similar levels when not 
treated. GlcCer levels started to decrease with increasing 1307RB20 concentration in 
the medium, being reduced to half at the concentration of 1 nM (Fig 5.12B). HEK293T 
LIMP-2 deficient cells present a massive storage of GlcSph, when compared to wild 
type cell lines. Surprisingly, again with 1307RB20 treatment rendered minor 
reductions in GlcSph. At higher concentrations of 1307RB20, GlcSph levels even 
started to increase again (Fig 5.12C). In sharp contrast, GlcChol already at the lowest 
concentration tested, 0.1 nM, showed a drastic reduction in both wild type and LIMP-2 
deficient HEK293T cells (Fig 5.12D).  
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5.4.3 Discussion  
 
Substrate reduction offers an alternative therapy to ERT for type 1 GD 
patients, especially for those patients who do not tolerate ERT well because of 
immunoreactivity, hypersensitivity, or poor venous access. SRT aims to inhibit the 
first step in the glycosphingolipid biosynthesis, catalyzed by GCS, and thus generate 
a better balance between biosynthesis and catabolism of glycosphingolipids [158, 
274, 282, 283]. In LIMP-2 deficiency, causing AMRF due to the lack of GCase, the 
levels of GlcCer and especially its deacylated form, GlcSph, are increased. Likewise, 
in GD and AMRF, accumulating GlcCer is actively converted to GlcSph by the 
lysosomal enzyme acid ceramidase [284]. Since in LIMP-2 deficiency, the monocyte 
lineage presents relatively high residual GCase activity, avoiding the formation of 
lipid-laden macrophages, ERT with a macrophage-targeted enzyme does not seem 
an ideal therapeutic approach [201, 218, 271, 285]. On the other hand, SRT seems to 
be an attractive option for treatment of lipid abnormalities caused by LIMP-2 
deficiency, due to the induced reduction in GlcCer. Wild type and LIMP-2 KO mice 
were treated daily, during 14 days, with 1 mg/kg of 1307RB20. Whilst the lack of 
effect of the inhibitor treatment on ceramide levels was expected, the fact that no 
reductions were seen in the levels of GlcCer or GlcSph in the treated animals was 
surprising. Only in the case of the duodenum, a slight reduction of GlcCer was 
observed for the treated mice. Given the lack of response to the inhibitor 1307RB20 
in GlcCer and GlcSph tissue concentrations in LIMP-2 KO mice, it suggests that the 
administered dose and/or the time period of drug treatment were insufficient to 
generate the desired response. 
The enzyme GBA2 is also inhibited by 1307RB20 and the reduction in tissues 
of treated mice of GlcChol, a lipid formed by GBA2 activity, suggest that the applied 
concentration was sufficient to significantly inhibit this enzyme in the animals. The 
IC50 of GBA2 for 1307RB20 (0.6 nM) is about 4-fold lower than that of GCS (2.5 nM). 
Therefore, it seems that treatment of animals with a 10-fold higher dose would have 
most likely resulted in a detectable reduction of GlcCer. Indeed, experiments with 
HEK293T cells indicated that 1307RB20 is able to lower GlcCer significantly at 
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concentration ranging from 1 – 10 nM. The findings obtained with HEK293T cells are 
consistent with earlier determined inhibitory parameters using different in vitro 
determinations [167]. The finding with LIMP-2 deficient HEK293T cells treated with 
1307RB20, which at concentrations of 10 nM leads to a reduction in GlcCer but 
without concomitant major reduction in GlcSph, remains puzzling. It is generally 
assumed that GlcSph is predominantly generated in GCase deficient lysosomes by 
deacylation of accumulating GlcCer through the action of acid ceramidase (ASAH1). 
The present findings on GlcSph in the LIMP-2 deficient cells are difficult to reconcile 
with this observation. Further investigations with LIMP-2 deficient HEK293T cells fed 
with 13C5 isotope-labelled GlcCer and GlcSph, which have recently become available 
by synthesis (Wisse, Ferraz, unpublished), will certainly shed some light on the 
observed phenomenon.  
It is of great importance to determine whether GlcSph abnormalities during 
LIMP-2 deficiency are responsive to SRT based on pharmacological GCS inhibition. 
Of note, treatment of type 1 GD patients with the latest generation GCS inhibitor, 
Eliglustat, did result in marked reduction of GlcSph in plasma (Ferraz, Smid, 
unpublished results). A comparison of the effects of Eliglustat and 1307RB20 on 
GlcSph metabolism in LIMP-2 deficient cells will be extremely informative to assess 
the potential of SRT for treatment of AMRF.  
Due to the lack of established treatments for AMRF, it seems mandatory to 
include LIMP-2 deficient cells in screenings for candidate drugs aiming to modify 
glycosphingolipid metabolism and ameliorate the symptomatology of AMRF patients.
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CONCLUSION 
 
The work here presented describes laboratory investigations on the 
consequences of lysosomal membrane protein LIMP-2 deficiency, focusing in to the 
impact on the lysosomal hydrolase GCase that degrades intralysosomally GlcCer.  
At the start of the thesis work, it was already known that LIMP-2 acts as a 
transporter of newly formed GCase to lysosomes [57]. It was also recognized that the 
rare inherited disease AMRF is caused by inherited defects in the SCARB2 gene 
encoding LIMP-2 [210].  Surprisingly, the clinical manifestation of AMRF differs 
completely from GD, which is caused by mutations in the GBA gene encoding GCase 
[218]. There were also already indications that LIMP-2 deficiency causes a cell-type 
specific reduction in GCase levels, with the decrease being particularly small in white 
blood cells [201]. The high residual GCase activity in white blood cells, including 
monocytes/macrophages, could explain the absence of lipid-laden macrophages in 
AMRF patients. In sharp contrast to this, lipid-laden macrophages, the “Gaucher 
cells”, are the hallmark of GD and are thought to underlie various clinical 
manifestations ranging from splenomegaly, hepatomegaly, pancytopenia, anemia, 
thrombocytopenia to skeletal deterioration [113]. None of these symptoms occur in 
AMRF patients [218]. Characteristic features of AMRF are neurological 
manifestations with prominent epileptic attacks and ataxia. Only severely affected 
type 2 and 3 GD patients develop neurological complications at infantile and juvenile 
age, respectively. Most GD patients however develop a non-neuronopathic (type 1) 
course of disease with variable severity and age of onset of visceral symptoms [87]. 
The aims of the thesis investigation were the following: establishment of an 
improved procedure for laboratory diagnosis of AMRF, obtain insight in the cell-type 
specificity of GCase deficiency during LIMP-2 deficiency and to examine potential 
therapeutic avenues for AMRF.  
 
A. Improved laboratory diagnosis of AMRF. 
The initial studies focused on the features of GCase in leukocytes and cultured 
fibroblasts as well as plasma specimens of AMRF patients, GD patients and normal 
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subjects [248]. These studies were largely conducted by the newly developed 
research tools for visualization of GCase enzyme [131, 133]. It was confirmed that 
GCase levels are extremely low in AMRF fibroblasts, even lower than in type 1 GD 
fibroblasts. The detection of GCase with this very sensitive method allowed the 
demonstration of partial secretion of residual GCase from AMRF fibroblasts, contrary 
to the situation observed for GD and wild type fibroblasts.  
Subsequent examination of plasma of an AMRF patient revealed increased 
amounts of GCase. Since GCase is unstable at neutral pH, enzyme activity is rapidly 
lost when plasma samples are not immediately frozen. Diagnosis of AMRF patients 
based on elevated GCase activity is therefore not reliable since false negatives may 
occur. 
Given the noted very low levels of GCase in AMRF fibroblasts and the earlier 
finding that GCase deficient Gaucher fibroblasts show markedly increased levels of 
GlcSph formed from accumulating GlcCer [117], the sphingoid base was studied in 
AMRF cells. Clear increases of GlcSph were noted for AMRF fibroblasts and 
subsequent analysis of plasma specimens of AMRF patients showed elevated 
GlcSph levels far above normal values. This finding was confirmed by investigation of 
plasma specimens of LIMP-2 KO and normal mice. Plasma GlcSph is also increased 
in symptomatic GD patients, which also typically show elevated plasma biomarkers 
derived from Gaucher cells like chitotriosidase [89]. Such lipid-laden macrophages 
are not present in AMRF patients [201] and consequently plasma chitotriosidase is in 
the normal range. Combining all the findings, a differential laboratory diagnosis of 
AMRF and GD can be made. The workflow for convenient laboratory diagnosis of 
AMRF, prior to sequencing of the SCARB2 gene, is as follows. If in an individual a 
markedly increased plasma GlcSph is detected in the absence of elevated 
chitotriosidase this is an indication for AMRF. Measurement of GCase activity in 
fibroblasts should show a reduced enzymatic activity to consider further the diagnosis 
AMRF. Such diagnosis can be further substantiated with the sequencing of the 
SCARB2 gene.  
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In conclusion, demonstration of functional GCase deficiency by detection of 
abnormal high GlcSph in plasma is an important step in identification of individuals 
suffering from deficiency in LIMP-2 [248]. 
 
B. Tissue and cell-type dependent impact of LIMP-2 deficiency on secondary GCase 
reduction and lipid abnormalities. 
Mutations in the SCARB2 gene cause defects in the integral membrane protein 
LIMP-2 and subsequent impaired transport of newly formed GCase to lysosomes of 
cells of AMRF patients. The marked phenotypic difference between GD and AMRF 
prompted a detailed investigation on abnormalities in GCase and functionally related 
lipid abnormalities. The number of identified AMRF patients is still small, limiting 
investigations with human material. Fortunately, a genuine animal model for AMRF 
was generated by Saftig and co-workers some years ago when generating a knock-
out of the SCARB2 gene. The disease symptoms of these LIMP-2 KO mice 
phenotypically resemble in many aspects AMRF in man [190]. As part of the thesis 
work, GCase and its lipid metabolites were examined in several tissues of LIMP-2 KO 
mice. First, it was examined whether LIMP-2 deficiency also affects other lysosomal 
matrix enzymes than GCase. For this purpose, the proteome of isolated lysosomes 
from hepatocytes of wild type and LIMP-2 KO mice was examined by LC-MSe. No 
significant differences were noted in lysosomal matrix proteins, except a major 
deficiency in GCase. Next, the level of active GCase molecules in various tissues of 
LIMP-2 KO mice was analyzed. Comparable results were obtained either by using 
conventional enzymatic assay or ABP, revealing a gradient in deficiency of functional 
GCase along LIMP-2 deficient tissues. Next, lipid levels were determined in the 
various tissues. Importantly, the concentrations of GlcCer did not correlate with the 
extent of GCase deficiency. For example, GlcCer was normal in liver despite an 
extremely low GCase level. In sharp contrast to the findings for GlcCer, GlcSph was 
markedly increased in tissues, which correlate with GCase deficiency.  The amount of 
sphingoid base was the highest in those tissues with lowest GCase content. The 
maximal increase in tissue GlcSph occurred already in very young (2 months old) 
LIMP-2 KO mice. Apparently, in most cell types of LIMP-2 mice, storage of GlcCer is 
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prevented by active deacylation of the lipid to GlcSph. This deacylation seems to be 
catalyzed by the lysosomal acid ceramidase (ASAH1) [89] (Ferraz et al ,unpublished 
results).  
At the Department of Medical Biochemistry, The Netherlands, another lipid 
abnormality in GD patients was recently identified (Marques et al. to be published). 
The hitherto unknown lipid GlcChol (GlcChol) is elevated in GD patients. Analysis of 
tissues of LIMP-2 KO mice also revealed elevated levels of GlcChol. This indicates 
that GCase normally degrades the glucosylated sterol. 
The marked differences in clinical symptoms of AMRF patients and GD 
patients are likely due to the absence of Gaucher cells in AMRF patients. The cause 
for this prominent difference was further investigated. Considerable residual GCase 
activity is present in LIMP-2 deficient white blood cells, sharply contrasting with the 
low residual GCase in AMRF fibroblasts. The cause for this striking difference was 
experimentally studied. It was observed a considerable uptake through (dynamin-
dependent) endocytosis of GCase from the medium by AMRF lymphoblasts, but not 
fibroblasts. Based on this observation, it seems likely that in AMRF patients the re-
uptake by leukocytes and macrophages of GCase secreted by tissue in plasma, 
renders sufficient residual GCase activity in these cells to prevent formation of 
Gaucher cells. 
In conclusion, investigations with LIMP-2 KO mice revealed that marked 
differences occur among tissues and cell types in the amount of residual GCase. 
White blood cells show high residual GCase levels, likely due to uptake from plasma 
of secreted enzyme from tissues. This may explain the absence of lipid-laden 
macrophages in the animals. Most LIMP-2 deficient tissues seem to compensate very 
efficiently for their lack in GCase very efficiently by de-acylating GlcCer to GlcSph. 
 
 
C. LIMP-2 deficiency: therapeutic approaches and intralysosomal interaction of LIMP-
2 and GCase. 
Although deficiency of GCase occurs both in GD and AMRF patients, no treatment is 
presently available for AMRF. For non-neuronopathic type 1 GD, however two 
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different kinds of therapies are registered: macrophage-targeted ERT and 
glycosphingolipid SRT. ERT aims to directly supplement macrophages in GD patients 
with GCase by chronic infusions with a macrophage-targeted recombinant GCase 
[145]. Since GCase is the prominent biochemical abnormality in AMRF patients we 
studied the feasibility of supplementing LIMP-2 deficient cells with recombinant 
GCase. For this purpose, we exposed cells to recombinant hrGCase (Cerezyme®) 
presently used in ERT of type 1 GD patients. Experiments were performed with 
normal and AMRF fibroblasts as well as with normal and LIMP-2 deficient HEK293T 
cells expressing mannose receptors to promote uptake of mannose-terminated 
Cerezyme®. In all cell types it was observed the endocytotic uptake and delivery to 
lysosomes, however GCase is rapidly degraded in LIMP-2 deficient lysosomes. The 
half-life of the enzyme in LIMP-2 lysosomes is far shorter than in corresponding 
normal lysosomes. Apparently, transient interactions of GCase with LIMP-2, in the 
lysosome, contribute to stabilization of the compact conformation of the enzyme and 
thus prevent its proteolytic breakdown. This notion is of great importance since it has 
important implications (see Fig. 6.1). It suggests that the amount of LIMP-2 in 
lysosomes installs an intrinsic limit for the efficacy with which lysosomal GCase 
activity can be increased by ERT. When too much enzyme is taken up, lack of 
interaction with the limited amount of LIMP-2 will promote rapid proteolytic 
breakdown. Based on this experimental findings, ERT for AMRF seems not a wise 
approach. The present enzyme used in ERT of type 1 GD is neither attractive as drug 
for neurologically affected AMRF patients since it is targeted to visceral macrophages 
and does not pass the BBB.  
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Figure 6.1 – Schematic model for uptake and stability of hrGBA. Presently accepted view (A); Proposed model for LIMP-2 
positive wild type cells (B); Model for LIMP-2 deficient cells (C).  
 
 
Given the drawbacks of ERT with GCase as treatment of AMRF, SRT may 
offer a more attractive therapy approach. SRT aims to reduce glycosphingolipid 
substrate levels for GCase by inhibiting GCS. A new generation of brain-permeable, 
potent GCS inhibitors, the so-called biphenyl-pentoxy-ido-deoxynojirimycins, has 
recently been developed by Aerts, Overkleeft and colleagues [167]. For this purpose 
LIMP-2 KO mice were orally treated with a brain-permeable GCS inhibitor at a 
nanomolar concentration. The dose used proved however to be too small to render 
sufficient inhibition of glycosphingolipid synthesis. Higher doses will be needed to 
establish the therapeutic efficacy in LIMP-2 KO mice.  
In conclusion, a treatment is not yet available to ameliorate symptoms in 
AMRF.  There is still an unmet need for this rare inherited disease. ERT with available 
(macrophage-targeted) GCase is not an attractive approach for treatment of AMRF. 
More promising is substrate reduction therapy using oral inhibitors of GlcCer 
synthesis. Further investigations on such approach in LIMP-2 KO mice are warranted.  
CONCLUSION 
148 
 
Another important conclusion is that LIMP-2 seems to influence GCase at 
various stages of its life cycle. Firstly, LIMP-2 through binding in the endoplasmic 
reticulum and Golgi apparatus transports newly formed GCase to lysosomes, and 
secondly, by transient interactions in the lysosome it stabilizes the fold of GCase, and 
consequently protects it against proteolytic breakdown. Thus, LIMP-2 has a dual 
action as transporter and as chaperone of GCase. 
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